NZ624336B2 - Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases - Google Patents
Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases Download PDFInfo
- Publication number
- NZ624336B2 NZ624336B2 NZ624336A NZ62433612A NZ624336B2 NZ 624336 B2 NZ624336 B2 NZ 624336B2 NZ 624336 A NZ624336 A NZ 624336A NZ 62433612 A NZ62433612 A NZ 62433612A NZ 624336 B2 NZ624336 B2 NZ 624336B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- rnai agent
- ttr
- nucleotides
- strand
- ligand
- Prior art date
Links
- 108010071690 Prealbumin Proteins 0.000 title claims abstract description 334
- 201000010099 disease Diseases 0.000 title claims abstract description 75
- 102000007584 Prealbumin Human genes 0.000 title claims abstract 18
- 239000000203 mixture Substances 0.000 title claims description 107
- 230000002987 rna-interference Effects 0.000 title description 2
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 454
- 230000025458 RNA interference Effects 0.000 claims abstract description 382
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 278
- 239000002773 nucleotide Substances 0.000 claims abstract description 248
- 230000004048 modification Effects 0.000 claims abstract description 149
- 238000006011 modification reaction Methods 0.000 claims abstract description 149
- 230000000692 anti-sense Effects 0.000 claims abstract description 130
- 229920000972 Sense strand Polymers 0.000 claims abstract description 107
- 230000000295 complement Effects 0.000 claims abstract description 39
- 239000003814 drug Substances 0.000 claims abstract description 21
- 230000027455 binding Effects 0.000 claims description 135
- 239000003446 ligand Substances 0.000 claims description 133
- 108020004999 Messenger RNA Proteins 0.000 claims description 87
- 229920002106 messenger RNA Polymers 0.000 claims description 87
- 230000014509 gene expression Effects 0.000 claims description 80
- 230000002401 inhibitory effect Effects 0.000 claims description 47
- 241000282414 Homo sapiens Species 0.000 claims description 44
- 238000007920 subcutaneous administration Methods 0.000 claims description 44
- 206010002022 Amyloidosis Diseases 0.000 claims description 34
- 206010002023 Amyloidosis Diseases 0.000 claims description 32
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 239000000243 solution Substances 0.000 claims description 20
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 18
- 229910052758 niobium Inorganic materials 0.000 claims description 18
- 210000003169 Central Nervous System Anatomy 0.000 claims description 16
- 229920001850 Nucleic acid sequence Polymers 0.000 claims description 16
- 239000011780 sodium chloride Substances 0.000 claims description 16
- 102100000087 LARP6 Human genes 0.000 claims description 14
- 101700066207 LARP6 Proteins 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 208000005846 Cardiomyopathy Diseases 0.000 claims description 10
- 206010036105 Polyneuropathy Diseases 0.000 claims description 10
- 208000004358 Polyneuropathy Diseases 0.000 claims description 10
- 239000007853 buffer solution Substances 0.000 claims description 10
- 201000008031 cardiomyopathy Diseases 0.000 claims description 10
- YACKEPLHDIMKIO-UHFFFAOYSA-L methylphosphonate(2-) Chemical compound CP([O-])([O-])=O YACKEPLHDIMKIO-UHFFFAOYSA-L 0.000 claims description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 8
- 239000010452 phosphate Substances 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- 201000003968 hyperthyroxinemia Diseases 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 206010016202 Familial amyloidosis Diseases 0.000 claims description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 4
- 206010064571 Gene mutation Diseases 0.000 claims description 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- 230000000640 hydroxylating Effects 0.000 claims description 2
- 102220412803 DTNA I61A Human genes 0.000 claims 2
- 241000956321 Kalanchoe mosaic virus Species 0.000 claims 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- OVRNDRQMDRJTHS-DJLPIQJZSA-N N-[(2S,3S,4S,5R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical class CC(=O)N[C@@H]1[C@@H](O)OC(CO)[C@H](O)[C@H]1O OVRNDRQMDRJTHS-DJLPIQJZSA-N 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 abstract description 37
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 102000009190 Transthyretin Human genes 0.000 description 313
- 210000004027 cells Anatomy 0.000 description 172
- -1 e.g. Substances 0.000 description 152
- 229920000272 Oligonucleotide Polymers 0.000 description 53
- 210000004185 Liver Anatomy 0.000 description 50
- 239000002585 base Substances 0.000 description 48
- 239000002502 liposome Substances 0.000 description 44
- 239000011734 sodium Substances 0.000 description 44
- 239000000523 sample Substances 0.000 description 42
- 150000002632 lipids Chemical class 0.000 description 40
- 108020004459 Small Interfering RNA Proteins 0.000 description 39
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 37
- 230000035492 administration Effects 0.000 description 36
- 230000001743 silencing Effects 0.000 description 32
- 239000002924 silencing RNA Substances 0.000 description 32
- 210000001519 tissues Anatomy 0.000 description 31
- 230000000694 effects Effects 0.000 description 27
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 26
- 230000001629 suppression Effects 0.000 description 25
- 102000004169 proteins and genes Human genes 0.000 description 24
- 108090000623 proteins and genes Proteins 0.000 description 24
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-[(3R,4R,5R,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical class CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 description 22
- 239000000969 carrier Substances 0.000 description 21
- 239000000562 conjugate Substances 0.000 description 21
- 210000002966 Serum Anatomy 0.000 description 20
- 230000015572 biosynthetic process Effects 0.000 description 19
- 210000000056 organs Anatomy 0.000 description 19
- 108020004707 nucleic acids Proteins 0.000 description 18
- 150000007523 nucleic acids Chemical class 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 17
- 150000002500 ions Chemical class 0.000 description 17
- 239000000126 substance Substances 0.000 description 17
- 108020004461 Double-Stranded RNA Proteins 0.000 description 16
- 241000700159 Rattus Species 0.000 description 16
- 239000012530 fluid Substances 0.000 description 16
- 210000002381 Plasma Anatomy 0.000 description 15
- 239000002253 acid Substances 0.000 description 15
- 150000001768 cations Chemical class 0.000 description 15
- 125000005647 linker group Chemical group 0.000 description 15
- 239000000693 micelle Substances 0.000 description 15
- 239000002953 phosphate buffered saline Substances 0.000 description 15
- 239000004094 surface-active agent Substances 0.000 description 15
- 241001606065 Aoa Species 0.000 description 14
- 238000004166 bioassay Methods 0.000 description 14
- 102000004196 processed proteins & peptides Human genes 0.000 description 14
- 108090000765 processed proteins & peptides Proteins 0.000 description 14
- 229940107161 Cholesterol Drugs 0.000 description 13
- 150000001720 carbohydrates Chemical group 0.000 description 13
- 235000012000 cholesterol Nutrition 0.000 description 13
- 238000000338 in vitro Methods 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 13
- 239000002023 wood Substances 0.000 description 13
- 102000008100 Human Serum Albumin Human genes 0.000 description 12
- 108091006822 Human Serum Albumin Proteins 0.000 description 12
- 241001446467 Mama Species 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 12
- 230000000875 corresponding Effects 0.000 description 12
- 125000004122 cyclic group Chemical group 0.000 description 12
- 229940079593 drugs Drugs 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 230000035772 mutation Effects 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 235000000346 sugar Nutrition 0.000 description 12
- 210000004369 Blood Anatomy 0.000 description 11
- 210000003734 Kidney Anatomy 0.000 description 11
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 11
- 239000011324 bead Substances 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 235000014633 carbohydrates Nutrition 0.000 description 11
- 238000005755 formation reaction Methods 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 239000000178 monomer Substances 0.000 description 11
- 210000001525 Retina Anatomy 0.000 description 10
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 10
- 125000002091 cationic group Chemical group 0.000 description 10
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 10
- 239000012071 phase Substances 0.000 description 10
- 229920000023 polynucleotide Polymers 0.000 description 10
- 239000002157 polynucleotide Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 125000002652 ribonucleotide group Chemical group 0.000 description 10
- 201000007905 transthyretin amyloidosis Diseases 0.000 description 10
- 239000011534 wash buffer Substances 0.000 description 10
- 101710037135 GAPC2 Proteins 0.000 description 9
- 101710037116 GAPC3 Proteins 0.000 description 9
- 101710025049 GAPDG Proteins 0.000 description 9
- 101710008404 GAPDH Proteins 0.000 description 9
- 102100006425 GAPDH Human genes 0.000 description 9
- 101710010461 Gapdh1 Proteins 0.000 description 9
- 101710025050 MK0970 Proteins 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 229920001914 Ribonucleotide Polymers 0.000 description 9
- 210000003491 Skin Anatomy 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- 101710025091 cbbGC Proteins 0.000 description 9
- 101710025070 gapdh-2 Proteins 0.000 description 9
- 230000036651 mood Effects 0.000 description 9
- 239000000816 peptidomimetic Substances 0.000 description 9
- 239000002336 ribonucleotide Substances 0.000 description 9
- 231100000730 tolerability Toxicity 0.000 description 9
- 210000003494 Hepatocytes Anatomy 0.000 description 8
- XUIIKFGFIJCVMT-LBPRGKRZSA-N L-thyroxine zwitterion Chemical compound IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-LBPRGKRZSA-N 0.000 description 8
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 8
- 230000009089 cytolysis Effects 0.000 description 8
- 230000004064 dysfunction Effects 0.000 description 8
- 230000000021 endosomolytic Effects 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 238000001990 intravenous administration Methods 0.000 description 8
- 230000002934 lysing Effects 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000002609 media Substances 0.000 description 8
- 230000000051 modifying Effects 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 8
- 229910052708 sodium Inorganic materials 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 230000002194 synthesizing Effects 0.000 description 8
- 230000001225 therapeutic Effects 0.000 description 8
- 238000001890 transfection Methods 0.000 description 8
- IYMAXBFPHPZYIK-BQBZGAKWSA-N (2S)-2-[[2-[[(2S)-2-azaniumyl-5-(diaminomethylideneazaniumyl)pentanoyl]amino]acetyl]amino]butanedioate Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 7
- 241000282693 Cercopithecidae Species 0.000 description 7
- 241001673391 Entandrophragma candollei Species 0.000 description 7
- 210000002216 Heart Anatomy 0.000 description 7
- 210000000496 Pancreas Anatomy 0.000 description 7
- 210000000952 Spleen Anatomy 0.000 description 7
- 206010047658 Vitreous opacity Diseases 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 7
- 125000004429 atoms Chemical group 0.000 description 7
- 230000001808 coupling Effects 0.000 description 7
- 238000010168 coupling process Methods 0.000 description 7
- 238000005859 coupling reaction Methods 0.000 description 7
- 230000002354 daily Effects 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 230000002708 enhancing Effects 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 230000030279 gene silencing Effects 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 235000021317 phosphate Nutrition 0.000 description 7
- 229920000768 polyamine Polymers 0.000 description 7
- 229960003471 retinol Drugs 0.000 description 7
- 102000030003 retinol binding proteins Human genes 0.000 description 7
- 108091000053 retinol binding proteins Proteins 0.000 description 7
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(Z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 6
- 229920002395 Aptamer Polymers 0.000 description 6
- 210000000170 Cell Membrane Anatomy 0.000 description 6
- 108060003412 GRP Proteins 0.000 description 6
- 102000015779 HDL Lipoproteins Human genes 0.000 description 6
- 206010029331 Neuropathy peripheral Diseases 0.000 description 6
- 102200084290 PRCD V30M Human genes 0.000 description 6
- LLKYUHGUYSLMPA-UHFFFAOYSA-N Phosphoramidite Chemical compound NP([O-])[O-] LLKYUHGUYSLMPA-UHFFFAOYSA-N 0.000 description 6
- 102100016858 TTR Human genes 0.000 description 6
- 229940034208 Thyroxine Drugs 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 125000004432 carbon atoms Chemical group C* 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 6
- 230000001976 improved Effects 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 229950008325 levothyroxine Drugs 0.000 description 6
- 238000011068 load Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 201000001119 neuropathy Diseases 0.000 description 6
- 230000000275 pharmacokinetic Effects 0.000 description 6
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 6
- 230000002829 reduced Effects 0.000 description 6
- 150000003839 salts Chemical group 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 230000032258 transport Effects 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- 229930003231 vitamins Natural products 0.000 description 6
- 230000003442 weekly Effects 0.000 description 6
- 108020005544 Antisense RNA Proteins 0.000 description 5
- 206010007509 Cardiac amyloidosis Diseases 0.000 description 5
- 208000003295 Carpal Tunnel Syndrome Diseases 0.000 description 5
- 210000001175 Cerebrospinal Fluid Anatomy 0.000 description 5
- 210000002987 Choroid Plexus Anatomy 0.000 description 5
- GZCGUPFRVQAUEE-KCDKBNATSA-N D-(+)-Galactose Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-KCDKBNATSA-N 0.000 description 5
- 235000002134 Jacaratia dodecaphylla Nutrition 0.000 description 5
- 244000172600 Jacaratia dodecaphylla Species 0.000 description 5
- 102000007330 LDL Lipoproteins Human genes 0.000 description 5
- 108010007622 LDL Lipoproteins Proteins 0.000 description 5
- 241000699660 Mus musculus Species 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 108010039918 Polylysine Proteins 0.000 description 5
- 210000003583 Retinal Pigment Epithelium Anatomy 0.000 description 5
- 229940035295 Ting Drugs 0.000 description 5
- 229940029983 VITAMINS Drugs 0.000 description 5
- 229940021016 Vitamin IV solution additives Drugs 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 239000012190 activator Substances 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 125000000129 anionic group Chemical group 0.000 description 5
- 102000004965 antibodies Human genes 0.000 description 5
- 108090001123 antibodies Proteins 0.000 description 5
- 229920002847 antisense RNA Polymers 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 5
- 229960002685 biotin Drugs 0.000 description 5
- 235000020958 biotin Nutrition 0.000 description 5
- 239000011616 biotin Substances 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 239000003184 complementary RNA Substances 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 230000002209 hydrophobic Effects 0.000 description 5
- 238000007918 intramuscular administration Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000001404 mediated Effects 0.000 description 5
- 150000003904 phospholipids Chemical class 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 229920000656 polylysine Polymers 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 239000007929 subcutaneous injection Substances 0.000 description 5
- 238000010254 subcutaneous injection Methods 0.000 description 5
- 229960001353 tafamidis Drugs 0.000 description 5
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 5
- WQZGKKKJIJFFOK-PHYPRBDBSA-N α-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 5
- 229960000643 Adenine Drugs 0.000 description 4
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Natural products NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 4
- WNROFYMDJYEPJX-UHFFFAOYSA-K Aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 4
- 229920002676 Complementary DNA Polymers 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 4
- 210000003792 Cranial Nerves Anatomy 0.000 description 4
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 4
- 206010012289 Dementia Diseases 0.000 description 4
- 201000005804 Eastern equine encephalitis Diseases 0.000 description 4
- 210000001163 Endosomes Anatomy 0.000 description 4
- 210000003414 Extremities Anatomy 0.000 description 4
- 208000004044 Hypesthesia Diseases 0.000 description 4
- 206010020937 Hypoaesthesia Diseases 0.000 description 4
- 241000229754 Iva xanthiifolia Species 0.000 description 4
- 206010033775 Paraesthesia Diseases 0.000 description 4
- 208000001647 Renal Insufficiency Diseases 0.000 description 4
- 206010038435 Renal failure Diseases 0.000 description 4
- 206010039911 Seizure Diseases 0.000 description 4
- ATHGHQPFGPMSJY-UHFFFAOYSA-N Spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 4
- 229940035893 Uracil Drugs 0.000 description 4
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 4
- 229940045997 Vitamin A Drugs 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 229910052783 alkali metal Inorganic materials 0.000 description 4
- 150000001340 alkali metals Chemical class 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 230000002567 autonomic Effects 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000009833 condensation Methods 0.000 description 4
- 230000005494 condensation Effects 0.000 description 4
- 230000021615 conjugation Effects 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 239000005547 deoxyribonucleotide Substances 0.000 description 4
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 235000019152 folic acid Nutrition 0.000 description 4
- 239000011724 folic acid Substances 0.000 description 4
- 230000002496 gastric Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000002068 genetic Effects 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 230000002045 lasting Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 230000036961 partial Effects 0.000 description 4
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 4
- 239000003380 propellant Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 210000004881 tumor cells Anatomy 0.000 description 4
- 235000019155 vitamin A Nutrition 0.000 description 4
- 239000011719 vitamin A Substances 0.000 description 4
- KWVJHCQQUFDPLU-YEUCEMRASA-N 2,3-bis[[(Z)-octadec-9-enoyl]oxy]propyl-trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KWVJHCQQUFDPLU-YEUCEMRASA-N 0.000 description 3
- 206010061666 Autonomic neuropathy Diseases 0.000 description 3
- 229940104302 Cytosine Drugs 0.000 description 3
- OPTASPLRGRRNAP-UHFFFAOYSA-N Cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 3
- IQFYYKKMVGJFEH-XLPZGREQSA-N DEOXYTHYMIDINE Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
- 102000033147 ERVK-25 Human genes 0.000 description 3
- 230000037217 Elimination half-life Effects 0.000 description 3
- 101710008209 FBLIM1 Proteins 0.000 description 3
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 3
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 3
- UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- UGQMRVRMYYASKQ-KMPDEGCQSA-N Inosine Natural products O[C@H]1[C@H](O)[C@@H](CO)O[C@@H]1N1C(N=CNC2=O)=C2N=C1 UGQMRVRMYYASKQ-KMPDEGCQSA-N 0.000 description 3
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 108090001007 Interleukin-8 Proteins 0.000 description 3
- 208000001083 Kidney Disease Diseases 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- 101700028499 LECG Proteins 0.000 description 3
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-ACETYL-D-GALACTOSAMINE Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 3
- 206010029149 Nephropathy Diseases 0.000 description 3
- 206010029151 Nephropathy Diseases 0.000 description 3
- 239000012124 Opti-MEM Substances 0.000 description 3
- 206010034620 Peripheral sensory neuropathy Diseases 0.000 description 3
- 208000007107 Stomach Ulcer Diseases 0.000 description 3
- 101700081234 TTR Proteins 0.000 description 3
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 150000001345 alkine derivatives Chemical class 0.000 description 3
- 150000008051 alkyl sulfates Chemical class 0.000 description 3
- 230000003942 amyloidogenic Effects 0.000 description 3
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide Chemical compound [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 3
- 239000003613 bile acid Substances 0.000 description 3
- 125000003636 chemical group Chemical group 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000001268 conjugating Effects 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 239000000412 dendrimer Substances 0.000 description 3
- 229920000736 dendritic polymer Polymers 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 201000005917 gastric ulcer Diseases 0.000 description 3
- 150000004676 glycans Polymers 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 229960003786 inosine Drugs 0.000 description 3
- 102000006495 integrins Human genes 0.000 description 3
- 108010044426 integrins Proteins 0.000 description 3
- 238000001361 intraarterial administration Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000002523 lectin Substances 0.000 description 3
- 210000004962 mammalian cells Anatomy 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 230000003278 mimic Effects 0.000 description 3
- 150000002772 monosaccharides Chemical class 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 230000002746 orthostatic Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000001575 pathological Effects 0.000 description 3
- 150000008300 phosphoramidites Chemical class 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 238000007747 plating Methods 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 150000004804 polysaccharides Polymers 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002062 proliferating Effects 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 235000020944 retinol Nutrition 0.000 description 3
- 239000011607 retinol Substances 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 229920002477 rna polymer Polymers 0.000 description 3
- 201000005572 sensory peripheral neuropathy Diseases 0.000 description 3
- 231100000486 side effect Toxicity 0.000 description 3
- MAKUBRYLFHZREJ-JWBQXVCJSA-M sodium;(2S,3S,4R,5R,6R)-3-[(2S,3R,5S,6R)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate Chemical compound [Na+].CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@H](O)[C@H]1O MAKUBRYLFHZREJ-JWBQXVCJSA-M 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 230000002459 sustained Effects 0.000 description 3
- DQJDBUPLRMRBAB-WZTVWXICSA-N tafamidis meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O1C2=CC(C(=O)O)=CC=C2N=C1C1=CC(Cl)=CC(Cl)=C1 DQJDBUPLRMRBAB-WZTVWXICSA-N 0.000 description 3
- 150000004044 tetrasaccharides Chemical class 0.000 description 3
- 230000000699 topical Effects 0.000 description 3
- 150000004043 trisaccharides Chemical class 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-Tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 2
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-Lutidine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 2
- LMWMTSCFTPQVCJ-UHFFFAOYSA-N 2-methylphenol;phenol Chemical compound OC1=CC=CC=C1.CC1=CC=CC=C1O LMWMTSCFTPQVCJ-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- GONFBOIJNUKKST-UHFFFAOYSA-N 5-ethylsulfanyl-2H-tetrazole Chemical compound CCSC=1N=NNN=1 GONFBOIJNUKKST-UHFFFAOYSA-N 0.000 description 2
- 108010003596 Antennapedia Homeodomain Protein Proteins 0.000 description 2
- 210000001367 Arteries Anatomy 0.000 description 2
- 230000036912 Bioavailability Effects 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 235000003197 Byrsonima crassifolia Nutrition 0.000 description 2
- 240000001546 Byrsonima crassifolia Species 0.000 description 2
- 101710032181 CXCL10 Proteins 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Calypsol Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N Cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
- 239000004380 Cholic acid Substances 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 108010069514 Cyclic Peptides Proteins 0.000 description 2
- 102000001189 Cyclic Peptides Human genes 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 210000000805 Cytoplasm Anatomy 0.000 description 2
- 150000008574 D-amino acids Chemical class 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229940009976 Deoxycholate Drugs 0.000 description 2
- KILNVBDSWZSGLL-KXQOOQHDSA-N Dipalmitoylphosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 2
- 241000271571 Dromaius novaehollandiae Species 0.000 description 2
- 108010092799 EC 2.7.7.49 Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 210000000981 Epithelium Anatomy 0.000 description 2
- 101700036477 FOLH1 Proteins 0.000 description 2
- 102100008453 FOLH1 Human genes 0.000 description 2
- 208000009760 Familial Amyloid Neuropathy Diseases 0.000 description 2
- 229940014144 Folate Drugs 0.000 description 2
- 229960000304 Folic Acid Drugs 0.000 description 2
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N Fucose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 2
- 101710015954 HVA1 Proteins 0.000 description 2
- 206010019889 Hereditary neuropathic amyloidosis Diseases 0.000 description 2
- 229940088597 Hormone Drugs 0.000 description 2
- 210000000936 Intestines Anatomy 0.000 description 2
- 101700065814 LEA2 Proteins 0.000 description 2
- 101700021338 LEC Proteins 0.000 description 2
- 101700077545 LECC Proteins 0.000 description 2
- 101700063913 LECT Proteins 0.000 description 2
- 229960004873 LEVOMENTHOL Drugs 0.000 description 2
- 239000012098 Lipofectamine RNAiMAX Substances 0.000 description 2
- SMEROWZSTRWXGI-HVATVPOCSA-N Lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 description 2
- 210000004072 Lung Anatomy 0.000 description 2
- 210000002751 Lymph Anatomy 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N M-Cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 102100002248 MAML2 Human genes 0.000 description 2
- 101700039750 MAML2 Proteins 0.000 description 2
- 230000036948 MRT Effects 0.000 description 2
- 229940041616 Menthol Drugs 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028570 Myelopathy Diseases 0.000 description 2
- 206010028640 Myopathy Diseases 0.000 description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N Naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- ODUCDPQEXGNKDN-UHFFFAOYSA-N Nitroxyl Chemical compound O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N Oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 101710034340 Os04g0173800 Proteins 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N Palmitic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 210000001428 Peripheral Nervous System Anatomy 0.000 description 2
- AQSJGOWTSHOLKH-UHFFFAOYSA-N Phosphite Chemical compound [O-]P([O-])[O-] AQSJGOWTSHOLKH-UHFFFAOYSA-N 0.000 description 2
- 229940067631 Phospholipids Drugs 0.000 description 2
- 229920002732 Polyanhydride Polymers 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 230000036141 SERUM STABILITY Effects 0.000 description 2
- 210000003296 Saliva Anatomy 0.000 description 2
- 210000004911 Serous fluid Anatomy 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M Sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N Spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 206010061367 Spinal cord disease Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- TXEIIPDJKFWEEC-UHFFFAOYSA-N Tafamidis Chemical compound O1C2=CC(C(=O)O)=CC=C2N=C1C1=CC(Cl)=CC(Cl)=C1 TXEIIPDJKFWEEC-UHFFFAOYSA-N 0.000 description 2
- 210000001550 Testis Anatomy 0.000 description 2
- 240000000280 Theobroma cacao Species 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N Thymine Chemical group CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 2
- 210000002700 Urine Anatomy 0.000 description 2
- 229940046009 Vitamin E Drugs 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000002015 acyclic group Chemical group 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 230000002730 additional Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 230000001668 ameliorated Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000001580 bacterial Effects 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 230000035514 bioavailability Effects 0.000 description 2
- 230000003115 biocidal Effects 0.000 description 2
- 239000008366 buffered solution Substances 0.000 description 2
- 235000005764 cacao Nutrition 0.000 description 2
- 235000005767 cacao Nutrition 0.000 description 2
- 235000001046 cacaotero Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 229960002471 cholic acid Drugs 0.000 description 2
- 235000019416 cholic acid Nutrition 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 229960005188 collagen Drugs 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000004059 degradation Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- KXGVEGMKQFWNSR-LLQZFEROSA-M deoxycholate Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-M 0.000 description 2
- 230000001419 dependent Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 230000003467 diminishing Effects 0.000 description 2
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 2
- 235000004879 dioscorea Nutrition 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 230000002222 downregulating Effects 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000000799 fusogenic Effects 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N glycolic acid Chemical class OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 239000001963 growth media Substances 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 150000002460 imidazoles Chemical class 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 101700036391 lecA Proteins 0.000 description 2
- 239000008206 lipophilic material Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000001926 lymphatic Effects 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 230000003211 malignant Effects 0.000 description 2
- 101700001016 mbhA Proteins 0.000 description 2
- 235000019988 mead Nutrition 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- 230000000813 microbial Effects 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 238000007431 microscopic evaluation Methods 0.000 description 2
- 201000010770 muscular disease Diseases 0.000 description 2
- 201000009623 myopathy Diseases 0.000 description 2
- 229960002009 naproxen Drugs 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Polymers 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 125000004437 phosphorous atoms Chemical group 0.000 description 2
- 229920001308 poly(aminoacid) Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 239000001294 propane Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 230000002633 protecting Effects 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002207 retinal Effects 0.000 description 2
- 239000003161 ribonuclease inhibitor Substances 0.000 description 2
- 231100000161 signs of toxicity Toxicity 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 229940063673 spermidine Drugs 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tBuOOH Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 101700082413 tant Proteins 0.000 description 2
- 102000015609 tat Gene Products Human genes 0.000 description 2
- 108010038756 tat Gene Products Proteins 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 238000004450 types of analysis Methods 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 150000003712 vitamin E derivatives Chemical class 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N α-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- PUDXUJRJLRLJIU-QYVSTXNMSA-N (2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-2-(hydroxymethyl)-4-(2-methoxyethoxy)oxolan-3-ol Chemical compound COCCO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(N)=C2N=C1 PUDXUJRJLRLJIU-QYVSTXNMSA-N 0.000 description 1
- HEGSGKPQLMEBJL-RQICVUQASA-N (2R,3S,4S,5R)-2-(hydroxymethyl)-6-octoxyoxane-3,4,5-triol Chemical compound CCCCCCCCOC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RQICVUQASA-N 0.000 description 1
- CALDMMCNNFPJSI-CRCLSJGQSA-N (3R,5S)-5-(hydroxymethyl)pyrrolidin-3-ol Chemical compound OC[C@@H]1C[C@@H](O)CN1 CALDMMCNNFPJSI-CRCLSJGQSA-N 0.000 description 1
- DDVBPZROPPMBLW-VREWCFMQSA-N (4R)-4-[(1R,4S,5E,7Z,11E,15R,17R)-17-hydroxy-4,11-dimethyl-13-oxo-14,18-dioxabicyclo[13.3.1]nonadeca-5,7,11-trien-17-yl]-1,3-thiazolidin-2-one Chemical compound C([C@H]1[C@@]2(O)C[C@H]3C[C@H](O2)CC[C@@H](\C=C\C=C/CC/C(C)=C/C(=O)O3)C)SC(=O)N1 DDVBPZROPPMBLW-VREWCFMQSA-N 0.000 description 1
- NEVQCHBUJFYGQO-DNRKLUKYSA-N 1-[(2R,3R,4R,5R)-4-hydroxy-5-(hydroxymethyl)-3-(2-methoxyethoxy)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound COCCO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C)=C1 NEVQCHBUJFYGQO-DNRKLUKYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- WALUVDCNGPQPOD-UHFFFAOYSA-M 2,3-di(tetradecoxy)propyl-(2-hydroxyethyl)-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCOCC(C[N+](C)(C)CCO)OCCCCCCCCCCCCCC WALUVDCNGPQPOD-UHFFFAOYSA-M 0.000 description 1
- BACYUWVYYTXETD-UHFFFAOYSA-N 2-[dodecanoyl(methyl)amino]acetic acid Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 1
- KJJPLEZQSCZCKE-UHFFFAOYSA-N 2-aminopropane-1,3-diol Chemical group OCC(N)CO KJJPLEZQSCZCKE-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-L 2-sulfobutanedioate Chemical class OS(=O)(=O)C(C([O-])=O)CC([O-])=O ULUAUXLGCMPNKK-UHFFFAOYSA-L 0.000 description 1
- XFOWYEKVIRMOBI-UHFFFAOYSA-N 3,3-dimethylbutanenitrile Chemical compound CC(C)(C)CC#N XFOWYEKVIRMOBI-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- ILBCSMHIEBDGJY-UHFFFAOYSA-N 3-[4-(3-aminopropylamino)butylamino]propylcarbamic acid Chemical compound NCCCNCCCCNCCCNC(O)=O ILBCSMHIEBDGJY-UHFFFAOYSA-N 0.000 description 1
- APRRQJCCBSJQOQ-UHFFFAOYSA-N 4-amino-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound OS(=O)(=O)C1=CC(O)=C2C(N)=CC(S(O)(=O)=O)=CC2=C1 APRRQJCCBSJQOQ-UHFFFAOYSA-N 0.000 description 1
- QXYRRCOJHNZVDJ-UHFFFAOYSA-N 4-pyren-1-ylbutanoic acid Chemical compound C1=C2C(CCCC(=O)O)=CC=C(C=C3)C2=C2C3=CC=CC2=C1 QXYRRCOJHNZVDJ-UHFFFAOYSA-N 0.000 description 1
- 102000037085 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091019276 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- 229920001383 5S-rRNA precursor Polymers 0.000 description 1
- 108010062307 AAVALLPAVLLALLAP Proteins 0.000 description 1
- 101700027746 AGO2 Proteins 0.000 description 1
- 102100001249 ALB Human genes 0.000 description 1
- 206010049460 Abasia Diseases 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000428352 Amma Species 0.000 description 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- 210000000709 Aorta Anatomy 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010002913 Asialoglycoproteins Proteins 0.000 description 1
- 229940009098 Aspartate Drugs 0.000 description 1
- 229960005261 Aspartic Acid Drugs 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- RHISNKCGUDDGEG-UHFFFAOYSA-N Bactenecin Chemical compound CCC(C)C1NC(=O)C(C(C)C)NC(=O)C(C(C)C)NC(=O)C(C(C)CC)NC(=O)C(CCCN=C(N)N)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(N)CCCN=C(N)N)CSSCC(C(=O)NC(CCCN=C(N)N)C(O)=O)NC(=O)C(C(C)C)NC(=O)C(CCCN=C(N)N)NC1=O RHISNKCGUDDGEG-UHFFFAOYSA-N 0.000 description 1
- 229940112871 Bisphosphonate drugs affecting bone structure and mineralization Drugs 0.000 description 1
- 241000270299 Boa Species 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- YIJMDMOBYHDLIK-UHFFFAOYSA-N CC(C)C(CNP([O-])[O-])(C#N)C(C)C Chemical compound CC(C)C(CNP([O-])[O-])(C#N)C(C)C YIJMDMOBYHDLIK-UHFFFAOYSA-N 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L Calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000007575 Calluna vulgaris Nutrition 0.000 description 1
- 240000002804 Calluna vulgaris Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108060001132 Cathelicidins Proteins 0.000 description 1
- 102000014509 Cathelicidins Human genes 0.000 description 1
- 108050004290 Cecropins Proteins 0.000 description 1
- 229920002301 Cellulose acetate Polymers 0.000 description 1
- 229940119217 Chamomile extract Drugs 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 229940009025 Chenodeoxycholate Drugs 0.000 description 1
- RUDATBOHQWOJDD-BSWAIDMHSA-N Chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- DJHJJVWPFGHIPH-OODMECLYSA-N Chitin Chemical compound O[C@@H]1C(NC(=O)C)[C@H](O)OC(CO)[C@H]1COC[C@H]1C(NC(C)=O)[C@@H](O)[C@H](COC[C@H]2C([C@@H](O)[C@H](O)C(CO)O2)NC(C)=O)C(CO)O1 DJHJJVWPFGHIPH-OODMECLYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000587718 Chlorurus sordidus Species 0.000 description 1
- 210000003161 Choroid Anatomy 0.000 description 1
- 230000037242 Cmax Effects 0.000 description 1
- 240000002347 Colocasia esculenta Species 0.000 description 1
- 210000001072 Colon Anatomy 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- 229940097362 Cyclodextrins Drugs 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 210000004292 Cytoskeleton Anatomy 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229940030606 DIURETICS Drugs 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N DL-aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- XULFJDKZVHTRLG-JDVCJPALSA-N DOSPA trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)CCNC(=O)C(CCCNCCCN)NCCCN)OCCCCCCCC\C=C/CCCCCCCC XULFJDKZVHTRLG-JDVCJPALSA-N 0.000 description 1
- NNBZCPXTIHJBJL-UHFFFAOYSA-N Decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 1
- 210000004207 Dermis Anatomy 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N Diethanolamine Chemical group OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 235000002723 Dioscorea alata Nutrition 0.000 description 1
- 235000007056 Dioscorea composita Nutrition 0.000 description 1
- 235000009723 Dioscorea convolvulacea Nutrition 0.000 description 1
- 235000005362 Dioscorea floribunda Nutrition 0.000 description 1
- 235000004868 Dioscorea macrostachya Nutrition 0.000 description 1
- 235000005361 Dioscorea nummularia Nutrition 0.000 description 1
- 235000005360 Dioscorea spiculiflora Nutrition 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 210000001198 Duodenum Anatomy 0.000 description 1
- 208000001939 Dystransthyretinemic Euthyroidal Hyperthyroxinemia Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102100003962 EMD Human genes 0.000 description 1
- 101700062884 EMD Proteins 0.000 description 1
- 201000009344 Emery-Dreifuss muscular dystrophy Diseases 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N Endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 210000003238 Esophagus Anatomy 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N Ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 241000736355 Euthyroides Species 0.000 description 1
- 229940012356 Eye Drops Drugs 0.000 description 1
- 210000000744 Eyelids Anatomy 0.000 description 1
- 108010087294 GALA peptide Proteins 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 229940049906 Glutamate Drugs 0.000 description 1
- 229940074045 Glyceryl Distearate Drugs 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 240000007842 Glycine max Species 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N Guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- NYHBQMYGNKIUIF-PXMDKTAGSA-N Guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1O[C@@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-PXMDKTAGSA-N 0.000 description 1
- 229940029575 Guanosine Drugs 0.000 description 1
- 206010073071 Hepatocellular carcinoma Diseases 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N Hexamethylphosphoramide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000005319 Human Immunodeficiency Virus tat Gene Products Human genes 0.000 description 1
- 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 235000012565 Hyphaene thebaica Nutrition 0.000 description 1
- 240000003297 Hyphaene thebaica Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 102100009001 IL18 Human genes 0.000 description 1
- 101700077335 IL18 Proteins 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 210000003405 Ileum Anatomy 0.000 description 1
- 208000005531 Immunoglobulin Light-chain Amyloidosis Diseases 0.000 description 1
- USSYUMHVHQSYNA-YDSZHKBTSA-N Indolicidin Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(N)=O)CC1=CNC2=CC=CC=C12 USSYUMHVHQSYNA-YDSZHKBTSA-N 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 210000003963 Intermediate Filaments Anatomy 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N Inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 Inulin Drugs 0.000 description 1
- 210000002510 Keratinocytes Anatomy 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 229960000448 Lactic acid Drugs 0.000 description 1
- 229920001320 Leader sequence (mRNA) Polymers 0.000 description 1
- 229940067606 Lecithin Drugs 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 229960004488 Linolenic Acid Drugs 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 210000001165 Lymph Nodes Anatomy 0.000 description 1
- 102100000918 MAPK14 Human genes 0.000 description 1
- 108060004828 MGMT Proteins 0.000 description 1
- 210000002540 Macrophages Anatomy 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L Magnesium hydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 1
- 230000035633 Metabolized Effects 0.000 description 1
- 240000004841 Meum athamanticum Species 0.000 description 1
- 210000003632 Microfilaments Anatomy 0.000 description 1
- 210000004688 Microtubules Anatomy 0.000 description 1
- 102000028664 Microtubules Human genes 0.000 description 1
- 108091022031 Microtubules Proteins 0.000 description 1
- 210000000214 Mouth Anatomy 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-Acetylglucosamine Chemical class CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- QNILTEGFHQSKFF-UHFFFAOYSA-N N-propan-2-ylprop-2-enamide Chemical compound CC(C)NC(=O)C=C QNILTEGFHQSKFF-UHFFFAOYSA-N 0.000 description 1
- 102100015978 NPY Human genes 0.000 description 1
- 108020001430 NPY Proteins 0.000 description 1
- 101700080605 NUC1 Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N Norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- SBQLYHNEIUGQKH-UHFFFAOYSA-N Omeprazole Chemical compound N1=C2[CH]C(OC)=CC=C2N=C1S(=O)CC1=NC=C(C)C(OC)=C1C SBQLYHNEIUGQKH-UHFFFAOYSA-N 0.000 description 1
- 229960003104 Ornithine Drugs 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 210000004681 Ovum Anatomy 0.000 description 1
- 101710038792 PALG1 Proteins 0.000 description 1
- 239000007990 PIPES buffer Substances 0.000 description 1
- 108060006601 PRM1 Proteins 0.000 description 1
- 101700008337 PSMA Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 108091005771 Peptidases Proteins 0.000 description 1
- 108010009711 Phalloidine Proteins 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Chemical compound C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N Phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- 230000036855 Plasma AUC Effects 0.000 description 1
- 241000232219 Platanista Species 0.000 description 1
- 229920001363 Polidocanol Polymers 0.000 description 1
- 241001272996 Polyphylla fullo Species 0.000 description 1
- RKCAIXNGYQCCAL-UHFFFAOYSA-N Porphin Chemical compound N1C(C=C2N=C(C=C3NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 RKCAIXNGYQCCAL-UHFFFAOYSA-N 0.000 description 1
- 235000002343 Primula veris Nutrition 0.000 description 1
- 235000016311 Primula vulgaris Nutrition 0.000 description 1
- 240000003122 Primula vulgaris Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 235000011158 Prunus mume Nutrition 0.000 description 1
- 240000002546 Prunus mume Species 0.000 description 1
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N Psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 102000007615 Pulmonary Surfactant-Associated Protein A Human genes 0.000 description 1
- 108010007100 Pulmonary Surfactant-Associated Protein A Proteins 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 229960003581 Pyridoxal Drugs 0.000 description 1
- 108010066717 Q beta Replicase Proteins 0.000 description 1
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 description 1
- 241001016380 Reseda luteola Species 0.000 description 1
- 206010038776 Retching Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 229960002477 Riboflavin Drugs 0.000 description 1
- AUNGANRZJHBGPY-OUCADQQQSA-N Riboflavin Natural products OC[C@@H](O)[C@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-OUCADQQQSA-N 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 229910020008 S(O) Inorganic materials 0.000 description 1
- 101700075376 SUS3 Proteins 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 235000002912 Salvia officinalis Nutrition 0.000 description 1
- 229910052772 Samarium Inorganic materials 0.000 description 1
- 210000003497 Sciatic Nerve Anatomy 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 230000037165 Serum Concentration Effects 0.000 description 1
- 235000015076 Shorea robusta Nutrition 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 229960000553 Somatostatin Drugs 0.000 description 1
- 240000005558 Sorbus aucuparia Species 0.000 description 1
- 210000000273 Spinal Nerve Roots Anatomy 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 210000002784 Stomach Anatomy 0.000 description 1
- 229960005322 Streptomycin Drugs 0.000 description 1
- 241000272534 Struthio camelus Species 0.000 description 1
- 241000251576 Styela clava Species 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- 241000282890 Sus Species 0.000 description 1
- 241001414851 Susana Species 0.000 description 1
- RJVBVECTCMRNFG-BDRNLNPRSA-N Swinholide A Chemical compound C1C(OC)CC(C)OC1CCC(C)C(O)C(C)C1C(C)C(O)CC(O)C(C)C(OC)CC(CC=C2)OC2CC(O)C/C=C(\C)/C=C/C(=O)OC(C(C)C(O)C(C)CCC2OC(C)CC(C2)OC)C(C)C(O)CC(O)C(C)C(OC)CC(CC=C2)OC2CC(O)C/C=C(\C)/C=C/C(=O)O1 RJVBVECTCMRNFG-BDRNLNPRSA-N 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 101710040537 TNF Proteins 0.000 description 1
- 108060008443 TPPP Proteins 0.000 description 1
- UMGDCJDMYOKAJW-UHFFFAOYSA-N Thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 1
- 229920000401 Three prime untranslated region Polymers 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 229940104230 Thymidine Drugs 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine Kinase Proteins 0.000 description 1
- 229940113082 Thymine Drugs 0.000 description 1
- 210000001541 Thymus Gland Anatomy 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 229940035626 Thyrotropin Class in ATC Drugs 0.000 description 1
- 229940116362 Tragacanth Drugs 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- STCOOQWBFONSKY-UHFFFAOYSA-N Tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N Trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- 229940117972 Triolein Drugs 0.000 description 1
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010068760 Ulcers Diseases 0.000 description 1
- 206010046566 Urinary tract disease Diseases 0.000 description 1
- 102100015249 VEGFA Human genes 0.000 description 1
- 101700072561 VM2T Proteins 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 229940088594 Vitamin Drugs 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- ISXSJGHXHUZXNF-LXZPIJOJSA-N [(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] N-[2-(dimethylamino)ethyl]carbamate;hydrochloride Chemical compound Cl.C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 ISXSJGHXHUZXNF-LXZPIJOJSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000004847 absorption spectroscopy Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- XVIYCJDWYLJQBG-UHFFFAOYSA-N acetic acid;adamantane Chemical compound CC(O)=O.C1C(C2)CC3CC1CC2C3 XVIYCJDWYLJQBG-UHFFFAOYSA-N 0.000 description 1
- 125000000641 acridinyl group Chemical class C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000003213 activating Effects 0.000 description 1
- 230000003044 adaptive Effects 0.000 description 1
- 239000004479 aerosol dispenser Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- PPQRONHOSHZGFQ-LMVFSUKVSA-N aldehydo-D-ribose 5-phosphate Chemical group OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PPQRONHOSHZGFQ-LMVFSUKVSA-N 0.000 description 1
- 230000002152 alkylating Effects 0.000 description 1
- 230000000172 allergic Effects 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 229960003473 androstanolone Drugs 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000001396 anti-anti-diuretic Effects 0.000 description 1
- 230000000844 anti-bacterial Effects 0.000 description 1
- 230000000840 anti-viral Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 235000006350 apichu Nutrition 0.000 description 1
- 102000005427 asialoglycoprotein receptor family Human genes 0.000 description 1
- 108010006523 asialoglycoprotein receptor family Proteins 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 108010016341 bactenecin Proteins 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical class [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 235000021324 borage oil Nutrition 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000020221 chamomile extract Nutrition 0.000 description 1
- 108050000299 chemokine receptors Proteins 0.000 description 1
- 102000009410 chemokine receptors Human genes 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 125000003346 cobalamin group Chemical group 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 239000005289 controlled pore glass Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 230000003111 delayed Effects 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- SNQXJPARXFUULZ-UHFFFAOYSA-N dioxolane Chemical compound C1COOC1 SNQXJPARXFUULZ-UHFFFAOYSA-N 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229950008597 drug INN Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 201000006044 dystransthyretinemic hyperthyroxinemia Diseases 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000002895 emetic Substances 0.000 description 1
- 101710017880 emm5 Proteins 0.000 description 1
- 230000003511 endothelial Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000002538 fungal Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 101700064335 gatY Proteins 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000005908 glyceryl ester group Chemical group 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 125000000267 glycino group Chemical group [H]N([*])C([H])([H])C(=O)O[H] 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical class OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000005842 heteroatoms Chemical group 0.000 description 1
- 238000010842 high-capacity cDNA reverse transcription kit Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 101700079842 hmeD Proteins 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 230000002055 immunohistochemical Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000266 injurious Effects 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 230000000968 intestinal Effects 0.000 description 1
- 238000000185 intracerebroventricular Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 101700078814 kbaY Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Chemical class 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 101710017890 large T Proteins 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 238000007834 ligase chain reaction Methods 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 125000002960 margaryl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 108091005593 modified peptides Proteins 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 229940074096 monoolein Drugs 0.000 description 1
- 235000013919 monopotassium glutamate Nutrition 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atoms Chemical group N* 0.000 description 1
- QTNLALDFXILRQO-UHFFFAOYSA-N nonadecane-1,2,3-triol Chemical compound CCCCCCCCCCCCCCCCC(O)C(O)CO QTNLALDFXILRQO-UHFFFAOYSA-N 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 101700006494 nucA Proteins 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- KREXGRSOTUKPLX-UHFFFAOYSA-N octadecanoic acid;zinc Chemical compound [Zn].CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O KREXGRSOTUKPLX-UHFFFAOYSA-N 0.000 description 1
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic Effects 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000004430 oxygen atoms Chemical group O* 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000863 peptide conjugate Substances 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- KPKZJLCSROULON-QKGLWVMZSA-N phalloidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C)NC(=O)[C@H](C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KPKZJLCSROULON-QKGLWVMZSA-N 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 238000005731 phosphitylation reaction Methods 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000000649 photocoagulation Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229960002226 polidocanol Drugs 0.000 description 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 108010064470 polyaspartate Proteins 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920002851 polycationic polymer Polymers 0.000 description 1
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 1
- 229920001601 polyetherimide Polymers 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 230000001737 promoting Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000036678 protein binding Effects 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 230000002685 pulmonary Effects 0.000 description 1
- 125000004219 purine nucleobase group Chemical group 0.000 description 1
- 239000002213 purine nucleotide Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 235000008164 pyridoxal Nutrition 0.000 description 1
- 239000011674 pyridoxal Substances 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 229910052761 rare earth metal Inorganic materials 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 229910052702 rhenium Inorganic materials 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 239000001296 salvia officinalis l. Substances 0.000 description 1
- COFLCBMDHTVQRA-UHFFFAOYSA-N sapphyrin Chemical compound N1C(C=2NC(C=C3N=C(C=C4NC(=C5)C=C4)C=C3)=CC=2)=CC=C1C=C1C=CC5=N1 COFLCBMDHTVQRA-UHFFFAOYSA-N 0.000 description 1
- 230000001953 sensory Effects 0.000 description 1
- 235000006414 serbal de cazadores Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000010865 sewage Substances 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 101710004799 sm-amp-x Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003445 sucroses Chemical class 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical compound OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 125000004434 sulfur atoms Chemical group 0.000 description 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N sulfur dioxide Inorganic materials O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
- 230000000576 supplementary Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 201000010874 syndrome Diseases 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 101700042113 tap Proteins 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 229960000874 thyrotropin Drugs 0.000 description 1
- 230000001748 thyrotropin Effects 0.000 description 1
- 101700031394 todF Proteins 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 230000002103 transcriptional Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 150000007971 urates Chemical class 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- KJZMZIMBDAXZCX-XNRWUJQLSA-N α-D-Manp-(1->3)-[α-D-Manp-(1->6)]-α-D-Manp Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](O)O1 KJZMZIMBDAXZCX-XNRWUJQLSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- SFVVQRJOGUKCEG-OPQSFPLASA-N β-MSH Chemical compound C1C[C@@H](O)[C@H]2C(COC(=O)[C@@](O)([C@@H](C)O)C(C)C)=CCN21 SFVVQRJOGUKCEG-OPQSFPLASA-N 0.000 description 1
- 239000002478 γ-tocopherol Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Abstract
Disclosed are double stranded RNAi agents comprising a sense strand complementary to an antisense strand, wherein said antisense strand comprises a sequence that is complementary to nucleotides 504 to 526 of the transthyretin (TTR) gene (SEQ ID NO:1), wherein the sense strand is 21 nucleotides in length and 5 the antisense strand is 23 nucleotides in length and wherein said RNAi agents comprise one or more motifs of three identical modifications on three consecutive nucleotides in one or both strands, including one such motif at or near the cleavage site of the agents. The invention also provides for the use of said RNAi agents for the manufacture of a medicament for treating a TTR-associated disease in a subject. ngth and 5 the antisense strand is 23 nucleotides in length and wherein said RNAi agents comprise one or more motifs of three identical modifications on three consecutive nucleotides in one or both strands, including one such motif at or near the cleavage site of the agents. The invention also provides for the use of said RNAi agents for the manufacture of a medicament for treating a TTR-associated disease in a subject.
Description
RNAi AGENTS, COMPOSITIONS AND METHODS OF USE THEREOF FOR
NG TRANSTHYRETIN {TTR} ASSOCIATED DISEASES
Related Applications
This ation claims priority to US. Provisional Application No. 61/561,710,
filed on November 18, 2011, US. Provisional Application No. 61/615,618, filed on
March 26, 2012, and US. ional Application No. ,098, filed on August 6,
2012, the entire contents of each of which are hereby orated herein by reference.
10 Seguence Listing
The instant application contains a Sequence Listing which has been submitted in
ASCII format Via EFS—Web and is hereby incorporated by reference in its entirety. Said
ASCII copy, created on November 13, 2012, is named 121301WO.txt and is 541,508
bytes in size.
15
Background of the Invention
Transthyretin (TTR) (also known as prealbumin) is found in serum and
cerebrospinal fluid (CSF). TTR transports retinol—binding protein (RBP) and thyroxine
(T4) and also acts as a carrier of retinol (vitamin A) through its association with RBP in
20 the blood and the CSF. Transthyretin is named for its transport of thyroxine and
retinol. TTR also functions as a protease and can cleave proteins including apoA-I (the
major HDL apolipoprotein), amyloid B—peptide, and neuropeptide Y. See Liz, MA. et
al. (2010) IUBMB Life, 62(6):429—435.
TTR is a tetramer of four identical 127—amino acid subunits (monomers) that are
25 rich in beta sheet structure. Each r has two 4—stranded beta sheets and the shape
of a prolate ellipsoid. Antiparallel beta—sheet interactions link monomers into dimers. A
short loop from each monomer forms the main dimer—dimer ction. These two pairs
of loops te the opposed, convex heets of the dimers to form an internal
channel.
W0 2013,:‘075035 PCT/U82012/065691
The liver is the major site of TTR sion. Other significant sites of
expression include the choroid plexus, retina (particularly the l pigment
epithelium) and pancreas.
Transthyretin is one of at least 27 distinct types of proteins that is a precursor
protein in the formation of amyloid fibrils. See Guan, J. et al. (Nov. 4, 2011) Current
perspectives on c amyloidosis, Am J Physiol Heart Circ Physiol,
doi:10.1 152/ajpheart.00815.2011. Extracellular deposition of amyloid fibrils in organs
and tissues is the hallmark of amyloidosis. Amyloid fibrils are composed of misfolded
protein aggregates, which may result from either excess production of or specific
10 mutations in precursor proteins. The amyloidogenic potential of TTR may be related to
its extensive beta sheet structure; X—ray crystallographic studies indicate that n
amyloidogenic mutations destabilize the tetrameric structure of the n. See, e.g.,
Saraiva M.J.M. (2002) Expert Reviews in Molecular Medicine, 4(12):1—1 1.
Amyloidosis is a general term for the group of amyloid diseases that are
15 characterized by amyloid deposits. Amyloid diseases are classified based on their
precursor protein; for example, the name starts with “A” for amyloid and is followed by
an iation of the precursor protein, e.g., ATTR for ogenic transthyretin.
Ibid.
There are numerous TTR—associated diseases, most of which are d
20 diseases. Normal—sequence TTR is associated with cardiac amyloidosis in people who
are elderly and is termed senile systemic amyloidosis (SSA) (also called senile cardiac
amyloidosis (SCA) or cardiac amyloidosis). SSA often is accompanied by microscopic
deposits in many other organs. TTR amyloidosis sts in various forms. When the
peripheral nervous system is affected more prominently, the disease is termed familial
25 amyloidotic polyneuropathy (FAP). When the heart is primarily involved but the
s system is not, the e is called familial amyloidotic cardiomyopathy (FAC).
A third major type of TTR amyloidosis is leptomeningeal amyloidosis, also known as
leptomeningeal or meningocerebrovascular amyloidosis, central nervous system (CNS)
amyloidosis, or dosis VII form. Mutations in TTR may also cause amyloidotic
30 vitreous opacities, carpal tunnel syndrome, and euthyroid hyperthyroxinemia, which is a
yloidotic disease thought to be secondary to an increased association of
W0 2013,:‘075035 PCT/U82012/065691
ine with TTR due to a mutant TTR molecule with increased affinity for thyroxine.
See, e.g., Moses et al. (1982) J. Clin. Invest, 86, 2025-2033.
Abnormal amyloidogenic proteins may be either inherited or acquired through
somatic mutations. Guan, J. et al. (Nov. 4, 2011) Current perspectives on cardiac
amyloidosis, Am J Physiol Heart Circ Physiol, doi:10.l152/ajpheart.00815.2011.
Transthyretin associated ATTR is the most nt form of hereditary systemic
amyloidosis. Lobato, L. (2003) J. Nephrol., 16:438—442. TTR mutations accelerate the
process of TTR amyloid formation and are the mo st important risk factor for the
development of ATTR. More than 85 dogenic TTR variants are known to cause
10 systemic familial amyloidosis. TTR mutations usually give rise to systemic amyloid
tion, with particular involvement of the peripheral nervous system, although some
mutations are associated with myopathy or Vitreous opacities. Ibid.
The V30M mutation is the most prevalent TTR mutation. See, e.3., Lobato, L.
(2003) J Nephrol, 16:438—442. The V1221 mutation is carried by 3.9% of the African
15 American population and is the most common cause of FAC. Jacobson, D.R. et al.
(1997) N. Engl. J. Med. 336 (7): 466—73. It is estimated that SSA affects more than 25%
of the population over age 80. Westermark, P. et al. (1990) Proc. Natl. Acad. Sci. USA.
87 (7): 2843—5.
Accordingly, there is a need in the art for effective treatments for TTR—associated
20 diseases.
Summary of the Invention
The t invention provides RNAi agents, e. g., double stranded RNAi agents,
targeting the Transthyretin (TTR) gene. The present ion also provides methods of
25 inhibiting expression of TTR and methods of treating or preventing a TTR—associated
disease in a subject using the RNAi agents, e. g. double ed RNAi agents, of the
ion. The present invention is based, at least in part, on the discovery that RNAi
agents that comprise particular chemical cations show a superior ability to inhibit
expression of TTR. Agents including a certain pattern of chemical modifications (e. 57.,
30 an alternating pattern) and a ligand are shown herein to be effective in ing the
activity of the TTR gene. Furthermore, agents including one or more motifs of three
W0 2013.:‘075035 PCT/U82012/065691
identical cations on three consecutive nucleotides, including one such motif at or
near the cleavage site of the agents, show surprisingly enhanced TTR gene silencing
activity. When a single such chemical motif is present in the agent, it is red to be
at or near the cleavage region for enhancing of the gene silencing ty. ge
region is the region surrounding the cleavage site, i.e., the site on the target mRNA at
which cleavage occurs.
Accordingly, in one aspect, the t invention features RNAi agents, e. g.,
double stranded RNAi agents, for inhibiting expression of a transthyretin (TTR). The
double ed RNAi agent includes a sense strand complementary to an antisense
10 strand. The antisense strand includes a region complementary to a part of an mRNA
encoding transthyretin. Each strand has 14 to 30 nucleotides, and the double ed
RNAi agent is represented by formula (III):
sense: 5' np -Na -(X X X) i-Nb -Y Y Y -Nb -(Z Z Z)j —Na — nCl 3'
antisense: 3' np'—Na'—(X'X’X’)k—Nb’—Y'Y’Y’—Nb’—(Z’Z’Z’)1—Na'— nq' 5'
15 (III).
In Formula III, i, j, k, and 1 are each independently 0 or 1; p, p’, q, and q' are each
independently 0—6; each Na and Na’ independently represents an oligonucleotide
sequence including 0—25 nucleotides which are either modified or unmodified or
combinations thereof, each sequence including at least two differently ed
20 nucleotides; each Nb and Nb’ independently represents an oligonucleotide sequence
including 0—10 nucleotides which are either modified or unmodified or combinations
thereof; each np, np', nq, and nq’ independently represents an ng nucleotide; XXX,
YYY, ZZZ, X’X'X', Y'Y'Y', and Z'Z'Z’ each independently represents one motif of three
identical modifications on three consecutive nucleotides; modifications on Nb differ
25 from the modification on Y and modifications on Nb’ differ from the modification on Y’.
In some embodiments, the sense strand is conjugated to at least one ligand, e.g., at least
one ligand, e.g., at least one ligand attached to the 3’ end of the sense strand. In other
embodiments, the ligand may be conjugated to the antisense strand.
In some embodiments, i is l;j is 1; or both i andj are 1.
30 In some embodiments, k is 1; 1 is 1; or both k and 1 are 1.
In some embodiments, i is 0; j is 1.
In some embodiments, i is 1, j is 0.
In some embodiments, k is 0; l is 1.
In some embodiments, k is 1; l is 0.
2F"KGE?"?E<G>CE?FLK&"777"CK"=GEHD?E?FL;JO"LG"7P7P7P&"888"CK"-"
=GEHD?E?FL;JO"LG"8P8P8P&";F>"999"CK"=GEHD?E?FL;JO"LG"9P9P9P("
In some embodiments, the YYY motif occurs at or near the cleavage site of the
sense strand.
2F"KGE?"?E<G>CE?FLK&"LB?"8P8P8P"EGLC@"G==MJK";L"LB?"**&"*+";F>"*,"HGKCLCGFK"G@"
10 the antisense strand from the 5'-end.
2F"KGE?"?E<G>CE?FLK&"LB?"8P"CK"+P'5'E?LBOD("
In some embodiments, the Y’ is 2’-fluoro.
In another aspect, the present invention es a double stranded RNAi agent
comprising a sense strand complementary to an antisense strand, n said antisense
15 strand ses a sequence that is complementary to nucleotides 504 to 526 of the
transthyretin (TTR) gene (SEQ ID NO:1), wherein the sense strand is 21 nucleotides in
length and the antisense strand is 23 nucleotides in length, wherein said double stranded
RNAi agent is represented by formula (III):
sense: 5' np -Na -(X X X)i-Nb -Y Y Y -Nb -(Z Z Z)j -Na - nq 3'
antisense: 3' npP'4aP'$7P7P7P%k-NbP'8P8P8P'4bP'$9P9P9P%l-NaP'"FqP"-#"+)"
(III)
wherein:
j = 1; and i, k, and l are 0;
p’ is 2; p, q, and q’ are 0;
each Na and NaP"CF>?H?F>?FLDO"J?HJ?K?FLK";F"GDCAGFM=D?GLC>?"K?IM?F=?"+-"
sing 2-10 nucleotides which are modified nucleotides;
each Nb and NbP"CF>?H?F>?FLDO"J?HJ?K?FLK";F"GDCAGFM=D?GLC>?"K?IM?F=?"
comprising 0-7 nucleotides which are ed nucleotides;
5
npP"J?HJ?K?FLK";F"GN?JB;FA"FM=D?GLC>?."
" 888&"999&";F>"8P8P8P&"?;=B"CF>?H?F>?FLDO"J?HJ?K?FL"GF?"EGLC@"G@"LBJ??"
identical modifications on three utive nucleotides, wherein the Y nucleotides
contain a 2’-fluoro modification, the Y’ nucleotides contain a 2’-O-methyl modification,
5 and the Z nucleotides contain a 2’-O-methyl cation; and
wherein the sense strand is ated to at least one ligand, wherein the
ligand is one or more GalNAc derivatives attached through a bivalent or trivalent
branched linker.
In some embodiments, a (III) is represented as formula (IIIa):
10 sense: 5' np -Na -Y Y Y -Nb -Z Z Z -Na-nq 3'
antisense: 3' npP'4aP'8P8P8P'4bP'9P9P9P'4aPFqP"-#""
(IIIa).
In formula IIIa, each Nb and Nb" independently represents an oligonucleotide sequence
ing 1-5 ed nucleotides.
15 In some embodiments, formula (III) is represented as formula (IIIb):
sense: 5' np-Na-X X X -Nb-Y Y Y -Na-nq 3'
antisense: 3' npP'4aP'7P7P7P'4bP'8P8P8P'4aP'FqP"-#"
(IIIb).
In formula IIIb each Nb and NbP"CF>?H?F>?FLDO"J?HJ?K?FLK";F"GDCAGFM=D?GLC>?"K?IM?F=?"
20 including 1-5 modified nucleotides.
5A
W0 ‘075035 PCT/U82012/065691
In some embodiments, formula (III) is represented as formula (IIIc):
sense: 5' np-Na-X X X -Nb-Y Y Y -Nb-Z Z Z -Na-ncl 3'
antisense: 3' np’—Na'-X'X'X'-Nb’-Y’Y’Y’—Nb’—Z’Z’Z’—Na’—nq’ 5'
(IIIc).
In formula IIIc, each Nb and —Nb’ independently represents an oligonucleotide sequence
including 1—5 modified nucleotides and each Na and Na’ independently represents an
oligonucleotide sequence including 2—10 modified nucleotides.
In many embodiments, the duplex region is 15—30 nucleotide pairs in length. In
some embodiments, the duplex region is 17—23 nucleotide pairs in length, 17—25
10 nucleotide pairs in length, 23—27 nucleotide pairs in length, 19-21 nucleotide pairs in
, or 21-23 tide pairs in length.
In certain embodiments, each strand has 15—30 nucleotides.
In some ments, the modifications on the nucleotides are selected from the
group ting of LNA, HNA, CeNA, 2’—methoxyethyl, 2’—O—alkyl, 2’—O—allyl, 2’—C—
15 allyl, ro, 2’—deoxy, 2’—hydroxyl, and combinations thereof. In some preferred
embodiments, the modifications on the nucleotides are 2’—O—methyl or 2’-fluoro.
In some embodiments, the ligand is one or more N—acetylgalactosamine
(GalNAc) derivatives attached through a bivalent or trivalent branched linker. In
particular embodiments, the ligand is
OH
HO
0 H H
HO O\/\/\n/N\/\/N O
AcHN
o
OH :
HO
O
O
HO o H H
AcHN \/\/\n/ \/\/ \n/\/0%“
O O
OH
HO
0
AcHN 03I2
20
W0 20132'075035 PCT/U82012/065691
In some embodiments, the ligand is ed to the 3’ end of the sense strand.
In some embodiments, the RNAi agent is ated to the ligand as shown in
the following schematic
3.
”ammo?
O=P—X
OH
0
N
o
o o o o
HO$0WE’HN’V‘N o
AcHN H
wherein X is O or S.
In some embodiments, the RNAi agent is conjugated to the ligand as shown in
the following schematic
In some embodiments, the RNAi agent further includes at least one
10 phosphorothioate or methylphosphonate internucleotide linkage. In some embodiments,
the phosphorothioate or methylphosphonate internucleotide linkage is at the 3’—terminal
of one strand. In some embodiments, the strand is the antisense strand. In other
embodiments, the strand is the sense strand.
W0 ‘075035 PCT/U82012/065691
In certain embodiments, the base pair at the 1 position of the 5’—end of the duplex
is an AU base pair.
In some embodiments, the Y nucleotides n a 2’—fluoro modification.
In some embodiments, the Y’ nucleotides contain a 2’—O—methyl modification.
In some embodiments, p’>0. In some such embodiments, each n is
complementary to the target mRNA. In other such embodiments, each n is non—
complementary to the target mRNA. In some embodiments, p, p’, q and q’ are l—6. In
some preferred embodiments, p’ = l or 2. In some preferred embodiments, p’=2. In
some such embodiments, q’=0, p20, q=0, and p’ overhang nucleotides are
10 complementary to the target mRNA. In other such ments, q’=0, p=0, q=0, and p’
overhang nucleotides are non—complementary to the target mRNA.
In some embodiments, the sense strand has a total of 21 nucleotides and the
antisense strand has a total of 23 nucleotides.
In certain embodiments, linkages between np’ include phosphorothioate linkages.
15 In some such embodiments, the linkages between np’ are phosphorothioate linkages.
In some embodiments, the RNAi agent is selected from the group of agents listed
in Table 1.
In preferred embodiments, the RNAi agent is selected from the group consisting
of AD—5 1544, AD-5 1545, AD—5 1546, and AD—51547.
20 In an even more preferred embodiment, the RNAi agent is 47 having the
following structure:
sense: 5 ’— UngfgAqufquAfogUfaachaAngfL96—3’ (SEQ ID
NO:2)
nse: 5’— quuUngfoUfaCfaugAfaAfquchasUfsc—3’ (SEQ ID
25 NO:3)
wherein lowercase nucleotides (a, u, g, c) indicate 2’-O-methyl nucleotides; Nf (e.g.,
Af) indicates a 2’-fluoro nucleotide; s indicates a phosphothiorate linkage; L96 indicates
a GalNAc3 ligand.
In another aspect, the present invention features a double stranded RNAi agent,
5 comprising a sense strand and an antisense strand, wherein the sense strand comprises
the nucleotide sequence 5’-UfgGfgAfuUfuCfAfUfgUfaacCfaAfgAfL96-3’ (SEQ ID
NO:2) and the antisense strand comprises the nucleotide sequence 5’-
uCfuUfgGfUfUfaCfaugAfaAfuCfcCfasUfsc-3’ (SEQ ID NO:3), wherein a, g, c, and u
;J?"+P'5'E?LBOD"$+P'53?%"/&"1&"0&";F>"6.""/@&"1@&"0@&";F>"6@";J?"+P'@DMGJG"/&"1&"0&";F>"
10 U; s is a phosphorothioate e; and L96 is a GalNAc3 ligand.
In another aspect, the present invention features a cell containing the RNAi
agent for inhibiting expression of TTR.
In a further aspect, the present invention features a pharmaceutical ition
sing an RNAi agent for inhibiting expression of TTR. In some embodiments, the
15 pharmaceutical composition is a solution comprising the RNAi agent. In some
embodiments, the solution sing the RNAi agent is an unbuffered solution, e.g.,
saline solution or water. In other embodiments, the solution is a buffered solution, e.g.,
a solution of phosphate buffered saline (PBS). In other embodiments, the
pharmaceutical composition is a liposome or a lipid formulation. In some
20 embodiments, the lipid formulation comprises a XTC or MC3.
In yet another aspect, the t invention features methods of inhibiting
expression of transthyretin (TTR) in a cell. The methods include contacting a cell with
an RNAi agent, e.g., a double stranded RNAi agent, in an amount effective to t
expression of TTR in the cell, thereby inhibiting expression of TTR in the cell.
25 In some embodiments, the sion of TTR is ted by at least about 10%,
at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least
about 60%, at least about 70%, at least about 80%, or at least about 90%.
In other ments, the cell is contacted in vitro with the RNAi agent. In
other embodiments, the cell is present within a subject. In preferred embodiments, the
30 subject is a human.
In further embodiments, the subject is a subject suffering from a TTR-associated
disease and the effective amount is a eutically effective amount. In other
9
embodiments, the subject is a subject at risk for developing a sociated disease
and the effective amount is a prophylactically effective amount. In some embodiments,
9A
W0 2013,:‘075035 PCT/U82012/065691
a subject at risk for develping a TTR—associated disease is a subject who carries a TTR
gene mutation that is associated with the development of a sociated disease.
In certain embodiments, the TTR—associated disease is selected from the group
consisting of senile systemic amyloidosis (SSA), systemic al amyloidosis, familial
amyloidotic polyneuropathy (FAP), familial amyloidotic cardiomyopathy (FAC),
leptomeningeal/Central Nervous System (CNS) amyloidosis, and hyperthyroxinemia.
In some embodiments, the t has a TTR—associated amyloidosis and the
method reduces an amyloid TTR deposit in the subject.
In other embodiments, the RNAi agent is stered to the t by an
10 administration means selected from the group ting of subcutaneous, intravenous,
intramuscular, intrabronchial, intrapleural, eritoneal, intraarterial, tic,
cerebrospinal, and any combinations thereof. In certain embodiments, the RNAi agent is
administered to the subject via subcutaneous or intravenous administration. In preferred
embodiments, the RNAi agent is administered to the subject via subcutaneous
15 administration. In some such embodiments, the subcutaneous administration includes
administration via a subcutaneous pump or subcutaneous depot.
In certain embodiments, the RNAi agent is administered to the subject such that
the RNAi agent is delivered to a specific site within the subject. In some embodiments,
the site is selected from the group consisting of liver, choroid , retina, and
20 pancreas. In preferred embodiments, the site is the liver. In some embodiments, the
delivery of the RNAi agent is mediated by asialoglycoprotein or (ASGP—R)
present in hepatocytes.
In some embodiments, the RNAi agent is administered at a dose of between
about 0.25 mg/kg to about 50 mg/kg, 6.57., between about 0.25 mg/kg to about 0.5
25 mg/kg, between about 0.25 mg/kg to about 1 mg/kg, between about 0.25 mg/kg to about
5 mg/kg, between about 0.25 mg/kg to about 10 mg/kg, between about 1 mg/kg to about
10 mg/kg, between about 5 mg/kg to about 15 mg/kg, between about 10 mg/kg to about
20 mg/kg, between about 15 mg/kg to about 25 mg/kg, between about 20 mg/kg to about
10
W0 2013,:‘075035 PCT/US2012/065691
30 mg/kg, between about 25 mg/kg to about 35 mg/kg, or between about 40 mg/kg to
about 50 mg/kg.
In some embodiments, the RNAi agent is administered at a dose of about 0.25
mg/kg, about 0.5 mg/kg, about 1 mg/kg, about 2 mg/kg, about 3 mg/kg, about 4 mg/kg,
about 5 mg/kg, about 6 mg/kg, about 7 mg/kg, about 8 mg/kg, about 9 mg/kg, about 10
mg/kg, about 11 mg/kg, about 12 mg/kg, about 13 mg/kg, about 14 mg/kg, about 15
mg/kg, about 16 mg/kg, about 17 mg/kg, about 18 mg/kg, about 19 mg/kg, about 20
mg/kg, about 21 mg/kg, about 22 mg/kg, about 23 mg/kg, about 24 mg/kg, about 25
mg/kg, about 26 mg/kg, about 27 mg/kg, about 28 mg/kg, about 29 mg/kg, 30 mg/kg,
10 about 31 mg/kg, about 32 mg/kg, about 33 mg/kg, about 34 mg/kg, about 35 mg/kg,
about 36 mg/kg, about 37 mg/kg, about 38 mg/kg, about 39 mg/kg, about 40 mg/kg,
about 41 mg/kg, about 42 mg/kg, about 43 mg/kg, about 44 mg/kg, about 45 mg/kg,
about 46 mg/kg, about 47 mg/kg, about 48 mg/kg, about 49 mg/kg or about 50 mg/kg.
15 In some ments, the RNAi agent is administered in two or more doses. In
particular embodiments, the RNAi agent is administered at intervals selected from the
group consisting of once every about 2 hours, once every about 3 hours, once every
about 4 hours, once every about 6 hours, once every about 8 hours, once every about 12
hours, once every about 24 hours, once every about 48 hours, once every about 72 hours,
20 once every about 96 hours, once every about 120 hours, once every about 144 hours,
once every about 168 hours, once every about 240 hours, once every about 336 hours,
once every about 504 hours, once every about 672 hours and once every about 720
hours.
In other embodiments, the method further includes assessing the level of TTR
25 mRNA expression or TTR protein expression in a sample d from the subject.
In red embodiments, administering the RNAi agent does not result in an
inflammatory response in the subject as assessed based on the level of a cytokine or
chemokine selected from the group ting of G—CSF, IFN—y, IL—10, IL—12 (p70),
ILlB, IL—lra, IL—6, IL—8, IP—10, MCP—l, MIP—lot, MIP—lB, TNFa, and any combinations
30 thereof, in a sample from the subject.
11
W0 2013,:‘075035 PCT/U82012/065691
In some embodiments, the RNAi agent is administered using a pharmaceutical
composition
In preferred embodiments, the RNAi agent is administered in a solution. In some
such embodiments, the siRNA is administered in an unbuffered solution. In one
embodiment, the siRNA is administered in water. In other ments, the siRNA is
administered with a buffer solution, such as an acetate buffer, a citrate buffer, a
prolamine buffer, a carbonate buffer, or a phosphate buffer or any ation thereof.
In some embodiments, the buffer solution is phosphate buffered saline (PBS).
In another embodiment, the pharmaceutical ition is a liposome or a lipid
10 formulation comprising SNALP or XTC. In one embodiment, the lipid formulation
comprises an MC3.
In another aspect, the invention provides s of ng or preventing a
TTR—associated disease in a subject. The methods e administering to the subject a
therapeutically ive amount or prophylactically effective amount of an RNAi agent,
15 e. g., a double ed RNAi agent, thereby treating or preventing the TTR—associated
disease in the subject.
In some embodiments, TTR expression in a sample derived from the subject is
inhibited by at least about 10%, at least about 20%, at least about 30%, at least about
40%, at least about 50%, at least about 60% or at least about 70% at least about 80%, or
20 at least about 90%.
In some ments, the subject is a human.
In some embodiments, the subject is a subject suffering from a TTR—associated
disease. In other embodiments, the subject is a subject at risk for developing a TTR—
associated disease.
25 In some embodiments, the subject is a subject who carries s a TTR gene mutation
that is associated with the development of a TTR—associated disease.
12
W0 ‘075035 PCT/U82012/065691
In certain embodiments, the sociated disease is ed from the group
consisting of senile systemic amyloidosis (SSA), systemic familial amyloidosis, familial
amyloidotic polyneuropathy (FAP), familial amyloidotic myopathy (FAC),
leptomeningeal/Central Nervous System (CNS) amyloidosis, and hyperthyroxinemia.
In some embodiments, the subject has a TTR—associated amyloidosis and the
method reduces an amyloid TTR deposit in the subject.
In some embodiments, the RNAi agent is stered to the t by an
administration means selected from the group consisting of subcutaneous, intravenous,
intramuscular, intrabronchial, intrapleural, intraperitoneal, intraarterial, lymphatic,
10 cerebrospinal, and any combinations thereof. In certain ments, the RNAi agent is
administered to the subject via subcutaneous or intravenous administration. In preferred
embodiments, the RNAi agent is administered to the subject via subcutaneous
administration. In some such embodiments, the subcutaneous stration includes
administration via a subcutaneous pump or subcutaneous depot.
15 In certain embodiments, the RNAi agent is administered to the subject such that
the RNAi agent is delivered to a specific site within the subject. In some such
embodiments, the site is selected from the group consisting of liver, d plexus,
retina, and as. In preferred embodiments, the site is the liver. In some
embodiments, the delivery of the RNAi agent is mediated by asialoglycoprotein receptor
20 (ASGP-R) present in hepatocytes.
In some embodiments, the RNAi agent is administered at a dose of between
about 0.25 mg/kg to about 50 mg/kg, 6.57., between about 0.25 mg/kg to about 0.5
mg/kg, between about 0.25 mg/kg to about 1 mg/kg, between about 0.25 mg/kg to about
5 mg/kg, between about 0.25 mg/kg to about 10 mg/kg, between about 1 mg/kg to about
25 10 mg/kg, between about 5 mg/kg to about 15 mg/kg, between about 10 mg/kg to about
20 mg/kg, between about 15 mg/kg to about 25 mg/kg, between about 20 mg/kg to about
30 mg/kg, between about 25 mg/kg to about 35 mg/kg, or between about 40 mg/kg to
about 50 mg/kg.
13
W0 2013,:‘075035 PCT/US2012/065691
In some embodiments, the RNAi agent is stered at a dose of about 0.25
mg/kg, about 0.5 mg/kg, about 1 mg/kg, about 2 mg/kg, about 3 mg/kg, about 4 mg/kg,
about 5 mg/kg, about 6 mg/kg, about 7 mg/kg, about 8 mg/kg, about 9 mg/kg, about 10
mg/kg, about 11 mg/kg, about 12 mg/kg, about 13 mg/kg, about 14 mg/kg, about 15
mg/kg, about 16 mg/kg, about 17 mg/kg, about 18 mg/kg, about 19 mg/kg, about 20
mg/kg, about 21 mg/kg, about 22 mg/kg, about 23 mg/kg, about 24 mg/kg, about 25
mg/kg, about 26 mg/kg, about 27 mg/kg, about 28 mg/kg, about 29 mg/kg, 30 mg/kg,
about 31 mg/kg, about 32 mg/kg, about 33 mg/kg, about 34 mg/kg, about 35 mg/kg,
about 36 mg/kg, about 37 mg/kg, about 38 mg/kg, about 39 mg/kg, about 40 mg/kg,
10 about 41 mg/kg, about 42 mg/kg, about 43 mg/kg, about 44 mg/kg, about 45 mg/kg,
about 46 mg/kg, about 47 mg/kg, about 48 mg/kg, about 49 mg/kg or about 50 mg/kg.
In some embodiments, the RNAi agent is administered in two or more doses. In
particular embodiments, the RNAi agent is administered at intervals selected from the
group consisting of once every about 2 hours, once every about 3 hours, once every
15 about 4 hours, once every about 6 hours, once every about 8 hours, once every about 12
hours, once every about 24 hours, once every about 48 hours, once every about 72 hours,
once every about 96 hours, once every about 120 hours, once every about 144 hours,
once every about 168 hours, once every about 240 hours, once every about 336 hours,
once every about 504 hours, once every about 672 hours and once every about 720
20 hours.
In other embodiments, the method further includes assessing the level of TTR
mRNA sion or TTR protein expression in a sample derived from the subject.
In preferred embodiments, administering the RNAi agent does not result in an
inflammatory response in the subject as assessed based on the level of a cytokine or
25 chemokine selected from the group consisting of G—CSF, IFN—y, IL—10, IL—12 (p70),
ILIB, IL—lra, IL—6, IL—8, IP—10, MCP—l, MIP—la, , TNFu, and any combinations
thereof, in a sample from the subject.
In some embodiments, the RNAi agent is administered using a pharmaceutical
ition, e.g., a liposome.
14
W0 2013,:‘075035 PCT/U82012/065691
In some embodiments, the RNAi agent is administered in a solution. In some
such embodiments, the siRNA is administered in an unbuffered on. In one
embodiment, the siRNA is administered in saline or water. In other embodiments, the
siRNA is administred with a buffer solution, such as an acetate buffer, a citrate buffer, a
ine , a carbonate buffer, or a phosphate buffer or any combination thereof.
In some embodiments, the buffer solution is phosphate buffered saline (PBS).
In another aspect, the present invention es a method of inhibiting
expression of transthyretin (TTR) in a cell, including contacting a cell with an RNAi
agent, e. g., a double stranded RNAi agent, in an amount effective to inhibit expression
10 of TTR in the cell. In one aspect, the double ed RNAi agent is ed from the
group of agents listed in Table 1, thereby inhibiting expression of transthyretin (TTR) in
the cell.
In r , the present invention provides a method of inhibiting
expression of transthyretin (TTR) in a cell, including contacting a cell with an RNAi
15 agent, e. g., a double stranded RNAi agent, in an amount effective to inhibit expression
of TTR in the cell. In one aspect, the double stranded RNAi agent is selected from the
group consisting of AD—51544, AD—51545, AD—S 1546, and AD—51547, thereby
inhibiting expression of transthyretin (TTR) in the cell.
In a further aspect, the present invention provides a method of treating or
20 preventing a TTR-associated disease in a subject, including administering to the subject
a therapeutically ive amount or a prophylactically effective amount of an RNAi
agent, e. g., a double stranded RNAi agent. In one aspect, the double stranded RNAi
agent is ed from the group of agents listed in Table 1, thereby treating or
preventing a TTR—associated disease in the subject.
25 In yet another aspect, the present invention provides a method of treating or
preventing a TTR—associated e in a subject, including administering to the subject
a therapeutically effective amount or a prophylactically ive amount of an RNAi
agent, e. g., a double stranded RNAi agent. In one aspect, the double stranded RNAi
15
W0 ‘075035 PCT/U82012/065691
agent is selected from the group consisting of AD—51544, 45, 46, and
AD-51547, y treating or preventing a TTR-associated disease in the subject.
In further aspects, the invention provides kits for performing the methods of the
invention. In one aspect, the invention provides a kit for performing a method of
inhibiting expression of transthyretin (TTR) in a cell comprising contacting a cell with
an RNAi agent, e.g., a double stranded RNAi agent, in an amount effective to inhibit
expression of said TTR in said cell, thereby inhibiting the expression of TTR in the cell.
The kit comprises an RNAi agent and instructions for use and, optionally, means for
administering the RNAi agent to the subject.
10 The present ion is further illustrated by the following detailed description
and drawins.
Brief Description of the Drawings
Figure 1 is a graph ing that administering to mice a single subcutaneous
dose of a GalNAc—conjugated RNAi agent targeting TTR resulted in dose—dependent
15 suppression of TTR mRNA.
Figure 2 is a graph depicting that administering to mice a single subcutaneous
dose of 7.5 mg/kg or 30 mg/kg of a GalNAc conjugated RNAi agent targeting TTR
resulted in long lasting suppression of TTR mRNA.
Figure 3 depicts the human TTR mRNA sequence.
20 Figure 4 is a graph depicting ed silencing activity of RNAi agents
modified relative to the parent AD—45163.
Figure 5 is a graph depicting improved silencing activity of RNAi agents
modified relative to the parent AD—45165.
Figure 6 is a graph depicting improved free uptake ing following 4 hour
25 incubation with RNAi agents modified relative to the parent AD-45163.
16
W0 2013,:‘075035 PCT/U82012/065691
Figure 7 is a graph depicting improved free uptake silencing following 24 hour
incubation with RNAi agents ed relative to the parent AD-45163.
Figure 8 is a graph depicting improved free uptake silencing following 4 hour
incubation with RNAi agents modified relative to the parent AD—45165.
Figure 9 is a graph depicting improved free uptake silencing following 24 hour
incubation with RNAi agents modified relative to the parent AD—45165.
Figure 10 is a graph depicting silencing of TTR mRNA in transgenic mice that
express hTTR V30M following administration of a single subcutaneous dose of RNAi
agents AD—51544, 45, AD—45163, AD—51546, AD-51547, or AD—45165.
10 Figure 11 is a graph depicting TTR protein suppression in transgenic mice that
s hTTR V30M following administration of a single subcutaneous dose of 5 mg/kg
or 1mg/kg of RNAi agents AD—51544, AD—51545, or AD—45163.
Figure 12 is a graph depicting TTR protein suppression in transgenic mice that
express hTTR V30M following administration of a single subcutaneous dose of 5 mg/kg
15 or ling/kg of RNAi agents AD—51546, AD—51547, or AD—45165.
Figure 13 depicts the protocol for post—dose blood draws in s that
ed kg RNAi agent (top line) or 1x25mg/kg RNAi agent (bottom line).
Figure 14 is a graph ing suppression of TTR protein in non-human
es following subcutaneous administration of five 5 mg/kg doses (top panel) or a
20 single 25mg/kg dose (bottom panel) of AD—45163, AD—51544, AD—51545, AD-51546,
or AD—51547.
Figure 15 is a graph ing suppression of TTR protein in non—human
primates ing subcutaneous administration of AD—51547 at 2.5 mg/kg (white
squares), 5 mg/kg (black squares) or 10 mg/kg (patterned squares) per dose, or
25 administration of PBS as a negative control (gray squares).
17
W0 2013,:‘075035 PCT/U82012/065691
Detailed Description of the Invention
The present invention provides RNAi agents, e. g., double stranded RNAi agents,
and compositions targeting the Transthyretin (TTR) gene. The t invention also
provides s of ting expression of TTR and methods of treating or preventing
a TTR—associated disease in a subject using the RNAi agents, e. g., double stranded
RNAi agents, of the invention. The present invention is based, at least in part, on the
discovery that RNAi agents that comprise particular chemical modifications show a
or y to inhibit expression of TTR. Agents including a certain pattern of
chemical modifications (e.g., an alternating n) and a ligand are shown herein to be
10 effective in silencing the activity of the TTR gene. Furthermore, agents including one or
more motifs of three identical modifications on three consecutive nucleotides, including
one such motif at or near the ge site of the agents, show surprisingly enhanced
TTR gene silencing activity. When a single such chemical motif is present in the agent,
it is preferred to be at or near the cleavage region for enhancing 0f the gene silencing
15 activity. Cleavage region is the region surrounding the cleavage site, i.e., the site on the
target mRNA at which cleavage occurs.
1. tions
As used herein, each of the following terms has the meaning associated with it in
20 this section.
The term "including" is used herein to mean, and is used interchangeably with,
the phrase "including but not d to".
The term "or" is used herein to mean, and is used interchangeably with, the term
"and/0r," unless context clearly tes otherwise.
25 As used herein, a “transthyretin” (“TTR”) refers to the well known gene and
protein. TTR is also known as prealbumin, HsT2651, PALB, and TBPA. TTR
functions as a transporter of retinol—binding protein (RBP), thyroxine (T4) and retinol,
and it also acts as a se. The liver secretes TTR into the blood, and the choroid
plexus secretes TTR into the cerebrospinal fluid. TTR is also expressed in the pancreas
30 and the retinal pigment epithelium. The greatest clinical relevance of TTR is that both
18
W0 2013,:‘075035 PCT/U82012/065691
normal and mutant TTR protein can form amyloid fibrils that aggregate into
extracellular ts, causing amyloidosis. See, e.g., Saraiva M.J.M. (2002) Expert
Reviews in Molecular Medicine, 4(12):1—ll for a review. The molecular cloning and
nucleotide sequence of rat hyretin, as well as the distribution of mRNA expression,
was described by Dickson, P.W. et a1. (1985) J. Biol. Chem. 260(13)8214—8219. The X—
ray crystal ure of human TTR was described in Blake, C.C. et al. (1974) J Mol Biol
88, 1—12. The sequence of a human TTR mRNA ript can be found at National
Center for Biotechnology Information (NCBI) RefSeq accession number NM_000371.
The sequence of mouse TTR mRNA can be found at RefSeq accession number
10 NM_013697.2, and the sequence of rat TTR mRNA can be found at RefSeq accession
number 681.1
As used herein, “target sequence” refers to a contiguous portion of the nucleotide
sequence of an mRNA molecule formed during the transcription of a TTR gene,
including mRNA that is a product of RNA processing of a primary transcription product.
15 As used herein, the term d comprising a sequence” refers to an
ucleotide comprising a chain of tides that is described by the sequence
referred to using the standard nucleotide nomenclature.
"G," "C," "A" and "U" each generally stand for a nucleotide that contains
guanine, cytosine, adenine, and uracil as a base, tively. “T” and “dT” are used
20 interchangeably herein and refer to a deoxyribonucleotide wherein the nucleobase is
thymine, e.g., deoxyribothymine, 2’—deoxythymidine or thymidine. However, it will be
understood that the term “ribonucleotide” or “nucleotide” or “deoxyribonucleotide” can
also refer to a modified nucleotide, as further detailed below, or a surrogate replacement
moiety. The skilled person is well aware that guanine, cytosine, adenine, and uracil may
25 be replaced by other moieties without substantially ng the base pairing properties of
an oligonucleotide comprising a nucleotide bearing such replacement moiety. For
example, t limitation, a nucleotide comprising inosine as its base may base pair
with tides ning adenine, cytosine, or uracil. Hence, nucleotides containing
uracil, guanine, or adenine may be replaced in the nucleotide sequences of the invention
30 by a nucleotide containing, for example, inosine. Sequences comprising such
replacement moieties are ments of the invention.
19
W0 2013,:‘075035 2012/065691
A “double stranded RNAi agent,” double—stranded RNA (dsRNA) molecule, also
referred to as “dsRNA ” “dsRNA”, “siRNA”, “iRNA agent,” as used
interchangeably herein, refers to a complex of ribonucleic acid molecules, having a
duplex structure comprising two anti—parallel and substantially complementary, as
defined below, c acid strands. In general, the majority of nucleotides of each
strand are ribonucleotides, but as described in detail herein, each or both strands can also
include one or more non—ribonucleotides, e.g. a deoxyribonucleotide and/or a modified
,
tide. In addition, as used in this specification, an “RNAi agent” may include
ribonucleotides with chemical modifications; an RNAi agent may include substantial
10 modifications at multiple nucleotides. Such modifications may include all types of
modifications sed herein or known in the art. Any such modifications, as used in a
siRNA type molecule, are encompassed by “RNAi agent” for the purposes of this
specification and claims.
In r embodiment, the RNAi agent may be a single—stranded siRNA that is
15 introduced into a cell or organism to inhibit a target mRNA. Single—stranded RNAi
agents bind to the RISC endonuclease Argonaute 2, which then cleaves the target
mRNA. The single—stranded siRNAs are generally 15—30 nucleotides and are chemically
modified. The design and testing of single—stranded siRNAs are described in US. Patent
No. 8,101,348 and in Lima et al., (2012) Cell 150: 883—894, the entire contents of each
20 of which are hereby incorporated herein by reference. Any of the antisense tide
sequences described herein may be used as a single—stranded siRNA as described herein
or as chemically modified by the methods bed in Lima er al, (2012) Cell
150;:883—894.
The two strands forming the duplex ure may be different portions of one
25 larger RNA le, or they may be separate RNA molecules. Where the two strands
are part of one larger molecule, and therefore are connected by an rrupted chain of
nucleotides n the 3’—end of one strand and the 5’—end of the respective other
strand forming the duplex structure, the connecting RNA chain is referred to as a
“hairpin loop.” Where the two strands are connected covalently by means other than an
30 uninterrupted chain of nucleotides between the 3’—end of one strand and the 5’—end of
20
W0 ‘075035 PCT/U82012/065691
the respective other strand forming the duplex structure, the connecting structure is
ed to as a “linker.” The RNA strands may have the same or a ent number of
nucleotides. The maximum number of base pairs is the number of nucleotides in the
shortest strand of the dsRNA minus any overhangs that are present in the duplex. In
addition to the duplex structure, an RNAi agent may comprise one or more nucleotide
overhangs. The term ” is also used herein to refer to an RNAi agent as described
above.
In another aspect, the agent is a —stranded antisense RNA molecule. An
antisense RNA molecule is complementary to a sequence within the target mRNA.
10 Antisense RNA can inhibit translation in a stoichiometric manner by base pairing to the
mRNA and physically cting the ation machinery, see Dias, N. et al., (2002)
M0! Cancer Ther 1:347—355. The antisense RNA molecule may have about 15-30
nucleotides that are complementary to the target mRNA. For example, the antisense
RNA molecule may have a sequence of at least 15, l6, 17, 18, 19, 20 or more
15 contiguous nucleotides from one of the antisense sequences of Table 1.
As used herein, a “nucleotide overhang” refers to the unpaired nucleotide or
nucleotides that protrude from the duplex ure of an RNAi agent when a 3'—end of
one strand of the RNAi agent extends beyond the 5'—end of the other strand, or vice
versa. “Blunt” or “blunt end” means that there are no unpaired nucleotides at that end of
20 the double stranded RNAi agent, i.e., no nucleotide overhang. A “blunt ended” RNAi
agent is a dsRNA that is double—stranded over its entire length, i.e., no nucleotide
overhang at either end of the molecule. The RNAi agents of the ion include RNAi
agents with nucleotide overhangs at one end (i. (3., agents with one overhang and one
blunt end) or with tide overhangs at both ends.
25 The term “antisense strand” refers to the strand of a double stranded RNAi agent
which includes a region that is substantially complementary to a target sequence (e.g. a
,
human TTR mRNA). As used herein, the term “region complementary to part of an
mRNA encoding transthyretin” refers to a region on the antisense strand that is
substantially complementary to part of a TTR mRNA sequence. Where the region of
30 complementarity is not fully complementary to the target sequence, the mismatches are
21
W0 2013,:‘075035 PCT/U82012/065691
most tolerated in the terminal regions and, if present, are generally in a terminal region
or regions, e.g., within 6, 5, 4, 3, or 2 nucleotides of the 5’ and/or 3’ terminus.
The term “sense strand,” as used , refers to the strand of a dsRNA that
includes a region that is substantially complementary to a region of the antisense strand.
As used , the term “cleavage region” refers to a region that is located
ately adjacent to the cleavage site. The cleavage site is the site on the target at
which cleavage occurs. In some embodiments, the cleavage region comprises three
bases on either end of, and immediately adjacent to, the cleavage site. In some
embodiments, the cleavage region comprises two bases on either end of, and
10 immediately adjacent to, the cleavage site. In some embodiments, the ge site
specifically occurs at the site bound by nucleotides 10 and 11 of the antisense strand,
and the cleavage region comprises nucleotides ll, 12 and 13.
As used , and unless otherwise ted, the term “complementary,” when
used to describe a first nucleotide sequence in on to a second nucleotide sequence,
15 refers to the ability of an oligonucleotide or polynucleotide comprising the first
nucleotide sequence to hybridize and form a duplex structure under certain conditions
with an oligonucleotide or polynucleotide comprising the second nucleotide sequence, as
will be understood by the skilled person. Such conditions can, for example, be stringent
conditions, where stringent conditions may e: 400 mM NaCl, 40 mM PIPES pH
20 6.4, 1 mM EDTA, 50°C or 70°C for 12—16 hours followed by g. Other
conditions, such as physiologically relevant conditions as may be encountered inside an
organism, can apply. The skilled person will be able to determine the set of conditions
most appropriate for a test of complementarity of two ces in accordance with the
te application of the hybridized nucleotides.
25 Sequences can be “fully complementary” with respect to each when there is
base—pairing of the nucleotides of the first nucleotide sequence with the nucleotides of
the second nucleotide sequence over the entire length of the first and second nucleotide
sequences. However, where a first ce is referred to as “substantially
complementary” with respect to a second sequence herein, the two ces can be
30 fully complementary, or they may form one or more, but generally not more than 4, 3 or
2 mismatched base pairs upon hybridization, while retaining the ability to hybridize
22
W0 ‘075035 PCT/U82012/065691
under the conditions most relevant to their ultimate application. However, where two
oligonucleotides are designed to form, upon hybridization, one or more single stranded
overhangs, such overhangs shall not be regarded as mismatches with regard to the
determination of complementarity. For example, a dsRNA comprising one
ucleotide 21 nucleotides in length and another oligonucleotide 23 nucleotides in
length, wherein the longer oligonucleotide comprises a sequence of 21 tides that
is fully complementary to the r oligonucleotide, may yet be referred to as “fully
complementary” for the es described herein.
“Complementary” sequences, as used herein, may also include, or be formed
10 entirely from, non—Watson—Crick base pairs and/or base pairs formed from non—natural
and modified nucleotides, in as far as the above requirements with respect to their ability
to hybridize are led. Such non-Watson-Crick base pairs includes, but not limited
to, G:U Wobble or Hoogstein base pairing.
The terms “complementary,” “fully complementary” and “substantially
15 complementary” herein may be used with respect to the base matching between the
sense strand and the antisense strand of a dsRNA, or between the antisense strand of a
dsRNA and a target sequence, as will be understood from the context of their use.
As used herein, a polynucleotide that is “substantially complementary to at least
part of’ a messenger RNA (mRNA) refers to a polynucleotide that is substantially
20 complementary to a contiguous portion of the mRNA of interest (e.g., an mRNA
encoding TTR) including a 5’ UTR, an open g frame (ORF), or a 3’ UTR. For
example, a polynucleotide is complementary to at least a part of a TTR mRNA if the
sequence is substantially complementary to a non—interrupted portion of an mRNA
encoding TTR.
25 The term iting,” as used herein, is used hangeably with “reducing,”
“silencing,” “downregulating,77 4‘suppressing” and other similar terms, and includes any
level of tion.
The phrase “inhibiting sion of a TTR,” as used herein, includes inhibition
of expression of any TTR gene (such as, 6.57., a mouse TTR gene, a rat TTR gene, a
30 monkey TTR gene, or a human TTR gene) as well as variants or mutants of a TTR gene.
Thus, the TTR gene may be a wild—type TTR gene, a mutant TTR gene (such as a
23
W0 2013.:‘075035 PCT/US2012/065691
mutant TTR gene giving rise to systemic amyloid deposition), or a transgenic TTR gene
in the context of a genetically manipulated cell, group of cells, or organism.
“Inhibiting sion of a TTR gene” includes any level of inhibition of a TTR
gene, e.g., at least partial suppression of the expression of a TTR gene, such as an
inhibition of at least about 5%, at least about 10%, at least about 15%, at least about
20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at
least about 45%, at least about 50%, at least about 55%, at least about 60%, at least
about 65%, at least about 70%, at least about 75%, at least about 80%, at least about
85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at
10 least about 94%. at least about 95%, at least about 96%, at least about 97%, at least
about 98%, or at least about 99%.
The expression of a TTR gene may be assessed based on the level of any
variable associated with TTR gene expression, e.g., TTR mRNA level, TTR protein
level, l binding n level, vitamin A level, or the number or extent of amyloid
15 deposits. Inhibition may be assessed by a decrease in an absolute or relative level of one
or more of these variables compared with a control level. The control level may be any
type of control level that is utilized in the art, e.g., a pre—dose baseline level, or a level
ined from a similar subject, cell, or sample that is untreated or treated with a
control (such as, e.g., buffer only l or inactive agent control).
20 The phrase cting a cell with an RNAi agent,” as used herein, includes
contacting a cell by any possible means. Contacting a cell with an RNAi agent, e. g., a
double stranded RNAi agent, includes contacting a cell in vitro with the RNAi agent or
contacting a cell in vivo with the RNAi agent. The contacting may be done directly or
indirectly. Thus, for example, the RNAi agent may be put into physical contact with the
25 cell by the individual performing the , or alternatively, the RNAi agent may be
put into a ion that will permit or cause it to subsequently come into contact with the
cell.
Contacting a cell in vitro may be done, for example, by incubating the cell with
the RNAi agent. Contacting a cell in viva may be done, for example, by injecting the
30 RNAi agent into or near the tissue where the cell is located, or by injecting the RNAi
agent into another area, e.g., the bloodstream or the subcutaneous space, such that the
24
W0 2013,:‘075035 PCT/U82012/065691
agent will subsequently reach the tissue where the cell to be ted is located. For
example, the RNAi agent may contain and/or be coupled to a , e.g., a GalNA03
ligand, that directs the RNAi agent to a site of interest, e.g., the liver. Combinations of
in vitro and in viva methods of contacting are also possible. In tion with the
methods of the invention, a cell might also be ted in vitro with an RNAi agent and
subsequently transplanted into a subject.
A "patient" or "subject," as used herein, is intended to e either a human or
non—human animal, preferably a mammal, 6.57., a . Most preferably, the subject
or t is a human.
10 A “TTR—associated disease,” as used herein, is ed to include any disease
associated with the TTR gene or protein. Such a disease may be caused, for example, by
excess production of the TTR protein, by TTR gene ons, by abnormal cleavage of
the TTR protein, by abnormal interactions between TTR and other proteins or other
endogenous or ous substances. A “TTR—associated disease” includes any type of
15 TTR amyloidosis (ATTR) wherein TTR plays a role in the formation of abnormal
extracellular aggregates or amyloid deposits. TTR—associated diseases include senile
systemic amyloidosis (SSA), systemic familial dosis, familial amyloidotic
polyneuropathy (FAP), familial amyloidotic cardiomyopathy (FAC),
leptomeningeal/Central Nervous System (CNS) amyloidosis, amyloidotic Vitreous
20 opacities, carpal tunnel syndrome, and hyperthyroxinemia. Symptoms of TTR
amyloidosis include sensory neuropathy (e.g., paresthesia, hypesthesia in distal limbs),
autonomic neuropathy (e.g., gastrointestinal dysfunction, such as gastric ulcer, or
orthostatic hypotension), motor neuropathy, seizures, dementia, myelopathy,
polyneuropathy, carpal tunnel syndrome, autonomic insufficiency, cardiomyopathy,
25 Vitreous opacities, renal insufficiency, nephropathy, substantially reduced mBMI
(modified Body Mass Index), cranial nerve dysfunction, and corneal lattice dystrophy.
"Therapeutically effective amount," as used herein, is intended to include the
amount of an RNAi agent that, when administered to a patient for treating a TTR
associated disease, is sufficient to effect treatment of the disease (e.g., by diminishing,
30 rating or maintaining the existing disease or one or more symptoms of disease).
The "therapeutically effective amount" may vary depending on the RNAi agent, how the
25
W0 2013.:‘075035 PCT/U82012/065691
agent is administered, the e and its severity and the history, age, weight, family
history, genetic makeup, stage of pathological processes mediated by TTR expression,
the types of preceding or concomitant treatments, if any, and other individual
characteristics of the patient to be treated.
“Prophylactically effective amount,” as used herein, is intended to include the
amount of an RNAi agent that, when administered to a subject who does not yet
experience or display symptoms of a TTR—associated disease, but who may be
predisposed to the disease, is sufficient to prevent or ameliorate the disease or one or
more symptoms of the disease. Symptoms that may be ameliorated include sensory
10 neuropathy (e.g., paresthesia, hypesthesia in distal limbs), mic neuropathy (e.g.,
gastrointestinal dysfunction, such as c ulcer, or orthostatic nsion), motor
neuropathy, seizures, dementia, athy, uropathy, carpal tunnel me,
autonomic insufficiency, cardiomyopathy, vitreous opacities, renal insufficiency,
nephropathy, ntially reduced mBMI (modified Body Mass Index), cranial nerve
15 dysfunction, and corneal e phy. rating the disease includes slowing
the course of the disease or reducing the severity of later—developing disease. The
"prophylactically effective amount" may vary depending on the RNAi agent, how the
agent is administered, the degree of risk of disease, and the history, age, weight, family
history, genetic makeup, the types of preceding or concomitant treatments, if any, and
20 other individual characteristics of the patient to be treated.
A "therapeutically—effective amount" or “prophylacticaly effective amount” also
includes an amount of an RNAi agent that produces some desired local or systemic
effect at a reasonable benefit/risk ratio applicable to any treatment. RNAi gents
employed in the methods of the present invention may be administered in a sufficient
25 amount to produce a reasonable benefit/risk ratio applicable to such treatment.
The term “sample,” as used herein, includes a collection of similar fluids, cells,
or s isolated from a t, as well as fluids, cells, or s present within a
subject. es of biological fluids include blood, serum and serosal fluids, plasma,
ospinal fluid, ocular fluids, lymph, urine, saliva, and the like. Tissue samples may
30 include samples from tissues, organs or localized regions. For example, samples may be
derived from particular organs, parts of organs, or fluids or cells within those organs. In
26
certain embodiments, samples may be derived from the liver (e.g., whole liver or certain
segments of liver or n types of cells in the liver, such as, e.g., hepatocytes), the
retina or parts of the retina (e.g., retinal pigment epithelium), the central nervous system
or parts of the central nervous system (e.g., ventricles or choroid plexus), or the
5 pancreas or certain cells or parts of the pancreas. In some embodiments, a “sample
derived from a subject” refers tocerebrospinal fluid obtained from the subject. In
preferred embodiments, a “sample derived from a subject” refers to blood or plasma
drawn from the subject. In further embodiments, a “sample derived from a t”
refers to liver tissue (or subcomponents thereof) or retinal tissue (or subcomponents
10 f) derived from the subject.
Throughout this specification the word ise", or variations such as
"comprises" or "comprising", will be understood to imply the inclusion of a stated
element, integer or step, or group of elements, integers or steps, but not the exclusion of
any other element, integer or step, or group of elements, integers or steps.
15 Any discussion of documents, acts, materials, devices, articles or the like which
has been included in the t specification is not to be taken as an admission that any
or all of these s form part of the prior art base or were common general
knowledge in the field relevant to the present disclosure as it existed before the ty
date of each claim of this ation.
20 II. RNAi Agents
The present invention provides RNAi agents with superior gene silencing
activity. It is shown herein and in Provisional Application No. 61/561,710 (to which the
present application claims priority) that a superior result may be obtained by introducing
one or more motifs of three identical modifications on three consecutive nucleotides
25 into a sense strand and/or antisense strand of a RNAi agent, particularly at or near the
cleavage site. The sense strand and antisense strand of the RNAi agent may ise
be completely ed. The introduction of these motifs interrupts the modification
pattern, if present, of the sense and/or antisense strand. The RNAi agent also optionally
conjugates with a GalNAc derivative , for instance on the sense strand. The
30 resulting RNAi agents present superior gene ing activity.
The inventors surprisingly discovered that when the sense strand and antisense
strand of the RNAi agent are completely modified, having one or more motifs of three
identical modifications on three consecutive nucleotides at or near the cleavage site of at
27
least one strand of a RNAi agent superiorly enhanced the gene silencing acitivity of the
RNAi agent.
Accordingly, the invention es RNAi agents, e.g., double stranded RNAi
agents, capable of inhibiting the expression of a target gene (i.e., a TTR gene) in vivo.
5 The RNAi agent comprises a sense strand and an antisense strand. Each strand of the
27A
W0 2013,:‘075035 PCT/U82012/065691
RNAi agent can range from 12—30 nucleotides in . For example, each strand can
be between 14-30 nucleotides in length, 17-30 nucleotides in length, 25-30 nucleotides
in length, 27—30 nucleotides in length, 17—23 nucleotides in length, 17—21 nucleotides in
length, 17—19 nucleotides in length, 19—25 nucleotides in length, 19—23 nucleotides in
length, 19—21 nucleotides in length, 21—25 nucleotides in length, or 21—23 nucleotides in
length.
The sense strand and antisense strand typically form a duplex double stranded
RNA A”), also ed to herein as an “RNAi agent.” The duplex region of an
RNAi agent may be 12—30 nucleotide pairs in length. For example, the duplex region
10 can be between 14—30 nucleotide pairs in length, 17—30 nucleotide pairs in length, 27—30
nucleotide pairs in length, 17 — 23 nucleotide pairs in length, 17-21 nucleotide pairs in
length, 17-19 tide pairs in length, 19-25 nucleotide pairs in length, 19-23
nucleotide pairs in length, 19— 21 nucleotide pairs in length, 21—25 nucleotide pairs in
, or 21—23 nucleotide pairs in length. In another e, the duplex region is
15 selected from 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, and 27.
In one embodiment, the RNAi agent may n one or more overhang regions
and/or capping groups of RNAi agent at , or 5’—end or both ends of a strand. The
overhang can be 1—6 nucleotides in length, for instance 2—6 nucleotides in length, 1—5
nucleotides in length, 2—5 nucleotides in length, 1—4 nucleotides in , 2—4
20 nucleotides in length, 1—3 nucleotides in length, 2—3 nucleotides in length, or 1—2
nucleotides in length. The ngs can be the result of one strand being longer than
the other, or the result of two strands of the same length being staggered. The overhang
can form a mismatch with the target mRNA or it can be complementary to the gene
ces being targeted or can be other sequence. The first and second strands can also
25 be joined, e.g., by additional bases to form a hairpin, or by other non—base linkers.
The RNAi agents provided by the present invention include agents with chemical
modifications as disclosed, for example, in US. ional Application No.
61/561,710, filed on November 18, 2011, International Application No.
PCT/US2011/051597, filed on September 15, 2010, and PCT Publication WO
30 2009/073809, the entire contents of each of which are incorporated herein by reference.
28
W0 2013,:‘075035 PCT/U82012/065691
In one embodiment, the nucleotides in the overhang region of the RNAi agent
can each independently be a modified or unmodified tide including, but no limited
to 2’—sugar ed, such as, 2—F, 2’—O—methyl, ine (T), 2‘—O—methoxyethyl—5—
methyluridine (Teo), 2‘—O—methoxyethyladenosine (Aeo), 2‘—O—methoxyethy1—5—
methylcytidine (mSCeo), and any combinations thereof. For example, TT can be an
overhang sequence for either end on either strand. The overhang can form a mismatch
with the target mRNA or it can be complementary to the gene sequences being targeted
or can be other sequence.
The 5’— or 3’— overhangs at the sense strand, antisense strand or both strands of
10 the RNAi agent may be orylated. In some ments, the ng region
contains two nucleotides having a phosphorothioate between the two nucleotides, where
the two nucleotides can be the same or different. In one ment, the overhang is
present at the 3’-end of the sense strand, antisense strand or both s. In one
embodiment, this 3’—overhang is present in the antisense strand. In one embodiment,
15 this 3’—overhang is present in the sense strand.
The RNAi agent may contain only a single overhang, which can strengthen the
interference activity of the RNAi, without affecting its overall stability. For example,
the single-stranded overhang is located at the 3'—terminal end of the sense strand or,
atively, at the 3'—terminal end of the antisense strand. The RNAi may also have a
20 blunt end, located at the 5’—end of the antisense strand (or the 3’-end of the sense strand)
or vice versa. Generally, the antisense strand of the RNAi has a nucleotide overhang at
the 3’-end, and the 5’-end is blunt. While the Applicants are not bound by theory, the
theoretical mechanism is that the asymmetric blunt end at the 5’—end of the antisense
strand and 3’—end overhang of the antisense strand favor the guide strand loading into
25 RISC s.
In one embodiment, the RNAi agent is a double ended bluntmer of 19 nt in
length, wherein the sense strand contains at least one motif of three 2’—F modifications
on three consecutive nucleotides at positions 7,8,9 from the 5’end. The antisense strand
contains at least one motif of three 2’—O—methyl modifications on three utive
30 nucleotides at positions 11, 12, 13 from the S’end.
29
W0 2013,:‘075035 2012/065691
In one embodiment, the RNAi agent is a double ended bluntmer of 20 nt in
length, wherein the sense strand contains at least one motif of three 2’-F modifications
on three consecutive nucleotides at positions 8,9,10 from the S’end. The antisense
strand contains at least one motif of three 2’—O—methyl modifications on three
consecutive nucleotides at ons 11, 12, 13 from the 5’end.
In one embodiment, the RNAi agent is a double ended bluntmer of 21 nt in
length, wherein the sense strand contains at least one motif of three 2’—F modifications
on three consecutive nucleotides at positions 9, 10, 11 from the 5’end. The antisense
strand contains at least one motif of three 2’—O—methyl modifications on three
10 consecutive nucleotides at positions 11, 12, 13 from the 5’end.
In one embodiment, the RNAi agent comprises a 21 nucleotides (nt) sense strand
and a 23 tides (nt) antisense strand, wherein the sense strand contains at least one
motif of three 2’—F modifications on three consecutive tides at positions 9,10,11
from the 5’end; the nse strand contains at least one motif of three 2’—O—methyl
15 modifications on three consecutive nucleotides at positions 11, 12, 13 from the 5’end,
wherein one end of the RNAi agent is blunt, while the other end comprises a 2 nt
overhang. Preferably, the 2 nt overhang is at the 3’—end of the antisense. Optionally, the
RNAi agent further comprises a ligand (preferably GalNAc3).
In one embodiment, the RNAi agent ses a sense and an antisense strand,
20 wherein the sense strand is 25—30 nucleotide residues in length, wherein starting from
the 5' terminal nucleotide (position 1) positions 1 to 23 of the first strand comprise at
least 8 ribonucleotides; antisense strand is 36-66 nucleotide residues in length and,
starting from the 3' terminal nucleotide, comprises at least 8 ribonucleotides in the
positions paired with positions 1— 23 of sense strand to form a duplex; wherein at least
25 the 3 ' al nucleotide of antisense strand is unpaired with sense strand, and up to 6
consecutive 3' terminal nucleotides are ed with sense strand, y forming a 3'
single stranded overhang of 1—6 tides; wherein the 5' terminus of antisense strand
comprises from 10—30 consecutive nucleotides which are unpaired with sense strand,
thereby forming a 10—30 nucleotide single stranded 5' overhang; n at least the
30 sense strand 5' terminal and 3' terminal nucleotides are base paired with nucleotides of
antisense strand when sense and antisense strands are aligned for maximum
30
W0 2013,:‘075035 PCT/U82012/065691
complementarity, thereby forming a ntially duplexed region between sense and
antisense strands; and nse strand is sufficiently complementary to a target RNA
along at least 19 ribonucleotides of antisense strand length to reduce target gene
expression when the double stranded nucleic acid is introduced into a mammalian cell;
and wherein the sense strand contains at least one motif of three 2’—F modifications on
three consecutive nucleotides, where at least one of the motifs occurs at or near the
cleavage site. The antisense strand contains at least one motif of three 2’—O—methyl
modifications on three consecutive nucleotides at or near the cleavage site.
In one embodiment, the RNAi agent comprises sense and antisense strands,
10 wherein the RNAi agent comprises a first strand having a length which is at least 25 and
at most 29 nucleotides and a second strand having a length which is at most 30
tides with at least one motif of three 2’-O-methy1 modifications on three
consecutive nucleotides at on 11,12,13 from the 5’ end; wherein the 3’ end of the
first strand and the 5’ end of the second strand form a blunt end and the second strand is
15 1—4 tides longer at its 3’ end than the first strand, n the duplex region which
is at least 25 nucleotides in length, and the second strand is sufficiently complemenatary
to a target mRNA along at least 19 nt of the second strand length to reduce target gene
expression when the RNAi agent is introduced into a mammalian cell, and wherein dicer
cleavage of the RNAi agent preferentially results in an siRNA comprising the 3’ end of
20 the second strand, thereby reducing expression of the target gene in the mammal.
Optionally, the RNAi agent further comprises a .
In one embodiment, the sense strand of the RNAi agent ns at least one
motif of three identical modifications on three consecutive nucleotides, where one of the
motifs occurs at the cleavage site in the sense strand.
25 In one embodiment, the antisense strand of the RNAi agent can also contain at
least one motif of three identical modifications on three consecutive nucleotides, where
one of the motifs occurs at or near the cleavage site in the antisense strand
For RNAi agent having a duplex region of 17—23 nt in length, the cleavage site of
the antisense strand is typically around the 10, 11 and 12 ons from the 5 ’—end.
30 Thus, the motifs of three identical modifications may occur at the 9, 10, 11 ons; 10,
11, 12 positions; 11, 12, 13 positions; 12, 13, 14 positions; or 13, 14, 15 positions of the
31
W0 2013,:‘075035 PCT/U82012/065691
antisense strand, the count starting from the 1St nucleotide from the 5’—end of the
nse strand, or, the count starting from the 1St paired nucleotide within the duplex
region from the 5’— end of the antisense strand. The cleavage site in the antisense strand
may also change according to the length of the duplex region of the RNAi from the 5’—
end.
The sense strand of the RNAi agent may contain at least one motif of three
identical modifications on three consecutive nucleotides at the ge site of the
strand; and the antisense strand may have at least one motif of three identical
modifications on three consecutive nucleotides at or near the cleavage site of the strand.
10 When the sense strand and the antisense strand form a dsRNA duplex, the sense strand
and the antisense strand can be so aligned that one motif of the three nucleotides on the
sense strand and one motif of the three nucleotides on the antisense strand have at least
one nucleotide overlap, i. e., at least one of the three nucleotides of the motif in the sense
strand forms a base pair with at least one of the three nucleotides of the motif in the
15 antisense strand. Alternatively, at least two nucleotides may overlap, or all three
nucleotides may overlap.
In one embodiment, the sense strand of the RNAi agent may contain more than
one motif of three identical modifications on three consecutive nucleotides. The first
motif should occur at or near the cleavage site of the strand and the other motifs may be
20 wing modifications. The term “wing modification” herein refers to a motif occurring at
another portion of the strand that is separated from the motif at or near the cleavage site
of the same strand. The wing cation is either adaj acent to the first motif or is
separated by at least one or more nucleotides. When the motifs are immediately adjacent
to each other than the chemistry of the motifs are ct from each other and when
25 the motifs are ted by one or more nucleotide than the chemistries can be the same
or different. Two or more wing cations may be present. For instance, when two
wing modifications are t, each wing modification may occur at one end relative to
the first motif which is at or near cleavage site or on either side of the lead motif.
Like the sense strand, the antisense strand of the RNAi agent may contain at least
30 two motifs of three identical modifications on three utive nucleotides, with at
least one of the motifs occurring at or near the ge site of the strand. This antisense
32
W0 2013,:‘075035 2012/065691
strand may also contain one or more wing modifications in an alignment similar to the
wing modifications that is t on the sense strand.
In one ment, the wing modification on the sense strand or antisense strand
of the RNAi agent typically does not include the first one or two terminal nucleotides at
the 3’—end, 5’—end or both ends of the strand.
In another embodiment, the wing modification on the sense strand or antisense
strand of the RNAi agent typically does not include the first one or two paired
nucleotides within the duplex region at the 3’—end, 5’—end or both ends of the strand.
When the sense strand and the antisense strand of the RNAi agent each contain at
10 least one wing modification, the wing modifications may fall on the same end of the
duplex region, and have an overlap of one, two or three nucleotides.
When the sense strand and the antisense strand of the RNAi agent each contain at
least two wing modifications, the sense strand and the antisense strand can be so aligned
that two modifications each from one strand fall on one end of the duplex region, having
15 an overlap of one, two or three tides; two modifications each from one strand fall
on the other end of the duplex region, having an overlap of one, two or three
tides; two modifications one strand fall on each side of the lead motif, having an
overlap of one, two or three nucleotides in the duplex region.
In one embodiment, every nucleotide in the sense strand and antisense strand of
20 the RNAi agent, including the nucleotides that are part of the motifs, may be modified.
Each nucleotide may be modified with the same or different cation which can
include one or more tion of one or both of the non-linking phosphate oxygens
and/or of one or more of the linking phosphate oxygens; alteration of a constituent of the
ribose sugar, e.g., of the 2’ hydroxyl on the ribose sugar; wholesale replacement of the
25 phosphate moiety with “dephospho” linkers; modification or replacement of a naturally
ing base; and replacement or modification of the ribose—phosphate backbone.
As nucleic acids are polymers of subunits, many of the modifications occur at a
position which is repeated within a nucleic acid, 6.57., a modification of a base, or a
phosphate moiety, or a non—linking O of a phosphate moiety. In some cases the
30 modification will occur at all of the subject positions in the nucleic acid but in many
cases it will not. By way of example, a modification may only occur at a 3’ or 5’
33
W0 2013,:‘075035 PCT/U82012/065691
terminal position, may only occur in a terminal region, e.g., at a position on a terminal
nucleotide or in the last 2, 3, 4, 5, or 10 nucleotides of a strand. A modification may
occur in a double strand region, a single strand , or in both. A cation may
occur only in the double strand region of a RNA or may only occur in a single strand
region of a RNA. For example, a phosphorothioate modification at a non—linking 0
position may only occur at one or both termini, may only occur in a terminal , e.g.,
at a position on a terminal nucleotide or in the last 2, 3, 4, 5, or 10 nucleotides of a
strand, or may occur in double strand and single strand regions, particularly at termini.
The 5’ end or ends can be phosphorylated.
10 It may be possible, e.g., to enhance stability, to include particular bases in
overhangs, or to e modified nucleotides or nucleotide surrogates, in single strand
overhangs, e.g., in a 5’ or 3’ overhang, or in both. For example, it can be desirable to
include purine nucleotides in overhangs. In some embodiments all or some of the bases
in a 3’ or 5’ overhang may be modified, e.g., with a cation described herein.
15 Modifications can include, 6.57., the use of modifications at the 2’ position of the ribose
sugar with modifications that are known in the art, e.g., the use of deoxyribonucleotides,
or 2’—O—methyl modified instead of the ribosugar of the
, 2’—deoxy—2’—fluoro (2’—F)
nucleobase and modifications in the ate group, e.g., phosphorothioate
,
modifications. Overhangs need not be gous with the target sequence.
20 In one embodiment, each residue of the sense strand and antisense strand is
independently modified with LNA, HNA, CeNA, 2’-methoxyethyl, 2’- yl, 2’-O-
allyl, 2’—C— allyl, 2’-deoxy, 2’—hydroxyl, or 2’—fluoro. The s can contain more than
one modification. In one embodiment, each residue of the sense strand and antisense
strand is independently modified with 2’— O—methyl or 2’—fluoro.
25 At least two different modifications are lly present on the sense strand and
antisense strand. Those two modifications may be the 2’— O—methyl or 2’—fluoro
modifications, or others.
In one embodiment, the Na and/or Nb comprise modifications of an alternating
pattern. The term “alternating motif” as used herein refers to a motif having one or more
30 modifications, each modification occurring on alternating tides of one strand. The
34
W0 2013,:‘075035 PCT/U82012/065691
alternating nucleotide may refer to one per every other nucleotide or one per every three
nucleotides, or a similar pattern. For example, if A, B and C each represent one type of
cation to the nucleotide, the alternating motif can be “ABABABABABAB. . .,”
ABBAABB. . .,” “AABAABAABAAB. . .,” “AAABAAABAAAB. . .,”
“AAABBBAAABBB. . .,” or “ABCABCABCABC. . .,” etc.
The type of modifications contained in the ating motif may be the same or
different. For example, if A, B, C, D each represent one type of modification on the
nucleotide, the alternating pattern, i.e., modifications on every other nucleotide, may be
the same, but each of the sense strand or antisense strand can be selected from several
10 possibilities of modifications within the ating motif such as “ABABAB. . .”,
“ACACAC...” “BDBDBD. . .” or “CDCDCD. . .,” etc.
In one embodiment, the RNAi agent of the invention comprises the modification
pattern for the alternating motif on the sense strand relative to the modification pattern
for the alternating motif on the antisense strand is d. The shift may be such that the
15 modified group of nucleotides of the sense strand corresponds to a differently ed
group of nucleotides of the antisense strand and Vice versa. For example, the sense
strand when paired with the antisense strand in the dsRNA duplex, the alternating motif
in the sense strand may start with “ABABAB” from 5’—3’ of the strand and the
alternating motif in the antisense strand may start with “BABABA” from 5’—3’of the
20 strand within the duplex . As r example, the alternating motif in the sense
strand may start with “AABBAABB” from 5’—3’ of the strand and the alternating motif
in the antisenese strand may start with “BBAABBAA” from 5’-3’ of the strand within
the duplex region, so that there is a complete or partial shift of the modification patterns
between the sense strand and the antisense .
25 In one embodiment, the RNAi agent comprises the pattern of the alternating
motif of 2'—O—methyl modification and 2’—F modification on the sense strand initially has
a shift relative to the pattern of the alternating motif of 2'—O—methyl modification and 2’—
F modification on the antisense strand initially, i.e. the ethyl modified nucleotide
,
on the sense strand base pairs with a 2'—F modified nucleotide on the antisense strand
30 and vice versa. The 1 position of the sense strand may start with the 2'—F modification,
and the 1 on of the antisense strand may start with the 2'- O—methyl modification.
35
W0 2013,:‘075035 PCT/U82012/065691
The introduction of one or more motifs of three identical modifications on three
consecutive nucleotides to the sense strand and/or antisense strand upts the initial
modification pattern present in the sense strand and/or nse strand. This
interruption of the cation pattern of the sense and/or antisense strand by
introducing one or more motifs of three identical modifications on three consecutive
tides to the sense and/or antisense strand surprisingly enhances the gene silencing
acitivty to the target gene.
In one embodiment, when the motif of three identical modifications on three
utive nucleotides is introduced to any of the strands, the modification of the
10 nucleotide next to the motif is a different modification than the modification of the
motif. For example, the portion of the sequence containing the motif is
“. . .NaYYYNb. . .,” where “Y” represents the modification of the motif of three identical
modifications on three consecutive nucleotide, and “Na” and “Nb” represent a
modification to the nucleotide next to the motif “YYY” that is different than the
15 cation of Y, and where Na and Nb can be the same or different modifications.
Altnernatively, Na and/or Nb may be present or absent when there is a wing modification
present.
The RNAi agent may further se at least one phosphorothioate or
methylphosphonate internucleotide linkage. The phosphorothioate or
20 methylphosphonate internucleotide linkage cation may occur on any nucleotide of
the sense strand or antisense strand or both in any on of the strand. For instance,
the internucleotide e modification may occur on every tide on the sense
strand or antisense strand; each internucleotide linkage modification may occur in an
alternating pattern on the sense strand or antisense strand; or the sense strand or
25 antisense strand may contain both internucleotide linkage modifications in an alternating
pattern. The alternating pattern of the internucleotide linkage modification on the sense
strand may be the same or different from the antisense strand, and the alternating pattern
of the internucleotide linkage modification on the sense strand may have a shift relative
to the alternating pattern of the internucleotide linkage modification on the nse
30 strand.
36
W0 2013,:‘075035 PCT/U82012/065691
In one embodiment, the RNAi comprises the phosphorothioate or
methylphosphonate internucleotide linkage modification in the overhang region. For
example, the overhang region may contain two nucleotides having a phosphorothioate or
methylphosphonate internucleotide e between the two nucleotides.
Internucleotide linkage modifications also may be made to link the overhang nucleotides
with the terminal paired nucleotides within duplex region. For example, at least 2, 3, 4,
or all the overhang nucleotides may be linked through phosphorothioate or
methylphosphonate internucleotide linkage, and optionally, there may be onal
phosphorothioate or methylphosphonate internucleotide linkages linking the ng
10 nucleotide with a paired tide that is next to the overhang nucleotide. For ce,
there may be at least two phosphorothioate internucleotide linkages between the terminal
three nucleotides, in which two of the three nucleotides are overhang nucleotides, and
the third is a paried nucleotide next to the overhang nucleotide. Preferably, these
terminal three nucleotides may be at the 3’—end of the antisense strand.
15 In one embodiment, the RNAi agent ses mismatch(es) with the target,
within the duplex, or combinations f. The mistmatch can occur in the overhang
region or the duplex region. The base pair can be ranked on the basis of their propensity
to promote dissociation or melting (e.g., on the free energy of association or dissociation
of a particular pairing, the simplest approach is to examine the pairs on an individual
20 pair basis, though next neighbor or similar analysis can also be used). In terms of
promoting iation: A:U is preferred over G:C; G:U is red over G:C; and LC
is preferred over G:C (I=inosine). Mismatches, e.g., nonical or other than
canonical pairings (as described elsewhere herein) are red over canonical (AzT,
A:U, G:C) pairings; and pairings which include a sal base are preferred over
25 canonical pairings.
In one embodiment, the RNAi agent comprises at least one of the first 1, 2, 3, 4,
or 5 base pairs within the duplex regions from the 5’— end of the antisense strand can be
chosen independently from the group of: A:U, GzU, 1C, and mismatched pairs, e.g.,
non—canonical or other than canonical pairings or pairings which include a universal
30 base, to e the dissociation of the antisense strand at the 5’-end of the duplex.
37
W0 2013,:‘075035 PCT/US2012/065691
In one embodiment, the nucleotide at the 1 position within the duplex region
from the 5’-end in the antisense strand is selected from the group consisting of A, dA,
dU, U, and dT. Alternatively, at least one of the first 1, 2 or 3 base pair within the
duplex region from the 5’— end of the nse strand is an AU base pair. For example,
the first base pair within the duplex region from the 5’— end of the antisense strand is an
AU base pair.
In one embodiment, the sense strand sequence may be represented by formula
(I):
5' np—Na-(X X X )i-Nb-Y Y Y -Nb-(Z Z Z )j-Na-nq 3' (I)
10 wherein:
i and j are each independently 0 or 1;
p and q are each independently 0-6;
each Na independently represents an oligonucleotide sequence comprising 0—25
modified nucleotides, each sequence comprising at least two ently modified
15 nucleotides;
each Nb independently represents an oligonucleotide ce comprising 0— 10
modified nucleotides;
each tip and nq independently ent an overhang nucleotide;
wherein Nb and Y do not have the same modification; and
20 XXX, YYY and ZZZ each ndently represent one motif of three cal
modifications on three consecutive nucleotides. Preferably YYY is all 2’—F ed
nucleotides.
In one embodiment, the Na and/or Nb comprise modifications of alternating
pattern.
25 In one embodiment, the YYY motif occurs at or near the cleavage site of the
sense strand. For example, when the RNAi agent has a duplex region of 17—23
nucleotides in length, the YYY motif can occur at or the vicinity of the cleavage site
(e.g.: can occur at positions 6, 7, 8, 7, 8, 9, 8, 9,10, 9,10,11,10,11,12 or 11, 12, 13) of
— the sense strand, the count starting from the 1St nucleotide, from the 5’—end; or
30 optionally, the count starting at the 1St paired nucleotide within the duplex region, from
the 5’— end.
38
W0 2013,:‘075035 PCT/U82012/065691
In one ment, i is 1 andj is 0, or i is 0 andj is 1, or both i andj are 1. The
sense strand can therefore be represented by the following formulas:
5' np—Na-YYY-Nb—ZZZ—Na—n01 3' (Ia);
5' np—Na—XXX—Nb—YYY—Na—nq 3' (lb); or
5' np—Na—XXX—Nb—YYY—Nb—ZZZ—Na—nq 3' (1c).
When the sense strand is ented by formula (Ia), Nb represents an
oligonucleotide sequence comprising 0—10, 0—7, 0—5, 0—4, 0—2 or 0 modified nucleotides.
Each Na independently can represent an oligonucleotide sequence comprising 2—20, 2—
15 or 2—10 modified nucleotides.
,
10 When the sense strand is represented as formula (Ib), Nb represents an
oligonucleotide sequence comprising 0—10, 0—7, 0—10, 0—7, 0-5, 0-4, 0—2 or 0 ed
nucleotides. Each Na can independently represent an ucleotide sequence
comprising 2—20, 2—15, or 2—10 ed nucleotides.
When the sense strand is represented as formula (1c), each Nb ndently
15 represents an oligonucleotide sequence comprising 0—10, 0—7, 0—5, 0—4, 0—2 or 0 modified
nucleotides. Preferably, Nb is 0, l, 2, 3, 4, 5 or 6 Each Na can independently represent
an oligonucleotide sequence comprising 2—20, 2—15, or 2—10 modified nucleotides.
Each of X, Y and Z may be the same or different from each other.
In one embodiment, the antisense strand sequence of the RNAi may be
20 represented by formula (II):
5' nq,—Na'—(Z’Z’Z’)k—Nb’—Y’Y’Y’—Nb’—(X’X’X’)1—N’a—np’ 3' (11)
wherein:
k and l are each independently 0 or 1;
p’ and q’ are each independently 0—6;
25 each Na' independently represents an oligonucleotide sequence comprising 0—25
modified nucleotides, each sequence comprising at least two differently modified
tides;
each Nb’ independently ents an oligonucleotide sequence comprising 0— 10
d nucleotides;
30 each np’ and nq’ independently represent an overhang nucleotide;
wherein Nb’ and Y’ do not have the same modification;
39
W0 2013,:‘075035 PCT/U82012/065691
and
X'X'X', Y'Y'Y' and Z'Z'Z' each independently represent one motif of three
identical modifications on three consecutive nucleotides.
In one ment, the Na’ and/or Nb’ comprise modifications of alternating
pattern.
The Y'Y'Y' motif occurs at or near the cleavage site of the nse strand. For
e, when the RNAi agent has a duplex region of 17—23 nt in length, the Y’Y’Y’
motifcan occur at positions 9, 10, 11;10, 11, 12; 11, 12, 13; 12, 13, 14 ; or 13, 14, 15 of
the antisense strand, with the count ng from the 1St nucleotide, from the 5’—end; or
10 optionally, the count starting at the 1St paired nucleotide within the duplex region, from
the 5’— end. Preferably, the Y’Y’Y’ motif occurs at positions 11, 12, 13.
In one embodiment, Y'Y'Y' motif is all 2’-OMe modified nucleotides.
In one ment, k is l and l is 0, or k is 0 and l is 1, or both k and 1 are l.
The antisense strand can therefore be represented by the ing formulas:
15 5' nq~—Na'-Z'Z'Z'-Nb’-Y’Y’Y’-Na’-np~ 3' (11a);
5' nq,-Na'-Y’Y’Y’-Nb’-X’X’X’-np~ 3' (IIb); or
5' nq,-Na’- Z’Z’Z’-Nb’-Y’Y’Y’-Nb’- X’X’X’-Na’-np~ 3' (IIc).
When the antisense strand is represented by formula (IIa), Nb, represents an
oligonucleotide ce comprising 0—10, 0—7, 0—10, 0—7, 0—5, 0—4, 0—2 or 0 modified
20 nucleotides. Each Na’ independently represents an oligonucleotide sequence comprising
2-20, 2—15, or 2—10 modified nucleotides.
When the nse strand is represented as formula (IIb), Nb’ represents an
oligonucleotide sequence comprising 0—10, 0—7, 0—10, 0—7, 0—5, 0—4, 0—2 or 0 modified
tides. Each Na’ independently represents an oligonucleotide sequence comprising
25 2—20, 2—15, or 2—10 modified nucleotides.
When the antisense strand is represented as formula (IIc), each Nb’
independently represents an oligonucleotide sequence comprising 0—10, 0—7, 0—10, 0—7,
0—5, 0—4, 0-2 or 0 modified nucleotides. Each Na’ independently represents an
oligonucleotide sequence comprising 2—20, 2—15, or 2—10 modified nucleotides.
30 Preferably, Nb is 0, 1, 2, 3, 4, 5 or 6.
Each of X', Y’ and 2’ may be the same or different from each other.
40
W0 2013,:‘075035 PCT/U82012/065691
Each nucleotide of the sense strand and antisense strand may be independently
d with LNA, HNA, CeNA, hoxyethyl, 2’-O-methy1, lly1, 2’-C-
allyl, 2’—hydroxy1, 2’—deoxy or 2’—fluoro. For example, each nucleotide of the sense
strand and antisense strand is independently modified with 2’—O—methy1 or 2’-fluoro.
Each X, Y, Z, X', Y' and Z’, in particular, may represent a 2’—O—methy1 modification or a
2’—fluoro modification.
In one embodiment, the sense strand of the RNAi agent may contain YYY motif
occurring at 9, 10 and 11 positions of the strand when the duplex region is 21 nt, the
count starting from the 1St nucleotide from the 5’—end, or optionally, the count starting at
10 the 18‘ paired tide within the duplex , from the 5’— end; and Y represents 2’—
F modification. The sense strand may additionally contain XXX motif or ZZZ motifs as
wing modifications at the opposite end of the duplex region; and XXX and ZZZ each
independently represents a 2’—OMe modification or 2’—F modification.
In one embodiment the antisense strand may contain Y’Y'Y’ motif occurring at
15 positions 11, 12, 13 of the strand, the count starting from the 1St nucleotide from the
5’—end, or optionally, the count starting at the 1St paired nucleotide within the duplex
region, from the 5’— end; and Y’ represents 2’—O—methy1 modification. The nse
strand may additionally contain X’X’X’ motif or Z’Z’Z’ motifs as wing modifications at
the te end of the duplex region; and X’X’X’ and Z’Z’Z’ each independently
20 represents a 2’—OMe modification or 2’—F cation.
The sense strand represented by any one of the above formulas (Ia), (1b) and (Ic)
forms a duplex with a antisense strand being represented by any one of formulas (Ila),
(IIb) and (IIc), respectively.
Accordingly, the RNAi agents of the invention may comprise a sense strand and
25 an antisense strand, each strand having 14 to 30 nucleotides, the RNAi duplex
represented by formula (III):
sense: 5' np —Na—(X X X), —Nb— Y Y Y —Nb —(Z Z Z)j—Na—nq 3'
antisense: 3' npg—Nag—(X’X’X’)k—Nba—Y’Y’Y’—Nb’—(Z’Z’Z')1—Na’—nq, 5'
(111)
30 wherein:
i, j, k, and l are each independently 0 or 1;
41
W0 2013.:‘075035 PCT/U82012/065691
p, p', q, and q' are each independently 0-6;
each Na and Na! independently represents an oligonucleotide sequence
comprising 0—25 modified nucleotides, each sequence comprising at least two differently
modified nucleotides;
each Nb and Nb, independently ents an oligonucleotide sequence
comprising 0—10 modified nucleotides;
wherein
each np’, np, nq’, and nq independently ents an overhang nucleotide; and
XXX, YYY, ZZZ, X’X’X’, Y’Y’Y’, and Z’Z’Z’ each independently represent one
10 motif of three cal modifications on three consecutive nucleotides.
In one embodiment, i is 1 andj is 0; or i is 0 andj is 1; or both i andj are 1. In
another embodiment, k is 1 and 1 is O; k is 0 and l is 1; or both k and l are 1.
Exemplary combinations of the sense strand and antisense strand forming a
RNAi duplex e the formulas below:
15 5' np —Na -Y Y Y -Nb -Z Z Z -Na-nq 3'
3' np,—Na'—Y’Y’Y’—Nb’—Z’Z’Z’—Nagnqg 5'
(111a)
5' np-Na- X X X -Nb -Y Y Y - Na-nq 3'
3' npi—Nag—X’X’XCNbg—Y’Y’Y’—Na’—nq’ 5'
20 (IIIb)
5' np -Na -X X X -Nb-Y Y Y -Nb- Z Z Z 'Na'nq 3'
3' npi-Nai-X'X'X'-Nbi-Y'Y’Y’-Nbi-Z'Z’Z’-Na-nqs 5'
(IIIc)
When the RNAi agent is represented by formula (Illa), each Nb independently
25 ents an oligonucleotide sequence comprising 1—10, 1—7, 1—5 or 1—4 modified
nucleotides. Each Na independently represents an oligonucleotide sequence comprising
2—20, 2— 15, or 2—10 modified nucleotides.
When the RNAi agent is represented as formula (IIIb), each Nb, Nb’
independently represents an oligonucleotide sequence comprising 0—10, 0—7, 0—10, 0—7,
30 0-5, 0—4, 0—2 or 0modified tides. Each Na independently represents an
oligonucleotide sequence comprising 2—20, 2—15, or 2-10 modified nucleotides.
42
W0 2013,:‘075035 PCT/U82012/065691
When the RNAi agent is represented as formula (IIIc), each Nb, Nb’
independently represents an oligonucleotide sequence comprising 0-10, 0-7, 0-10, 0-7,
0—5, 0—4, 0—2 or ied nucleotides. Each Na, Na, independently ents an
oligonucleotide sequence comprising 2—20, 2—15, or 2—10 modified nucleotides. Each of
Na, Na’, Nb and Nb, ndently comprises modifications of alternating pattern.
Each of X, Y and Z in as (III), (Illa), (IIIb) and (IIIc) may be the same or
different from each other.
When the RNAi agent is represented by formula (III), (IIIa), (IIIb) or (IIIc), at
least one of the Y nucleotides may form a base pair with one of the Y' nucleotides.
10 Alternatively, at least two of the Y nucleotides form base pairs with the corresponding
Y' nucleotides; or all three of the Y tides all form base pairs with the
corresponding Y' tides.
When the RNAi agent is ented by formula (IIIa) or (1110), at least one of
the Z nucleotides may form a base pair with one of the Z’ nucleotides. Alternatively, at
15 least two of the Z nucleotides form base pairs with the corresponding Z' nucleotides; or
all three of the Z nucleotides all form base pairs with the corresponding Z' nucleotides.
When the RNAi agent is represented as formula (IIIb) or (IIIc), at least one of the
X nucleotides may form a base pair with one of the X’ nucleotides. atively, at
least two of the X tides form base pairs with the corresponding X' nucleotides; or
20 all three of the X nucleotides all form base pairs with the corresponding X’ nucleotides.
In one embodiment, the modification on the Y nucleotide is different than the
modification on the Y’ nucleotide, the modification on the Z nucleotide is different than
the cation on the Z’ nucleotide, and/or the modification on the X nucleotide is
different than the modification on the X’ nucleotide.
25 In one embodiment, the RNAi agent is a multimer containing at least two
duplexes represented by formula (III), (IIIa), (IIIb) or (IIIc), wherein the duplexes are
connected by a linker. The linker can be cleavable or non—cleavable. Optionally, the
multimer further comprise a ligand. Each of the duplexes can target the same gene or
two different genes; or each of the duplexes can target same gene at two different target
30 sites.
43
W0 2013,:‘075035 PCT/US2012/065691
In one embodiment, the RNAi agent is a multimer containing three, four, five,
six or more duplexes represented by a (III), , (IIIb) or , wherein the
duplexes are connected by a linker. The linker can be cleavable or non—cleavable.
Optionally, the multimer further comprises a ligand. Each of the duplexes can target the
same gene or two different genes; or each of the duplexes can target same gene at two
different target sites.
In one embodiment, two RNAi agents represented by formula (III), , (IIIb)
or (IIIc) are linked to each other at the 5’ end, and one or both of the 3’ ends of the are
optionally ated to to a ligand. Each of the agents can target the same gene or two
10 different genes; or each of the agents can target same gene at two different target sites.
Various publications describe multimeric RNAi agents . Such publications
e W02007/O91269, US Patent No. 7858769, W02010/141511, W02007/117686,
W02009/014887 and W02011/031520 the entire contents of which are hereby
incorporated herein by reference.
15 The RNAi agent that ns conjugations of one or more carbohydrate moieties
to a RNAi agent can optimize one or more properties of the RNAi agent. In many cases,
the carbohydrate moiety will be attached to a modified subunit of the RNAi agent. For
e, the ribose sugar of one or more ribonucleotide subunits of a dsRNA agent can
be replaced with another moiety, 6.57., a non—carbohydrate (preferably cyclic) carrier to
20 which is attached a carbohydrate ligand. A ribonucleotide subunit in which the ribose
sugar of the subunit has been so replaced is referred to herein as a ribose replacement
modification subunit (RRMS). A cyclic carrier may be a carbocyclic ring system, i.e.,
all ring atoms are carbon atoms, or a heterocyclic ring system, i.e., one or more ring
atoms may be a heteroatom, e.g., nitrogen, , sulfur. The cyclic carrier may be a
25 monocyclic ring system, or may contain two or more rings, 6.g. fused rings. The cyclic
carrier may be a fully saturated ring system, or it may contain one or more double bonds.
The ligand may be attached to the polynucleotide Via a r. The carriers
include (i) at least one “backbone attachment point,” preferably two “backbone
attachment points” and (ii) at least one “tethering attachment point.” A “backbone
30 attachment point” as used herein refers to a functional group, 6.57. a hydroxyl group, or
generally, a bond ble for, and that is suitable for oration of the carrier into
44
W0 2013,:‘075035 PCT/US2012/065691
the backbone, e.g., the phosphate, or modified phosphate, e.g., sulfur containing,
backbone, of a ribonucleic acid. A “tethering ment point” (TAP) in some
embodiments refers to a constituent ring atom of the cyclic carrier, e.g., a carbon atom or
a atom nct from an atom which provides a backbone attachment point), that
connects a selected moiety. The moiety can be, 6.57., a carbohydrate, ag.
ccharide, disaccharide, trisaccharide, tetrasaccharide, oligosaccharide and
polysaccharide. Optionally, the selected moiety is ted by an intervening tether to
the cyclic carrier. Thus, the cyclic carrier will often include a functional group, e.g., an
amino group, or generally, provide a bond, that is suitable for oration or tethering
10 of another chemical entity, e.g., a ligand to the constituent ring.
The RNAi agents may be conjugated to a ligand via a carrier, wherein the carrier
can be cyclic group or acyclic group; preferably, the cyclic group is selected from
pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, olidinyl, piperidinyl,
piperazinyl, [l,3]dioxolane, oxazolidinyl, isoxazolidinyl, morpholinyl, lidinyl,
15 isothiazolidinyl, quinoxalinyl, pyridazinonyl, tetrahydrofuryl and and decalin;
preferably, the acyclic group is selected from serinol backbone or diethanolamine
backbone.
In certain specific embodiments, the RNAi agent of the invention is an agent
selected from the group of agents listed in Table 1 and consisting of D1000, D1001,
20 D1002, D1003, D1004, D1005, D1006, D1007, D1008, D1009, D1010, D1011, D1012,
D1013, D1014, D1015, D1016, D1017, D1018, D1019, D1020, D1021, D1022, D1023,
D1024, D1025, D1026, D1027, D1028, D1029, D1030, D1031, D1032, D1033, D1034,
D1035, D1036, D1037, D1038, D1039, D1040, D1041, D1042, D1043, D1044, D1045,
D1046, D1047, D1048, D1049, D1050, D1051, D1052, D1053, D1054, D1055, D1056,
25 D1057, D1058, D1059, D1060, D1061, D1062, D1063, D1064, D1065, D1066, D1067,
D1068, D1069, D1070, D1071, D1072, D1073, D1074, D1075, D1076, D1077, D1078,
D1079, D1080, D1081, D1082, D1083, D1084, D1085, D1086, D1087, D1088, D1089,
D1090, D1091, D1092, D1093, D1094, D1095, D1096, D1097, D1098, D1099, D1100,
D1101, D1102, D1103, D1104, D1105, D1106, D1107, D1108, D1109, D1110, D1111,
30 D1112, D1113, D1114, D1115, D1116, D1117, D1118, D1119, D1120, D1121, D1122,
D1123, D1124, D1125, D1126, D1127, D1128, D1129, D1130, D1131, D1132, D1133,
45
W0 75035 PCT/US2012/065691
D1134, D1135, D1136, D1137, D1138, D1139, D1140, D1141, D1142, D1143, D1144,
D1145, D1146, D1147, D1148, D1149, D1150, D1151, D1152, D1153, D1154, D1155,
D1156, D1157, D1158, D1159, D1160, D1161, D1162, D1163, D1164, D1165, D1166,
D1167, D1168, D1169, D1170, D1171, D1172, D1173, D1174, D1175, D1176, D1177,
D1178, D1179, D1180, D1181, D1182, D1183, D1184, D1185, D1186, D1187, D1188,
D1189, D1190, D1191, D1192, D1193, D1194, D1195, D1196, D1197, D1198, D1199,
D1200, D1201, D1202, D1203, D1204, D1205, D1206, D1207, D1208, D1209, D1210,
D1211, D1212, D1213, D1214, D1215, D1216, D1217, D1218, D1219, D1220, D1221,
D1222, D1223, D1224, D1225, D1226, D1227, D1228, D1229, D1230, D1231, D1232,
10 D1233, D1234, D1235, D1236, D1237, D1238, D1239, D1240, D1241, D1242, D1243,
D1244, D1245, D1246, D1247, D1248, D1249, D1250, D1251, D1252, D1253, D1254,
D1255, D1256, D1257, D1258, D1259, D1260, D1261, D1262, D1263, D1264, D1265,
D1266, D1267, D1268, D1269, D1270, D1271, D1272, D1273, D1274, D1275, D1276,
D1277, D1278, D1279, D1280, D1281, D1282, D1283, D1284, D1285, D1286, D1287,
15 D1288, D1289, D1290, D1291, D1292, D1293, D1294, D1295, D1296, D1297, D1298,
D1299, D1300, D1301, D1302, D1303, D1304, D1305, D1306, D1307, D1308, D1309,
D1310, D1311, D1312, D1313, D1314, D1315, D1316, D1317, D1318, D1319, D1320,
D1321, D1322, D1323, D1324, D1325, D1326, D1327, D1328, D1329, D1330, D1331,
D1332, D1333, D1334, D1335, D1336, D1337, D1338, D1339, D1340, D1341, D1342,
20 D1343, D1344, D1345, D1346, D1347, D1348, D1349, D1350, D1351, D1352, D1353,
D1354, D1355, D1356, D1357, D1358, D1359, D1360, D1361, D1362, D1363, D1364,
D1365, D1366, D1367, D1368, D1369, D1370, D1371, D1372, D1373, D1374, D1375,
D1376, D1377, D1378, D1379, D1380, D1381, D1382, D1383, D1384, D1385, D1386,
D1387, D1388, D1389, D1390, D1391, D1392, D1393, D1394, D1395, D1396, D1397,
25 D1398, D1399, D1400, D1401, D1402, D1403, D1404, D1405, D1406, D1407, D1408,
D1409, D1410, D1411, D1412, D1413, D1414, D1415, D1416, D1417, D1418, D1419,
D1420, D1421, D1422, D1423, D1424, D1425, D1426, D1427, D1428, D1429, D1430,
D1431, D1432, D1433, D1434, D1435, D1436, D1437, D1438, D1439, D1440, D1441,
D1442, D1443, D1444, D1445, D1446, D1447, D1448, D1449, D1450, D1451, D1452,
30 D1453, D1454, D1455, D1456, D1457, D1458, D1459, D1460, D1461, D1462, D1463,
D1464, D1465, D1466, D1467, D1468, D1469, D1470, D1471, D1472, D1473, D1474,
46
W0 75035 PCT/US2012/065691
D1475, D1476, D1477, D1478, D1479, D1480, D1481, D1482, D1483, D1484, D1485,
D1486, D1487, D1488, D1489, D1490, D1491, D1492, D1493, D1494, D1495, D1496,
D1497, D1498, D1499, . D1500, D1501, D1502, D1503, D1504, D1505, D1506,
D1507, D1508, D1509, D1510, D1511, D1512, D1513, D1514, D1515, D1516, D1517,
D1518, D1519, D1520, D1521, D1522, D1523, D1524, D1525, D1526, D1527, D1528,
D1529, D1530, D1531, D1532, D1533, D1534, D1535, D1536, D1537, D1538, D1539,
D1540, D1541, D1542, D1543, D1544, D1545, D1546, D1547, D1548, D1549, D1550,
D1551, D1552, D1553, D1554, D1555, D1556, D1557, D1558, D1559, D1560, D1561,
D1562, D1563, D1564, D1565, D1566, D1567, D1568, D1569, D1570, D1571, D1572,
10 D1573, D1574, D1575, D1576, D1577, D1578, D1579, D1580, D1581, D1582, D1583,
D1584, D1585, D1586, D1587, D1588, D1589, D1590, D1591, D1592, D1593, D1594,
D1595, D1596, D1597, D1598, D1599, D1600, D1601, D1602, D1603, D1604, D1605,
D1606, D1607, D1608, D1609, D1610, D1611, D1612, D1613, D1614, D1615, D1616,
D1617, D1618, D1619, D1620, D1621, D1622, D1623, D1624, D1625, D1626, D1627,
15 D1628, D1629, D1630, D1631, D1632, D1633, D1634, D1635, D1636, D1637, D1638,
D1639, D1640, D1641, D1642, D1643, D1644, D1645, D1646, D1647, D1648, D1649,
D1650, D1651, D1652, D1653, D1654, D1655, D1656, D1657, D1658, D1659, D1660,
D1661, D1662, D1663, D1664, D1665, D1666, D1667, D1668, D1669, D1670, D1671,
D1672, D1673, D1674, D1675, D1676, D1677, D1678, D1679, D1680, D1681, D1682,
20 D1683, D1684, D1685, D1686, D1687, D1688, D1689, D1690, D1691, D1692, D1693,
D1694, D1695, D1696, D1697, D1698, D1699, D1700, D1701, D1702, D1703, D1704,
D1705, D1706, D1707, D1708, D1709, D1710, D1711, D1712, D1713, D1714, D1715,
D1716, D1717, D1718, D1719, D1720, D1721, D1722, D1723, D1724, D1725, D1726,
D1727, D1728, D1729, D1730, D1731, D1732, D1733, D1734, D1735, D1736, D1737,
25 D1738, D1739, D1740, D1741, D1742, D1743, D1744, D1745, D1746, D1747, D1748,
D1749, D1750, D1751, D1752, D1753, D1754, D1755, D1756, D1757, D1758, D1759,
D1760, D1761, D1762, D1763, D1764, D1765, D1766, D1767, D1768, D1769, D1770,
D1771, D1772, D1773, D1774, D1775, D1776, D1777, D1778, D1779, D1780, D1781,
D1782, D1783, D1784, D1785, D1786, D1787, D1788, D1789, D1790, D1791, D1792,
30 D1793, D1794, D1795, D1796, D1797, D1798, D1799, D1800, D1801, D1802, D1803,
D1804, D1805, D1806, D1807, D1808, D1809, D1810, D1811, D1812, D1813, D1814,
47
W0 75035 PCT/US2012/065691
D1815, D1816, D1817, D1818, D1819, D1820, D1821, D1822, D1823, D1824, D1825,
D1826, D1827, D1828, D1829, D1830, D1831, D1832, D1833, D1834, D1835, D1836,
D1837, D1838, D1839, D1840, D1841, D1842, D1843, D1844, D1845, D1846, D1847,
D1848, D1849, D1850, D1851, D1852, D1853, D1854, D1855, D1856, D1857, D1858,
D1859, D1860, D1861, D1862, D1863, D1864, D1865, D1866, D1867, D1868, D1869,
D1870, D1871, D1872, D1873, D1874, D1875, D1876, D1877, D1878, D1879, D1880,
D1881, D1882, D1883, D1884, D1885, D1886, D1887, D1888, D1889, D1890, D1891,
D1892, D1893, D1894, D1895, D1896, D1897, D1898, D1899, D1900, D1901, D1902,
D1903, D1904, D1905, D1906, D1907, D1908, D1909, D1910, D1911, D1912, D1913,
10 D1914, D1915, D1916, D1917, D1918, D1919, D1920, D1921, D1922, D1923, D1924,
D1925, D1926, D1927, D1928, D1929, D1930, D1931, D1932, D1933, D1934, D1935,
D1936, D1937, D1938, D1939, D1940, D1941, D1942, D1943, D1944, D1945, D1946,
D1947, D1948, D1949, D1950, D1951, D1952, D1953, D1954, D1955, D1956, D1957,
D1958, D1959, D1960, D1961, D1962, D1963, D1964, D1965, D1966, D1967, D1968,
15 D1969, D1970, D1971, D1972, D1973, D1974, D1975, D1976, D1977, D1978, D1979,
D1980, D1981, D1982, D1983, D1984, D1985, D1986, D1987, D1988, D1989, D1990,
D1991, D1992, D1993, D1994, D1995, D1996, D1997, D1998, D1999, D2000, D2001,
D2002, D2003, D2004, D2005, D2006, D2007, D2008, D2009, D2010, D2011, D2012,
D2013, D2014, D2015, D2016, D2017, D2018, D2019, D2020, D2021, D2022, D2023,
20 D2024, D2025, D2026, D2027, D2028, D2029, D2030, D2031, D2032, D2033, D2034,
D2035, D2036, D2037, D2038, D2039, D2040, D2041, D2042, D2043, D2044, D2045,
D2046, D2047, D2048, D2049, D2050, D2051, D2052, D2053, D2054, D2055, D2056,
D2057, D2058, D2059, D2060, D2061, D2062, D2063, D2064, D2065, D2066, D2067,
D2068, D2069, D2070, D2071, D2072, D2073, D2074, D2075, D2076, D2077, D2078,
25 D2079, D2080, D2081, D2082, D2083, D2084, D2085, D2086, D2087, D2088, D2089,
D2090 and D2091.
These agents may further comprise a ligand, such as a GalNAc ligand.
Ligands
30 The RNAi agents of the invention, e.g., double stranded RNAi agents, may
optionally be conjugated to one or more ligands. The ligand can be attached to the sense
48
W0 2013,:‘075035 PCT/U82012/065691
strand, antisense strand or both strands, at the , 5’-end or both ends. For instance,
the ligand may be conjugated to the sense strand. In preferred embodiments, the ligand
is conjgated to the 3’-end of the sense strand. In one preferred embodiment, the ligand
is a GalNAc ligand. In particularly preferred embodiments, the ligand is GalNAC3:
OH
HO
HO \/\/
AcHN W
OH K
HO
O
O
HO o H H
ACHN \/\/\g/ \/\/ %“0 O
o I
HO O\/\/\n/N/\/\N o
AcHN H H
o
A wide y of entities can be coupled to the RNAi agents of the present
invention. red moieties are ligands, which are coupled, preferably covalently,
either directly or indirectly via an intervening tether.
10 In preferred embodiments, a ligand alters the distribution, targeting or lifetime of
the molecule into which it is incorporated. In preferred embodiments a ligand provides
an enhanced affinity for a selected target, e.g., molecule, cell or cell type, compartment,
receptor e.g., a ar or organ compartment, , organ or region of the body, as,
e.g., compared to a species absent such a ligand. Ligands providing enhanced affinity
15 for a selected target are also termed targeting ligands.
Some ligands can have molytic properties. The endosomolytic ligands
promote the lysis of the endosome and/or transport of the composition of the invention,
or its components, from the endosome to the cytoplasm of the cell. The endosomolytic
ligand may be a polyanionic peptide or peptidomimetic which shows pH—dependent
20 membrane activity and fusogenicity. In one embodiment, the endosomolytic ligand
assumes its active conformation at endosomal pH. The “active” conformation is that
conformation in which the endosomolytic ligand promotes lysis of the endosome and/or
transport of the ition of the invention, or its components, from the endosome to
the cytoplasm of the cell. Exemplary endosomolytic s include the GALA peptide
49
W0 2013,:‘075035 PCT/U82012/065691
(Subbarao et (11., Biochemistry, 1987, 26: 972), the EALA peptide (V0gel et al., J.
Am. Chem. Soc., 1996, 118: 1581-1586), and their derivatives (Turk et (11., Biochem.
Biophys. Acta, 2002, 1559: 56—68). In one embodiment, the endosomolytic component
may contain a chemical group (e.g., an amino acid) which Will undergo a change in
charge or ation in response to a change in pH. The endosomolytic component
may be linear or branched.
Ligands can improve transport, hybridization, and specificity properties and may
also e nuclease resistance of the resultant natural or modified oligoribonucleotide,
or a polymeric molecule comprising any combination of monomers described herein
10 and/or natural or modified ribonucleotides.
Ligands in general can include therapeutic modifiers, e.g., for enhancing uptake;
diagnostic compounds or reporter groups e. g., for monitoring distribution; cross-linking
agents; and nuclease—resistance conferring moieties. l examples include lipids,
steroids, vitamins, , proteins, peptides, polyamines, and peptide mimics.
15 Ligands can include a naturally occurring substance, such as a n (e.g.,
human serum albumin (HSA), nsity lipoprotein (LDL), high—density otein
(HDL), or globulin); a carbohydrate (e.g., a dextran, pullulan, chitin, chitosan, inulin,
cyclodextrin or hyaluronic acid); or a lipid. The ligand may also be a recombinant or
synthetic molecule, such as a synthetic polymer, e.g., a synthetic polyamino acid, an
20 oligonucleotide (6.57., an aptamer). Examples of polyamino acids include polyamino
acid is a sine (PLL), poly L—aspartic acid, poly L—glutamic acid, styrene—maleic
acid anhydride copolymer, poly(L—lactide-co-glycolied) copolymer, l ether-maleic
anhydride copolymer, N-(2—hydroxypropyl)methacrylamide copolymer (HMPA),
polyethylene glycol (PEG), polyvinyl alcohol (PVA), polyurethane, poly(2—ethylacryllic
25 acid), N—isopropylacrylamide polymers, or osphazine. Example of polyamines
e: polyethylenimine, polylysine (PLL), spermine, spermidine, polyamine,
pseudopeptide—polyamine, peptidomimetic polyamine, dendrimer polyamine, ne,
amidine, protamine, cationic lipid, cationic porphyrin, quaternary salt of a polyamine, or
an alpha helical e.
30 Ligands can also include targeting groups, e.g., a cell or tissue ing agent,
e.g., a lectin, glycoprotein, lipid or protein, e.g., an antibody, that binds to a specified
50
W0 2013,:‘075035 PCT/U82012/065691
cell type such as a kidney cell. A targeting group can be a thyrotropin, melanotropin,
lectin, glycoprotein, surfactant protein A, Mucin carbohydrate, multivalent lactose,
multivalent galactose, N—acetyl—galactosamine, N—acetyl—gulucosamine multivalent
mannose, alent fucose, glycosylated polyaminoacids, multivalent galactose,
errin, bisphosphonate, utamate, polyaspartate, a lipid, cholesterol, a steroid,
bile acid, folate, vitamin B12, biotin, an RGD peptide, an RGD peptide mimetic or an
aptamer.
Other examples of ligands include dyes, intercalating agents (e.g., acridines),
linkers (e.g., psoralene, cin C), porphyrins (TPPC4, texaphyrin,
10 Sapphyrin), polycyclic aromatic hydrocarbons (e.g., phenazine, dihydrophenazine),
artificial endonucleases or a chelator (e.g., EDTA), lipophilic molecules, e.g.,
cholesterol, cholic acid, adamantane acetic acid, 1-pyrene butyric acid,
dihydrotestosterone, s—O(hexadecyl)glycerol, geranyloxyhexyl group,
hexadecylglycerol, bomeol, menthol, l,3—propanediol, heptadecyl group, palmitic acid,
15 ic acid,O3—(oleoyl)lithocholic acid, O3—(oleoyl)cholenic acid, dimethoxytrityl, or
phenoxazine)and peptide conjugates (e.g., antennapedia peptide, Tat peptide), alkylating
, phosphate, amino, mercapto, PEG (e.g., PEG—40K), MPEG, [MPEG]2,
polyamino, alkyl, tuted alkyl, radiolabeled markers, s, haptens (e.g.,
biotin), transport/absorption facilitators (e.g., aspirin, vitamin E, folic acid), tic
20 ribonucleases (e.g., imidazole, bisimidazole, histamine, imidazole clusters, acridine—
imidazole ates, Eu3+ complexes of tetraazamacrocycles), dinitrophenyl, HRP, or
AP.
Ligands can be proteins, e.g., glycoproteins, or peptides, e.g., molecules having a
specific ty for a co—ligand, or antibodies e.g., an antibody, that binds to a specified
25 cell type such as a cancer cell, elial cell, or bone cell. Ligands may also include
hormones and hormone receptors. They can also include non—peptidic species, such as
lipids, lectins, carbohydrates, vitamins, cofactors, multivalent lactose, multivalent
galactose, N—acetyl—galactosamine, N—acetyl—gulucosamine multivalent mannose,
multivalent fucose, or aptamers. The ligand can be, for example, a lipopolysaccharide,
30 an activator of p38 MAP kinase, or an activator of NF-KB.
51
W0 2013,:‘075035 PCT/U82012/065691
The ligand can be a substance, e.g., a drug, which can increase the uptake of the
iRNA agent into the cell, for example, by disrupting the cell’s cytoskeleton, e.g., by
disrupting the cell’s microtubules, microfilaments, and/or intermediate filaments. The
drug can be, for example, taxon, stine, stine, cytochalasin, zole,
5 japlakinolide, latrunculin A, phalloidin, swinholide A, indanocine, or myoservin.
The ligand can increase the uptake of the oligonucleotide into the cell by, for
example, activating an inflammatory response. Exemplary ligands that would have such
an effect include tumor is factor alpha (TNFalpha), interleukin—1 beta, or gamma
eron.
10 In one aspect, the ligand is a lipid or lipid—based molecule. Such a lipid or lipid—
based molecule preferably binds a serum protein, e.g., human serum albumin (HSA).
An HSA binding ligand allows for distribution of the conjugate to a target tissue, e.g., a
non—kidney target tissue of the body. For example, the target tissue can be the liver,
including parenchymal cells of the liver. Other molecules that can bind HSA can also be
15 used as ligands. For example, naproxen or aspirin can be used. A lipid or lipid—based
ligand can (a) increase resistance to degradation of the ate, (b) increase targeting
or ort into a target cell or cell membrane, and/or (c) can be used to adjust binding
to a serum protein, e.g., HSA.
A lipid based ligand can be used to modulate, e.g., control the binding of the
20 conjugate to a target tissue. For example, a lipid or lipid—based ligand that binds to HSA
more ly will be less likely to be targeted to the kidney and therefore less likely to
be cleared from the body. A lipid or lipid-based ligand that binds to HSA less strongly
can be used to target the conjugate to the kidney.
In a preferred embodiment, the lipid based ligand binds HSA. Preferably, it
25 binds HSA with a sufficient affinity such that the conjugate will be preferably
distributed to a non—kidney tissue. However, it is preferred that the affinity not be so
strong that the HSA—ligand binding cannot be reversed.
In r preferred embodiment, the lipid based ligand binds HSA weakly or
not at all, such that the ate will be preferably distributed to the kidney. Other
30 moieties that target to kidney cells can also be used in place of or in addition to the lipid
based ligand.
52
W0 2013,:‘075035 PCT/U82012/065691
In another aspect, the ligand is a moiety, e.g., a vitamin, which is taken up by a
target cell, e.g., a proliferating cell. These are particularly useful for treating disorders
characterized by unwanted cell proliferation, e.g., of the malignant or non—malignant
type, e.g., cancer cells. Exemplary vitamins include n A, E, and K. Other
exemplary ns include B vitamins, e.g., folic acid, B12, riboflavin, biotin,
pyridoxal or other vitamins or nutrients taken up by cancer cells. Also included are
HAS, low density lipoprotein (LDL) and high—density lipoprotein (HDL).
In another aspect, the ligand is a cell—permeation agent, preferably a helical cell—
permeation agent. Preferably, the agent is amphipathic. An exemplary agent is a
10 peptide such as tat or antennopedia. If the agent is a peptide, it can be modified,
including a peptidylmimetic, invertomers, non—peptide or —peptide linkages, and
use of D-amino acids. The helical agent is preferably an alpha-helical agent, which
preferably has a lipophilic and a lipophobic phase.
The ligand can be a e or peptidomimetic. A peptidomimetic (also referred
15 to herein as an oligopeptidomimetic) is a molecule capable of folding into a defined
three—dimensional structure similar to a natural peptide. The peptide or omimetic
moiety can be about 5—50 amino acids long, e.g., about 5, 10, 15, 20, 25, 30, 35, 40, 45,
or 50 amino acids long. A peptide or peptidomimetic can be, for example, a cell
permeation peptide, cationic peptide, amphipathic peptide, or hydrophobic peptide (e.g.,
20 consisting primarily of Tyr, Trp or Phe). The e moiety can be a dendrimer
e, ained peptide or crosslinked peptide. In another alternative, the peptide
moiety can include a hobic ne translocation sequence (MTS). An
exemplary hydrophobic MTS—containing peptide is RFGF having the amino acid
sequence AAVALLPAVLLALLAP (SEQ ID NO:4). An RFGF analogue (e.g., amino
25 acid sequence AALLPVLLAAP) (SEQ ID NO:5) containing a hydrophobic MTS can
also be a targeting . The peptide moiety can be a “delivery” peptide, which can
carry large polar les including peptides, oligonucleotides, and protein across cell
membranes. For example, sequences from the HIV Tat protein (GRKKRRQRRRPPQ)
(SEQ ID NO:6) and the Drosophila Antennapedia n (RQIKIWFQNRRMKWKK)
30 (SEQ ID NO:7) have been found to be e of functioning as delivery peptides. A
peptide or peptidomimetic can be encoded by a random sequence of DNA, such as a
53
W0 2013,:‘075035 PCT/U82012/065691
peptide identified from a phage—display library, or one—bead-one-compound (OBOC)
combinatorial library (Lam er al., Nature, 354:82-84, 1991). Preferably the peptide or
peptidomimetic tethered to an iRNA agent via an incorporated r unit is a cell
targeting peptide such as an arginine—glycine—aspartic acid (RGD)—peptide, or RGD
mimic. A peptide moiety can range in length from about 5 amino acids to about 40
amino acids. The peptide moieties can have a structural cation, such as to
increase stability or direct conformational properties. Any of the structural
modifications described below can be utilized.An RGD peptide moiety can be used to
target a tumor cell, such as an endothelial tumor cell or a breast cancer tumor cell
10 (Zitzmann et al., Cancer Res., 62:5139—43, 2002). An RGD peptide can facilitate
ing of an iRNA agent to tumors of a variety of other tissues, including the lung,
kidney, spleen, or liver (Aoki et al., Cancer Gene Therapy 8:783-787, 2001).
Preferably, the RGD peptide will facilitate targeting of an iRNA agent to the kidney.
The RGD peptide can be linear or cyclic, and can be modified, e. g., glycosylated or
15 methylated to facilitate ing to specific tissues. For example, a ylated RGD
peptide can deliver an iRNA agent to a tumor cell sing (xx/133 (Haubner et al. , Joar.
Nucl. Med., 42:326—336, 2001). Peptides that target s ed in proliferating
cells can be used. For example, RGD containing peptides and peptidomimetics can
target cancer cells, in particular cells that exhibit an integrin. Thus, one could use RGD
20 peptides, cyclic es containing RGD, RGD peptides that include D—amino acids, as
well as synthetic RGD mimics. In addition to RGD, one can use other moieties that
target the integrin ligand. lly, such ligands can be used to l proliferating
cells and angiogeneis. Preferred conjugates of this type of ligand target PECAM—l,
VEGF, or other cancer gene, e.g., a cancer gene bed herein.
25 A “cell permeation peptide” is capable of permeating a cell, e.g., a microbial cell,
such as a bacterial or fungal cell, or a mammalian cell, such as a human cell. A
microbial cell—perrneating peptide can be, for example, an (it—helical linear peptide (e.g.,
LL—37 or Ceropin P1), a disulfide bond—containing peptide (e. g., (x —defensin, B—defensin
or bactenecin), or a peptide containing only one or two dominating amino acids (e.g.,
30 PR-39 or indolicidin). A cell permeation peptide can also include a nuclear localization
signal (NLS). For example, a cell permeation peptide can be a bipartite amphipathic
54
W0 2013.:‘075035 PCT/U82012/065691
peptide, such as MPG, which is derived from the fusion peptide domain of HIV—1 gp41
and the NLS of SV40 large T antigen (Simeoni et al., Nucl. Acids Res. 31:2717—2724,
2003).
In one embodiment, a targeting peptide can be an amphipathic cal peptide.
Exemplary amphipathic (X-hCllCal es include, but are not limited to, cecropins,
xins, paradaxins, buforin, CPF, bombinin—like e (BLP), cathelicidins,
ceratotoxins, S. clava es, h intestinal antimicrobial peptides (HFIAPs),
magainines, brevinins—Z, eptins, ins, pleurocidin, H2A peptides, Xenopus
peptides, esculentinis—l, and s. A number of factors will preferably be ered
10 to maintain the integrity of helix stability. For example, a maximum number of helix
stabilization residues will be utilized (e.g., leu, ala, or lys), and a minimum number helix
destabilization residues will be utilized (e.g., proline, or cyclic monomeric units. The
capping e will be considered (for example Gly is an exemplary N—capping residue
and/or C—terminal amidation can be used to e an extra H—bond to stabilize the
15 helix. Formation of salt bridges between es with te charges, separated by i
i 3, or i i 4 positions can provide stability. For example, cationic residues such as
lysine, arginine, homo—arginine, ornithine or histidine can form salt bridges with the
anionic residues glutamate or aspartate.
Peptide and peptidomimetic ligands include those having naturally occurring or
20 modified peptides, 6.57., D or L peptides; or, B, or y peptides; N—methyl peptides;
azapeptides; peptides having one or more amide, i.e., peptide, linkages replaced with one
or more urea, thiourea, carbamate, or sulfonyl urea linkages; or cyclic peptides.
The targeting ligand can be any ligand that is capable of targeting a specific
receptor. Examples are: folate, GalNAc, galactose, mannose, mannose—6P, clusters of
25 sugars such as GalNAc cluster, mannose cluster, galactose cluster, or an apatamer. A
cluster is a combination of two or more sugar units. The targeting ligands also include
integrin receptor ligands, Chemokine receptor s, transferrin, biotin, serotonin
receptor ligands, PSMA, endothelin, GCPII, somatostatin, LDL and HDL ligands. The
ligands can also be based on c acid, 6.57., an aptamer. The aptamer can be
30 unmodified or have any combination of modifications disclosed herein.
55
W0 2013,:‘075035 PCT/U82012/065691
Endosomal release agents include imidazoles, poly or oligoimidazoles, PEIs,
peptides, fusogenic peptides, polycaboxylates, polyacations, masked oligo or poly
cations or anions, acetals, polyacetals, ketals/polyketyals, sters, polymers with
masked or unmasked cationic or anionic charges, dendrimers with masked or unmasked
cationic or anionic s.
PK modulator stands for pharmacokinetic modulator. PK modulators include
lipophiles, bile acids, steroids, phospholipid analogues, peptides, protein binding agents,
PEG, vitamins etc. Examplary PK modulators include, but are not limited to, cholesterol,
fatty acids, cholic acid, lithocholic acid, dialkylglycerides, diacylglyceride,
10 phospholipids, sphingolipids, naproxen, ibuprofen, vitamin E, biotin etc.
Oligonucleotides that comprise a number of phosphorothioate linkages are also known
to bind to serum protein, thus short Oligonucleotides, e.g., Oligonucleotides of about 5
bases, 10 bases, 15 bases or 20 bases, sing le phosphorothioate linkages in
the one are also amenable to the t invention as s (e.g., as PK
15 modulating ligands).
In addition, aptamers that bind serum components (e.g., serum proteins) are also
amenable to the present invention as PK modulating ligands.
Other ligand conjugates amenable to the invention are described in US. Patent
Applications USSN: 10/916,185, filed August 10, 2004; USSN: 10/946,873, filed
20 September 21, 2004; USSN: 10/833,934, filed August 3, 2007; USSN: 11/115,989 filed
April 27, 2005 and USSN: 11/944,227 filed November 21, 2007, which are orated
by reference in their entireties for all purposes.
When two or more s are present, the ligands can all have same properties,
all have different properties or some ligands have the same properties while others have
25 ent ties. For example, a ligand can have targeting properties, have
endosomolytic activity or have PK modulating properties. In a preferred ment, all
the ligands have different properties.
Ligands can be coupled to the Oligonucleotides at various places, for example,
3’—end, 5’—end, and/or at an internal position. In preferred embodiments, the ligand is
30 attached to the Oligonucleotides via an intervening tether, e.g., a carrier described herein.
The ligand or tethered ligand may be t on a monomer when the monomer is
56
W0 2013,:‘075035 PCT/U82012/065691
incorporated into the growing strand. In some embodiments, the ligand may be
incorporated via coupling to a “precursor” monomer after the “precursor” r has
been incorporated into the growing strand. For example, a monomer having, e.g., an
amino—terminated tether (i.e., having no associated ligand), e.g., TAP—(CH2)HNH2 may
be incorporated into a growing oligonucelotide strand. In a uent operation, i.e.,
after incorporation of the precursor monomer into the strand, a ligand having an
electrophilic group, 6.57., a uorophenyl ester or aldehyde group, can subsequently
be ed to the precursor monomer by coupling the electrophilic group of the ligand
with the terminal philic group of the precursor monomer’s tether.
10 In another example, a monomer having a chemical group le for taking part
in Click try reaction may be incorporated, e. g., an azide or alkyne terminated
tether/linker. In a subsequent operation, i.e., after incorporation of the precursor
monomer into the strand, a ligand having complementary chemical group, e.g. an alkyne
or azide can be attached to the precursor monomer by ng the alkyne and the azide
15 er.
For double— stranded oligonucleotides, s can be attached to one or both
strands. In some embodiments, a double—stranded iRNA agent contains a ligand
conjugated to the sense strand. In other embodiments, a double—stranded iRNA agent
contains a ligand conjugated to the antisense strand.
20 In some ments, ligand can be conjugated to nucleobases, sugar moieties,
or internucleosidic linkages of nucleic acid molecules. Conjugation to purine
nucleobases or derivatives thereof can occur at any position including, endocyclic and
exocyclic atoms. In some embodiments, the 2—, 6—, 7—, or 8—positions of a purine
base are attached to a conjugate moiety. ation to pyrimidine nucleobases
25 or derivatives thereof can also occur at any position. In some ments, the 2—, 5—,
and 6—positions of a pyrimidine nucleobase can be substituted with a conjugate moiety.
Conjugation to sugar moieties of nucleosides can occur at any carbon atom. Example
carbon atoms of a sugar moiety that can be attached to a conjugate moiety include the 2',
3', and 5' carbon atoms. The 1' position can also be attached to a conjugate moiety, such
30 as in an abasic residue. Internucleosidic linkages can also bear conjugate moieties. For
phosphorus—containing linkages (e.g., phosphodiester, phosphorothioate,
57
W0 2013,:‘075035 PCT/U82012/065691
phosphorodithiotate, phosphoroamidate, and the like), the conjugate moiety can be
ed ly to the phosphorus atom or to an O, N, or S atom bound to the
phosphorus atom. For amine— or amide—containing internucleosidic linkages (e.g., PNA),
the conjugate moiety can be attached to the en atom of the amine or amide or to an
adjacent carbon atom.
Any suitable ligand in the field of RNA interference may be used, although the
ligand is typically a carbohydrate e.g. monosaccharide (such as GalNAc), disaccharide,
trisaccharide, tetrasaccharide, polysaccharide.
Linkers that conjugate the ligand to the nucleic acid include those discussed
10 above. For e, the ligand can be one or more GalNAc (N—acetylglucosamine)
derivatives attached through a bivalent or trivalent branched linker.
In one embodiment, the dsRNA of the invention is conjugated to a bivalent and
trivalent branched s include the structures shown in any of formula (IV) — (VII):
PZA-QZA-RZA, A
2A
q JP3A'Q3A'R3Al3—AT3A'L3Aq
mN
PZB-QZB-RZB ]?TZB_LZB \fP3B_Q3B_R3B]3TT3B_|—SB
‘1 q
Formula (1V) Formula (V)
P4A_Q4A_R4A]_T4A_L4A
4A
q
P4B-Q4B-R lWT4B 4B-L4B
C1
Formula (VI)
15 or
,
P5A_Q5A_R5A I T5A_L5A
5A
q
P5B—Q513—R513 ]5—BT5B_L53
q
PSC-QSC-RSC L5C
q
Formula (VII)
wherein:
58
W0 2013,:‘075035 PCT/U82012/065691
qu, q2B 3A 4B and q5C represent independently for each
, q , q3B, q4A, q , qSA, q5B
ence 0-20 and wherein the repeating unit can be the same or different;
PZA P213 P3A P313 P4A P413 PSA P513 Psc TZA T213 T3A T313 T4A T413 T4A T513 Tsc are
each independently for each occurrence absent, CO, NH, O, S, OC(O), NHC(O), CH2,
CH2NH or CHZO;
QZA, QZB, Q3A, Q33, Q4A, Q43, QSA, Q53, Q5C are independently for each
occurrence absent, alkylene, substituted alkylene wherin one or more methylenes can be
upted or terminated by one or more of O, S, S(O), S02, N(RN), C(R’)=C(R”), CEC
or C(O);
10 RZA, RZB, R3A, R33, R“, R43, RSA, R53, R5C are each independently for each
occurrence absent, NH, O, S, CH2, C(O)O, C(O)NH, NHCH(Ra)C(O), —C(O)—CH(Ra)—
O
0
HO 8—8
v“
,CH=N-O,J~“NHi WM W><H, ,
8—8
W \pi" 8—8
,W Wor heterocyclyl;
LZA, LZB, L3A, L33, L4A, L43, LSA, L513 and L5C represent the ligand; i. 6. each
15 independently for each occurrence a monosaccharide (such as GalNAc), haride,
trisaccharide, tetrasaccharide, oligosaccharide, or polysaccharide; and
R21 is H or amino acid side chain.
Trivalent conjugating GalNAc derivatives are particularly useful for use with
RNAi agents for inhibiting the expression of a target gene, such as those of formula
20 (VII):
P5A_Q5A_R5A I T5A_L5A
5A
q
PSB-QSB-RSB iKTSB—LSB
q
PSC-QSC-RSC ]TTSC_L5C
q
Formula (VII)
9
- 5A 513 5c
wherein L L and L .
, represent a monosaccharide, such as GalNAc
derivative.
Examples of le bivalent and trivalent ed linker groups conjugating GalNAc
25 derivatives include, but are not limited to, the following compounds:
59
WO 75035 PCT/U82012/065691
HO
60
W0 2013,:‘075035 PCT/U82012/065691
HO OH HO OH
H O
O
HO OWN HO&/O\/\/\_O
HO OH NHAc
NHAC O
HO OH /\/\_05§
NHACHO O
O OH
\/\/\n/ Ho&: 0
NHAc O NHAc
,
OH
HO
O
0 H
O
HO O\/\)J\N/\/\/\/N
AcHN H \g/
O“
HO
O
o
H
HO
AHN OMNWNTOC H
O
OH
HO
O
AcHN H
OH
H
OH
HO
0
HO O\/\O/\/O\/\N O
5 AcHN H ,or
HO OH
O
o H
HO N T
ACHN H O
HO OH
flOA H
N
O
HO OH
61
W0 2013,:‘075035 PCT/U82012/065691
In other ments, the RNAi agent of the invention is an agent selected from
the group consisting of AD-45163, AD-45165, AD-51544, AD-S 1545, AD-51546, and
AD—S 1547.
III. Pharmaceutical Compositions
The RNAi agents of the invention may be formulated for administration in any
convenient way for use in human or veterinary medicine, by analogy with other
pharmaceuticals. The pharmaceutical compositions comprising RNAi agents of the
invention may be, for example, solutions with or without a buffer, or compositions
10 containing pharmaceutically acceptable carriers. Such compositions include, for
example, aqueous or crystalline compositions, liposomal formulations, micellar
formulations, emulsions, and gene therapy vectors.
In the methods of the invention, the RNAi agent may be administered in a
solution. A free RNAi agent may be administered in an unbuffered solution, e.g., in
15 saline or in water. Alternatively, the free siRNA may also be administred in a suitable
buffer solution. The buffer on may comprise acetate, e, ine, carbonate,
or phosphate, or any combination thereof. In a preferred embodiment, the buffer
solution is phosphate buffered saline (PBS). The pH and osmolarity of the buffer
on containing the RNAi agent can be adjusted such that it is suitable for
20 administering to a subject.
In some embodiments, the buffer solution further comprises an agent for
controlling the osmolarity of the solution, such that the osmolarity is kept at a desired
value, e.g., at the physiologic values of the human plasma. Solutes which can be added
to the buffer solution to control the osmolarity include, but are not limited to, proteins,
25 es, amino acids, non—metabolized polymers, ns, ions, sugars, metabolites,
organic acids, lipids, or salts. In some ments, the agent for controlling the
osmolarity of the on is a salt. In certain embodiments, the agent for controlling the
osmolarity of the solution is sodium chloride or potassium de.
In other embodiments, the RNAi agent is formulated as a composition that
30 includes one or more RNAi agents and a pharmaceutically acceptable r. As used
herein the language “pharmaceutically acceptable carrier” is intended to include any and
62
W0 2013,:‘075035 PCT/U82012/065691
all solvents, sion media, coatings, antibacterial and antifungal , isotonic and
absorption delaying agents, and the like, compatible with pharmaceutical administration.
The use of such media and agents for pharmaceutically active substances is well known
in the art. Except insofar as any conventional media or agent is incompatible with the
active compound, use thereof in the compositions is contemplated. Supplementary active
compounds can also be incorporated into the compositions.
In one ment, the RNAi agent preparation includes at least a second
therapeutic agent (e.g., an agent other than an RNA or a DNA). For example, an RNAi
agent ition for the treatment of a sociated disease, e.g., a transthyretin—
10 related hereditary amyloidosis (familial amyloid polyneuropathy, FAP), may include a
known drug for the amelioration of PAP, e.g., Tafamidis (INN, or Fx—1006A or
Vyndaqel).
A formulated RNAi agent composition can assume a variety of states. In some
examples, the composition is at least partially crystalline, uniformly crystalline, and/or
15 anhydrous (e.g., it contains less than 80, 50, 30, 20, or 10% of water). In another
example, the RNAi agent is in an aqueous phase, 6.57., in a solution that includes water.
The aqueous phase or the crystalline compositions can be incorporated into a
delivery vehicle, 6.57., a liposome (particularly for the aqueous phase) or a particle (e.g.,
a article as can be appropriate for a crystalline composition). Generally, the
20 RNAi agent composition is formulated in a manner that is compatible with the intended
method of administration, as described herein. For example, in particular embodiments
the composition is prepared by at least one of the following methods: spray drying,
lyophilization, vacuum drying, evaporation, fluid bed drying, or a combination of these
techniques; or sonication with a lipid, —drying, condensation and other self—
25 assembly.
An RNAi agent preparation can be formulated in combination with another
agent, e.g., another therapeutic agent or an agent that izes RNAi agent, e.g., a
n that complexes with the RNAi agent to form an iRNP. Still other agents e
chelators, e.g., EDTA (6.57., to remove nt cations such as Mg2+), salts, RNAse
30 inhibitors (e.g., a broad specificity RNAse inhibitor such as RNAsin) and so forth.
63
W0 2013,:‘075035 PCT/U82012/065691
In one ment, the RNAi agent preparation es another siRNA
compound, e.g., a second RNAi agent that can mediate RNAi with respect to a second
gene, or with respect to the same gene. Still other preparation can include at least 3, 5,
ten, twenty, fifty, or a hundred or more different RNAi agent species. Such RNAi
agents can mediate RNAi with respect to a similar number of different genes.
The iRNA agents of the invention may be formulated for pharmaceutical use.
Pharmaceutically acceptable compositions comprise a therapeutically—or
prophylactically effective amount of one or more of the the dsRNA agents in any of the
preceding ments, taken alone or formulated together with one or more
10 pharmaceutically acceptable carriers ives), ent and/or diluents.
Methods of ing pharmaceutical itions of the invention include the
step of bringing into association an RNAi agent of the present invention with the carrier
and, optionally, one or more accessory ingredients. In general, the compositionsare
prepared by uniformly and intimately bringing into ation an RNAi agent of the
15 present invention with liquid carriers, or finely d solid carriers, or both, and then,
if necessary, shaping the product.
The pharmaceutical compositions may be specially formulated for administration
in solid or liquid form, including those adapted for the following: (1) oral
administration, for example, drenches (aqueous or non—aqueous solutions or
20 suspensions), tablets, e. g., those targeted for buccal, sublingual, and systemic absorption,
boluses, powders, granules, pastes for application to the tongue; (2) parenteral
administration, for example, by subcutaneous, intramuscular, enous or epidural
injection as, for example, a sterile solution or suspension, or sustained—release
ation; (3) topical application, for example, as a cream, ointment, or a controlled—
25 release patch or spray applied to the skin; (4) intravaginally or intrarectally, for example,
as a pessary, cream or foam; (5) sublingually; (6) ocularly; (7) transdermally; or (8)
nasally. Delivery using subcutaneous or intravenous methods can be particularly
advantageous.
The phrase "pharmaceutically able" is employed herein to refer to those
30 compounds, materials, compositions, and/or dosage forms which are, within the scope of
sound medical judgment, suitable for use in t with the tissues of human beings and
64
W0 2013,:‘075035 PCT/U82012/065691
animals without excessive ty, irritation, allergic response, or other problem or
complication, commensurate with a reasonable t/risk ratio.
The phrase "pharmaceutically—acceptable carrier" as used herein means a
ceutically—acceptable material, composition or vehicle, such as a liquid or solid
filler, diluent, excipient, manufacturing aid (e. g., lubricant, talc magnesium, calcium or
zinc stearate, or steric acid), or solvent encapsulating material, involved in carrying or
transporting the subject compound from one organ, or portion of the body, to another
organ, or portion of the body. Each carrier must be "acceptable" in the sense of being
ible with the other ingredients of the compositionand not injurious to the patient.
10 Some examples of materials which can serve as pharmaceutically—acceptable carriers
include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn
starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl
cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6)
n; (7) lubricating agents, such as magnesium state, sodium lauryl sulfate and talc;
15 (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil,
cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols,
such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and
polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (l3) agar; (14)
buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic
20 acid; (16) pyrogen—free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl
alcohol; (20) pH buffered solutions; (21) polyesters, polycarbonates and/or
polyanhydrides; (22) bulking agents, such as polypeptides and amino acids (23) serum
component, such as serum albumin, HDL and LDL; and (22) other non—toxic ible
substances employed in pharmaceuticalcompositions.
25 The compositions may conveniently be ted in unit dosage form and may
be ed by any methods well known in the art of cy. The amount of RNAi
agent which can be combined with a carrier material to produce a single dosage form
will vary ing upon the host being treated, and the particular mode of
administration. The RNAi agent which can be ed with a r material to
30 produce a single dosage form will generally be that amount of the RNAi agent which
produces a d effect, e. g., therapeutic or prophylactic effect. Generally, out of one
65
W0 2013,:‘075035 PCT/U82012/065691
hundred per cent, this amount will range from about 0.1 per cent to about ninety—nine
percent of RNAi agent, preferably from about 5 per cent to about 70 per cent, most
preferably from about 10 per cent to about 30 per cent.
In n embodiments, a composition of the present ion comprises an
excipient selected from the group consisting of cyclodextrins, celluloses, liposomes,
micelle forming , e.g., bile acids, and polymeric carriers, e.g., polyesters and
polyanhydrides; and an RNAi agent of the present invention. In certain embodiments,
an aforementioned composition renders orally bioavailable an RNAi agent of the present
invention.
10 In some cases, in order to prolong the effect of an RNAi agent, it is desirable to
slow the absorption of the agent from subcutaneous or intramuscular ion. This
may be accomplished by the use of a liquid suspension of crystalline or amorphous
material having poor water solubility. The rate of tion of the RNAi agent then
depends upon its rate of dissolution which, in turn, may depend upon crystal size and
15 lline form. atively, delayed tion of a parenterally—administered RNAi
agent may be accomplished by dissolving or suspending the agent in an oil vehicle.
Liposomes
An RNAi agent of the invention can be formulated for delivery in a membranous
molecular assembly, 6.57., a liposome or a micelle. As used herein, the term “liposome”
20 refers to a vesicle composed of amphiphilic lipids arranged in at least one r, e.g.,
one bilayer or a plurality of bilayers. Liposomes include unilamellar and multilamellar
vesicles that have a ne formed from a lipophilic material and an aqueous
interior. The aqueous portion contains the RNAi agent composition. The lipophilic
material isolates the aqueous interior from an aqueous exterior, which typically does not
25 include the RNAi agent composition, although in some examples, it may. Liposomes
are useful for the transfer and delivery of active ients to the site of action.
Because the liposomal membrane is structurally similar to biological membranes, when
liposomes are applied to a tissue, the liposomal bilayer fuses with bilayer of the cellular
membranes. As the merging of the me and cell progresses, the internal aqueous
30 ts that include the RNAi agent are delivered into the cell where the RNAi agent
can specifically bind to a target RNA and can mediate RNAi. In some cases the
66
W0 2013,:‘075035 PCT/US2012/065691
liposomes are also specifically targeted, e.g., to direct the RNAi agent to particular cell
types.
A liposome containing an RNAi agent can be prepared by a variety of methods.
In one example, the lipid component of a liposome is ved in a ent so that
es are formed with the lipid component. For example, the lipid component can be
an amphipathic cationic lipid or lipid conjugate. The detergent can have a high critical
micelle tration and may be nonionic. Exemplary detergents include e,
CHAPS, octylglucoside, deoxycholate, and lauroyl sarcosine. The RNAi agent
preparation is then added to the micelles that include the lipid ent. The cationic
10 groups on the lipid interact with the RNAi agent and condense around the RNAi agent to
form a liposome. After condensation, the detergent is removed, e.g., by dialysis, to yield
a liposomal preparation of RNAi agent.
If necessary a carrier compound that assists in condensation can be added during
the condensation reaction, e.g., by controlled addition. For example, the carrier
15 compound can be a polymer other than a nucleic acid (e.g., ne or spermidine). pH
can also be ed to favor condensation.
Methods for producing stable polynucleotide delivery vehicles, which
incorporate a polynucleotide/cationic lipid complex as structural components of the
delivery vehicle, are further described in, 6.57., WO 96/37194, the entire contents of
20 which are incorporated herein by reference. Liposome formation can also include one or
more s of ary methods described in Felgner, P. L. et LIL, Proc. Natl. Acad.
Sci., USA 8:7413-7417, 1987; US. Pat. No. 4,897,355; US. Pat. No. 5,171,678;
Bangham, er al. M. Mol. Biol. 23:238, 1965; Olson, er al. Biochim. Biophys. Acta 557:9,
1979; Szoka, et al. Proc. Natl. Acad. Sci. 75: 4194, 1978; Mayhew, et al. Biochim.
25 Biophys. Acta 775:169, 1984; Kim, et al. Biochim. Biophys. Acta 728:339, 1983; and
Fukunaga, et al. Endocrinol. 115:757, 1984. Commonly used techniques for preparing
lipid aggregates of appropriate size for use as delivery vehicles include sonication and
freeze—thaw plus extrusion (see, e.g., Mayer, et al. Biochim. Biophys. Acta 858:161,
1986). uidization can be used when consistently small (50 to 200 nm) and
30 relatively uniform aggregates are desired (Mayhew, et al. Biochim. Biophys. Acta
67
W0 2013,:‘075035 PCT/US2012/065691
775: 169, 1984). These s are readily adapted to packaging RNAi agent
ations into mes.
Liposomes that are pH—sensitive or negatively—charged entrap nucleic acid
molecules rather than complex with them. Since both the nucleic acid les and the
lipid are similarly charged, repulsion rather than complex formation occurs.
Nevertheless, some nucleic acid molecules are entrapped within the aqueous interior of
these liposomes. pH—sensitive liposomes have been used to deliver DNA encoding the
thymidine kinase gene to cell monolayers in culture. Expression of the exogenous gene
was detected in the target cells (Zhou et al., l of Controlled Release, 19, (1992)
10 4).
One major type of liposomal composition includes phospholipids other than
naturally-derived phosphatidylcholine. Neutral liposome compositions, for example,
can be formed from dimyristoyl phosphatidylcholine (DMPC) or dipalmitoyl
phosphatidylcholine (DPPC). Anionic liposome compositions generally are formed
15 from dimyristoyl atidylglycerol, while c fusogenic liposomes are formed
primarily from dioleoyl phosphatidylethanolamine (DOPE). Another type of liposomal
composition is formed from phosphatidylcholine (PC) such as, for example, soybean
PC, and egg PC. Another type is formed from mixtures of phospholipid and/or
phosphatidylcholine and/or cholesterol.
20 Examples of other methods to introduce liposomes into cells in vitro and in vivo
include U.S. Pat. No. 5,283,185; U.S. Pat. No. 678; WO 94/00569; WO 93/24640;
W0 91/16024; Felgner, J. Biol. Chem. 269:2550, 1994; Nabel, Proc. Natl. Acad. Sci.
90:11307, 1993; Nabel, Human Gene Ther. 3:649, 1992; Gershon, Biochem. 32:7143,
1993; and Strauss EMBO J. 11:417, 1992.
25 In one embodiment, ic liposomes are used. Cationic mes possess the
advantage of being able to fuse to the cell membrane. Non—cationic liposomes, although
not able to fuse as efficiently with the plasma membrane, are taken up by hages
in vivo and can be used to deliver RNAi agents to macrophages.
Further advantages of liposomes include: liposomes obtained from natural
30 olipids are biocompatible and biodegradable; liposomes can incorporate a wide
range of water and lipid soluble drugs; liposomes can protect encapsulated RNAi agents
68
W0 2013,:‘075035 PCT/U82012/065691
in their internal compartments from lism and degradation (Rosoff, in
"Pharmaceutical Dosage Forms," man, Rieger and Banker (Eds), 1988, volume 1,
p. 245). ant considerations in the preparation of liposome formulations are the
lipid surface charge, vesicle size and the aqueous volume of the liposomes.
A positively charged tic cationic lipid, N—[l—(2,3—dioleyloxy)propyl]—
N,N,N—trimethylammonium chloride (DOTMA) can be used to form small liposomes
that interact spontaneously with nucleic acid to form lipid—nucleic acid complexes which
are capable of fusing with the negatively charged lipids of the cell membranes of tissue
culture cells, resulting in delivery of RNAi agent (see, e.g., Felgner, P. L. et al., Proc.
10 Natl. Acad. Sci., USA 8:7413—7417, 1987 and US. Pat. No. 4,897,355 for a description
of DOTMA and its use with DNA).
A DOTMA analogue, 1,2-bis(oleoyloxy)(trimethylammonia)propane
(DOTAP) can be used in combination with a phospholipid to form DNA—complexing
vesicles. LipofectinTM Bethesda Research Laboratories, Gaithersburg, Md.) is an
15 effective agent for the delivery of highly c nucleic acids into living tissue culture
cells that comprise positively charged DOTMA liposomes which interact neously
with vely charged polynucleotides to form complexes. When enough positively
charged liposomes are used, the net charge on the resulting complexes is also positive.
Positively charged complexes prepared in this way spontaneously attach to negatively
20 charged cell surfaces, fuse with the plasma membrane, and efficiently deliver functional
nucleic acids into, for example, tissue culture cells. Another commercially available
cationic lipid, 1,2-bis(oleoyloxy)-3,3-(trimethylammonia)propane (“DOTAP”)
(Boehringer im, Indianapolis, Indiana) differs from DOTMA in that the oleoyl
es are linked by ester, rather than ether linkages.
25 Other reported cationic lipid compounds include those that have been conjugated
to a variety of moieties ing, for example, carboxyspermine which has been
conjugated to one of two types of lipids and includes compounds such as 5—
carboxyspermylglycine dioctaoleoylamide (“DOGS”) (TransfectamTM, Promega,
n, Wisconsin) and itoylphosphatidylethanolamine 5—carboxyspermyl—
30 amide (“DPPES”) (see, 6.57., US. Pat. No. 5,171,678).
69
W0 2013,:‘075035 PCT/U82012/065691
r cationic lipid conjugate includes tization of the lipid with
cholesterol (“DC-Chol”) which has been formulated into liposomes in combination with
DOPE (See, Gao, X. and Huang, L., Biochim. Biophys. Res. Commun. 179:280, 1991).
Lipopolylysine, made by conjugating polylysine to DOPE, has been reported to be
effective for transfection in the presence of serum (Zhou, X. er al., Biochim. Biophys.
Acta 1065 :8, 1991). For certain cell lines, these liposomes containing conjugated
cationic lipids, are said to exhibit lower toxicity and provide more efficient transfection
than the DOTMA—containing compositions. Other commercially available cationic lipid
ts e DMRIE and DMRIE—HP (Vical, La Jolla, California) and
10 Lipofectamine (DOSPA) (Life Technology, Inc., Gaithersburg, nd). Other
cationic lipids suitable for the delivery of oligonucleotides are described in WO
98/39359 and WO 96/37194.
Liposomal formulations are particularly suited for topical administration,
liposomes present several ages over other formulations. Such advantages include
15 d side effects related to high systemic absorption of the administered drug,
increased accumulation of the stered drug at the desired target, and the ability to
administer RNAi agent into the skin. In some implementations, liposomes are used for
delivering RNAi agent to epidermal cells and also to enhance the penetration of RNAi
agent into dermal s, e.g., into skin. For example, the liposomes can be applied
20 lly. Topical delivery of drugs formulated as liposomes to the skin has been
documented (see, e. g., Weiner et al., Journal ofDrug Targeting, 1992, vol. 2,405—410
and du Plessis er al., Antiviral Research, 18, 1992, 259-265; Mannino, R. J. and Fould-
Fogerite, S., Biotechniques 6:682—690, 1988; Itani, T. et al. Gene 56:267—276. 1987;
Nicolau, C. et al. Meth. Enz. 7—176, 1987; Straubinger, R. M. and
25 Papahadjopoulos, D. Meth. Enz. 101:512—527, 1983; Wang, C. Y. and Huang, L., Proc.
Natl. Acad. Sci. USA 84:7851—7855, 1987).
Non—ionic liposomal systems have also been ed to determine their utility
in the delivery of drugs to the skin, in particular systems comprising non-ionic tant
and cholesterol. Non—ionic liposomal formulations comprising Novasome I (glyceryl
30 dilaurate/cholesterol/polyoxyethylene—10—stearyl ether) and Novasome II (glyceryl
distearate/ cholesterol/polyoxyethylene— lO—stearyl ether) were used to deliver a drug into
70
W0 2013,:‘075035 PCT/US2012/065691
the dermis of mouse skin. Such formulations with RNAi agent are useful for treating a
dermatological disorder.
Liposomes that e RNAi agent can be made highly deformable. Such
deformability can enable the liposomes to penetrate through pore that are smaller than
the average radius of the liposome. For example, transfersomes are a type of
deformable liposomes. Transferosomes can be made by adding surface edge activators,
usually surfactants, to a standard liposomal composition. Transfersomes that include
RNAi agent can be delivered, for example, subcutaneously by infection in order to
deliver RNAi agent to keratinocytes in the skin. In order to cross intact mammalian
10 skin, lipid vesicles must pass through a series of fine pores, each with a diameter less
than 50 nm, under the influence of a suitable transdermal gradient. In addition, due to
the lipid ties, these transferosomes can be self-optimizing (adaptive to the shape
of pores, 6.3., in the skin), self—repairing, and can frequently reach their targets t
nting, and often self—loading.
15 Other formulations amenable to the present invention are described in United
States provisional ation serial Nos. 61/018,616, filed y 2, 2008; 61/018,611,
filed January 2, 2008; 61/039,748, filed March 26, 2008; 61/047,087, filed April 22,
2008 and 61/051,528, filed May 8, 2008. PCT application no PCT/US2007/080331,
filed October 3, 2007 also describes formulations that are amenable to the present
20 invention.
Surfactants
Surfactants find wide application in formulations such as emulsions (including
microemulsions) and mes (see above). RNAi agent (or a precursor, e.g., a larger
dsiRNA which can be processed into a siRNA, or a DNA which encodes a siRNA or
25 precursor) compositions can include a surfactant. In one ment, the siRNA is
formulated as an emulsion that es a surfactant. The most common way of
classifying and ranking the properties of the many different types of surfactants, both
natural and synthetic, is by the use of the hydrophile/lipophile e (HLB). The
nature of the hilic group provides the most useful means for categorizing the
30 different surfactants used in formulations (Rieger, in “Pharmaceutical Dosage Forms,”
Marcel Dekker, Inc., New York, NY, 1988, p. 285).
71
W0 2013,:‘075035 PCT/US2012/065691
If the surfactant molecule is not ionized, it is classified as a nonionic surfactant.
Nonionic tants find wide application in pharmaceutical products and are usable
over a wide range of pH values. In general their HLB values range from 2 to about 18
depending on their structure. Nonionic tants include nonionic esters such as
ethylene glycol esters, propylene glycol esters, glyceryl esters, polyglyceryl esters,
an esters, sucrose esters, and ethoxylated esters. Nonionic alkanolamides and
ethers such as fatty alcohol ethoxylates, propoxylated alcohols, and
ethoxylated/propoxylated block polymers are also included in this class. The
yethylene surfactants are the most popular members of the nonionic surfactant
10 class.
If the surfactant le carries a negative charge when it is dissolved or
dispersed in water, the surfactant is classified as anionic. Anionic surfactants include
carboxylates such as soaps, acyl lactylates, acyl amides of amino acids, esters of sulfuric
acid such as alkyl sulfates and ethoxylated alkyl sulfates, ates such as alkyl
15 benzene sulfonates, acyl isethionates, acyl es and sulfosuccinates, and phosphates.
The most important members of the anionic surfactant class are the alkyl sulfates and the
soaps.
If the surfactant molecule carries a positive charge when it is dissolved or
dispersed in water, the tant is classified as cationic. Cationic surfactants include
20 quaternary ammonium salts and lated amines. The quaternary ammonium salts
are the most used members of this class.
If the surfactant molecule has the ability to carry either a ve or negative
, the surfactant is classified as eric. Amphoteric surfactants include acrylic
acid derivatives, substituted alkylamides, N—alkylbetaines and phosphatides.
25 The use of surfactants in drug products, formulations and in emulsions has been
reviewed (Rieger, in “Pharmaceutical Dosage Forms,” Marcel Dekker, Inc., New York,
NY, 1988, p. 285).
Micelles and other Membranous Formulations
The RNAi agents of the invention can also be provided as micellar formulations.
30 “Micelles” are defined herein as a particular type of molecular assembly in which
amphipathic molecules are arranged in a spherical structure such that all the
72
W0 2013,:‘075035 PCT/U82012/065691
hydrophobic portions of the molecules are directed inward, leaving the hydrophilic
portions in contact with the surrounding aqueous phase. The converse arrangement
exists if the environment is hydrophobic.
A mixed ar formulation suitable for ry through transdermal
membranes may be prepared by mixing an aqueous solution of the siRNA ition,
an alkali metal C8 to C22 alkyl sulphate, and a micelle forming compound. Exemplary
micelle forming compounds include lecithin, hyaluronic acid, pharmaceutically
acceptable salts of hyaluronic acid, glycolic acid, lactic acid, chamomile extract,
cucumber extract, oleic acid, ic acid, linolenic acid, monoolein, eates,
10 urates, borage oil, evening of primrose oil, menthol, trihydroxy oxo cholanyl
glycine and pharmaceutically acceptable salts thereof, in, ycerin, lysine,
polylysine, triolein, polyoxyethylene ethers and analogues thereof, polidocanol alkyl
ethers and analogues thereof, chenodeoxycholate, deoxycholate, and mixtures thereof.
The micelle forming compounds may be added at the same time or after on of the
15 alkali metal alkyl sulphate. Mixed micelles will form with ntially any kind of
mixing of the ingredients but vigorous mixing in order to provide r size micelles.
In one method a first micellar composition is prepared which contains the siRNA
composition and at least the alkali metal alkyl sulphate. The first micellar composition is
then mixed with at least three micelle forming compounds to form a mixed micellar
20 composition. In another method, the micellar composition is prepared by mixing the
siRNA composition, the alkali metal alkyl sulphate and at least one of the micelle
forming compounds, followed by addition of the remaining micelle forming compounds,
with vigorous mixing.
Phenol and/or m—cresol may be added to the mixed micellar composition to
25 stabilize the formulation and protect against bacterial growth. Alternatively, phenol
and/or m—cresol may be added with the micelle g ingredients. An ic agent
such as glycerin may also be added after formation of the mixed micellar composition.
For ry of the micellar formulation as a spray, the formulation can be put
into an aerosol dispenser and the dispenser is d with a propellant. The propellant,
30 which is under pressure, is in liquid form in the dispenser. The ratios of the ingredients
are adjusted so that the aqueous and propellant phases become one, i.e., there is one
73
W0 2013,:‘075035 PCT/U82012/065691
phase. If there are two phases, it is necessary to shake the dispenser prior to dispensing
a portion of the contents, e.g., through a metered valve. The sed dose of
pharmaceutical agent is propelled from the metered valve in a fine spray.
Propellants may include hydrogen—containing fluorocarbons, en—
containing fluorocarbons, dimethyl ether and diethyl ether. In certain embodiments,
HFA 134a (l,l,l,2 tetrafluoroethane) may be used.
The ic concentrations of the essential ingredients can be determined by
relatively straightforward experimentation. For absorption through the oral cavities, it is
often ble to increase, e.g., at least double or triple, the dosage for through injection
10 or administration h the gastrointestinal tract.
Particles
In another embodiment, an RNAi agent of the invention may be incorporated
into a particle, e.g., a microparticle. Microparticles can be produced by drying,
but may also be produced by other methods including lyophilization, ation, fluid
15 bed drying, vacuum drying, or a combination of these techniques.
IV. Methods For Inhibiting TTR Expression
The present invention also es methods of inhibiting expression of a
transthyretin (TTR) in a cell. The methods include contacting a cell with an RNAi
20 agent, e. g., double stranded RNAi agent, in an amount effective to inhibit expression of
TTR in the cell, thereby inhibiting expression of TTR in the cell.
Contacting of a cell with an RNAi agent, e. g., a double stranded RNAi agent,
may be done in vitro or in vivo. Contacting a cell in vivo with the RNAi agent includes
contacting a cell or group of cells within a subject, e.g., a human subject, with the RNAi
25 agent. Combinations of in vitro and in viva methods of contacting a cell are also
possible. Contacting a cell may be direct or indirect, as discussed above. Furthermore,
contacting a cell may be accomplished via a targeting ligand, including any ligand
described herein or known in the art. In preferred embodiments, the targeting ligand is a
carbohydrate , e.g. a GalNAC3 ligand, or any other ligand that directs the RNAi
,
30 agent to a site of interest, e.g., the liver of a subject.
74
W0 2013,:‘075035 2012/065691
The term iting,” as used herein, is used interchangeably with “reducing,”
“silencing,” “downregulating”, essing”, and other similar terms, and includes any
level of inhibition.
The phrase “inhibiting expression of a TTR” is intended to refer to inhibition of
expression of any TTR gene (such as, e.g., a mouse TTR gene, a rat TTR gene, a
monkey TTR gene, or a human TTR gene) as well as variants or s of a TTR gene.
Thus, the TTR gene may be a wild—type TTR gene, a mutant TTR gene (such as a
mutant TTR gene giving rise to amyloid deposition), or a transgenic TTR gene in the
context of a genetically manipulated cell, group of cells, or organism.
10 iting expression of a TTR gene” includes any level of inhibition of a TTR
gene, e.g., at least partial suppression of the expression of a TTR gene. The expression
of the TTR gene may be assessed based on the level, or the change in the level, of any
variable associated with TTR gene expression, e.g., TTR mRNA level, TTR protein
level, or the number or extent of amyloid deposits. This level may be assessed in an
15 individual cell or in a group of cells, including, for example, a sample derived from a
subject.
Inhibition may be assessed by a decrease in an absolute or relative level of one or
more variables that are associated with TTR expression compared with a control level.
The control level may be any type of control level that is utilized in the art, 6.57., a pre—
20 dose baseline level, or a level determined from a similar t, cell, or sample that is
untreated or treated with a control (such as, e.g., buffer only control or inactive agent
control).
In some embodiments of the methods of the invention, expression of a TTR gene
is inhibited by at least about 5%, at least about 10%, at least about 15%, at least about
25 20%, at least about 25%, at least about 30%, at least about 35%,at least about 40%, at
least about 45%, at least about 50%, at least about 55%, at least about 60%, at least
about 65%, at least about 70%, at least about 75%, at least about 80%, at least about
85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at
least about 94%. at least about 95%, at least about 96%, at least about 97%, at least
30 about 98%, or at least about 99%.
75
W0 2013,:‘075035 PCT/U82012/065691
Inhibition of the expression of a TTR gene may be manifested by a ion of
the amount of mRNA expressed by a first cell or group of cells (such cells may be
present, for example, in a sample derived from a subject) in which a TTR gene is
transcribed and which has or have been treated (e.g., by contacting the cell or cells with
an RNAi agent of the invention, or by administering an RNAi agent of the invention to a
subject in which the cells are or were present) such that the expression of a TTR gene is
inhibited, as compared to a second cell or group of cells substantially identical to the
first cell or group of cells but which has not or have not been so treated (control cell(s)).
In preferred embodiments, the inhibition is assessed by expressing the level of mRNA in
10 treated cells as a percentage of the level of mRNA in control cells, using the following
formula:
(mRNA in control cells) - (mRNA in d cells)
0100%
(mRNA in control cells)
Alternatively, inhibition of the expression of a TTR gene may be assessed in
terms of a reduction of a parameter that is functionally linked to TTR gene expression,
15 e.g., TTR protein expression, retinol binding protein level, vitamin A level, or presence
of amyloid deposits comprising TTR. TTR gene ing may be determined in any
cell expressing TTR, either constitutively or by genomic ering, and by any assay
known in the art. The liver is the major site of TTR expression. Other significant sites
of expression include the d plexus, retina and pancreas.
20 Inhibition of the expression of a TTR protein may be manifested by a reduction
in the level of the TTR protein that is expressed by a cell or group of cells (e.g., the level
of protein expressed in a sample d from a subject). As explained above for the
assessment of mRNA suppression, the inhibiton of protein expression levels in a treated
cell or group of cells may rly be sed as a percentage of the level of protein
25 in a control cell or group of cells.
A control cell or group of cells that may be used to assess the inhibition of the
expression of a TTR gene includes a cell or group of cells that has not yet been
contacted with an RNAi agent of the invention. For example, the control cell or group
of cells may be derived from an individual subject (e.g., a human or animal subject)
30 prior to treatment of the subject with an RNAi agent.
76
W0 2013,:‘075035 PCT/U82012/065691
The level of TTR mRNA that is expressed by a cell or group of cells, or the level
of circulating TTR mRNA, may be ined using any method known in the art for
assessing mRNA expression. In one embodiment, the level of expression of TTR in a
sample is determined by ing a transcribed polynucleotide, or portion thereof, e.g.,
mRNA of the TTR gene. RNA may be extracted from cells using RNA extraction
ques including, for example, using acid phenol/guanidine isothiocyanate
extraction (RNAzol B; esis), RNeasy RNA preparation kits (Qiagen) or PAXgene
(PreAnalytix, Switzerland). Typical assay formats utilizing ribonucleic acid
hybridization include nuclear run—on assays, RT—PCR, RNase protection assays (Melton
10 er al., Nuc. Acids Res. 12:7035), rn blotting, in situ hybridization, and microarray
analysis. Circulating TTR mRNA may be detected using methods the described in
PCT/U82012/043584, the entire contents of which are hereby incorporated herein by
reference.
In one embodiment, the level of expression of TTR is determined using a nucleic
15 acid probe. The term "probe", as used herein, refers to any molecule that is capable of
selectively binding to a specific TTR. Probes can be synthesized by one of skill in the
art, or derived from appropriate biological preparations. Probes may be specifically
designed to be labeled. Examples of molecules that can be utilized as probes include, but
are not limited to, RNA, DNA, proteins, antibodies, and organic molecules.
20 Isolated mRNA can be used in hybridization or amplification assays that e,
but are not limited to, Southern or Northern analyses, polymerase chain reaction (PCR)
es and probe arrays. One method for the determination of mRNA levels involves
contacting the isolated mRNA with a nucleic acid molecule (probe) that can hybridize to
TTR mRNA. In one embodiment, the mRNA is immobilized on a solid surface and
25 ted with a probe, for example by running the isolated mRNA on an agarose gel
and transferring the mRNA from the gel to a membrane, such as nitrocellulose. In an
alternative embodiment, the s) are lized on a solid surface and the mRNA
is contacted with the s), for example, in an Affymetrix gene chip array. A skilled
artisan can readily adapt known mRNA detection methods for use in determining the
30 level of TTR mRNA.
77
W0 ‘075035 PCT/U82012/065691
An alternative method for ining the level of expression of TTR in a
sample involves the s of nucleic acid amplification and/or reverse transcriptase (to
prepare cDNA) of for example mRNA in the sample, e.g., by RT—PCR (the experimental
embodiment set forth in Mullis, 1987, US. Pat. No. 4,683,202), ligase chain reaction
(Barany (1991) Proc. Natl. Acad. Sci. USA 88:189—193), self sustained ce
replication (Guatelli et al. (1990) Proc. Natl. Acad. Sci. USA 87:1874—1878),
transcriptional amplification system (Kwoh et al. (1989) Proc. Natl. Acad. Sci. USA
86:1173—1177), Q—Beta Replicase (Lizardi et al. (1988) Bio/Technology 6:1197), rolling
circle replication (Lizardi et al., US. Pat. No. 5,854,033) or any other c acid
10 amplification method, ed by the detection of the amplified molecules using
techniques well known to those of skill in the art. These detection schemes are especially
useful for the detection of nucleic acid molecules if such molecules are present in very
low numbers. In particular aspects of the invention, the level of expression of TTR is
determined by quantitative fluorogenic RT—PCR (i.e. the TaqManTM ).
,
15 The expression levels of TTR mRNA may be red using a membrane blot
(such as used in hybridization analysis such as Northern, Southern, dot, and the like), or
microwells, sample tubes, gels, beads or fibers (or any solid support comprising bound
nucleic acids). See US. Pat. Nos. 5,770,722, 219, 5,744,305, 5,677,195 and
5,445,934, which are incorporated herein by reference. The determination of TTR
20 expression level may also comprise using nucleic acid probes in solution.
In preferred embodiments, the level of mRNA expression is assessed using
branched DNA (bDNA) assays or real time PCR (qPCR). The use of these methods is
described and exemplified in the es presented herein.
The level of TTR protein expression may be determined using any method
25 known in the art for the measurement of n levels. Such methods include, for
example, ophoresis, capillary electrophoresis, high performance liquid
chromatography (HPLC), thin layer chromatography (TLC), hyperdiffusion
chromatography, fluid or gel precipitin reactions, absorption spectroscopy, a
colorimetric assays, spectrophotometric assays, flow cytometry, immunodiffusion
30 (single or double), immunoelectrophoresis, Western blotting, radioimmunoassay (RIA),
78
W0 2013,:‘075035 PCT/U82012/065691
enzyme—linked immunosorbent assays (ELISAs), fluorescent assays,
electrochemiluminescence assays, and the like.
In some embodiments, the efficacy of the methods of the invention can be
monitored by detecting or monitoring a reduction in an amyloid TTR deposit. ng
an amyloid TTR deposit, as used , includes any decrease in the size, number, or
severity of TTR deposits, or to a tion or reduction in the formation of TTR
deposits, within an organ or area of a subject, as may be assessed in vitro or in viva
using any method known in the art. For example, some methods of assessing amyloid
deposits are described in Gertz, M.A. & mar, S.V. (Editors) (2010), Amyloidosis:
10 Diagnosis and Treatment, New York: Humana Press. Methods of assessing amyloid
deposits may include biochemical analyses, as well as visual or computerized
assessment of d deposits, as made visible, e.g., using immunohistochemical
ng, fluorescent labeling, light microscopy, on microscopy, fluorescence
microscopy, or other types of microscopy. Invasive or noninvasive imaging ties,
15 including, e.g., CT, PET, or NMR/MRI g may be employed to assess amyloid
deposits.
The methods of the invention may reduce TTR deposits in any number of tissues
or regions of the body including but not limited to the heart, liver, spleen, esophagus,
stomach, intestine (ileum, duodenum and colon), brain, sciatic nerve, dorsal root
20 ganglion, kidney and retina.
The term “sample” as used herein refers to a collection of similar fluids, cells, or
tissues isolated from a subject, as well as fluids, cells, or tissues present within a t.
Examples of biological fluids include blood, serum and serosal fluids, plasma, lymph,
urine, cerebrospinal fluid, saliva, ocular fluids, and the like. Tissue samples may include
25 samples from s, organs or localized regions. For example, samples may be derived
from particular organs, parts of organs, or fluids or cells within those s. In certain
embodiments, samples may be derived from the liver (e.g., whole liver or certain
segments of liver or certain types of cells in the liver, such as, e.g., hepatocytes), the
retina or parts of the retina (e.g., retinal pigment epithelium), the central nervous system
30 or parts of the central nervous system (e.g., ventricles or choroid plexus), or the pancreas
or certain cells or parts of the as. In preferred embodiments, a “sample derived
79
W0 2013,:‘075035 PCT/U82012/065691
from a subject” refers to blood or plasma drawn from the t. In further
embodiments, a e d from a subject” refers to liver tissue or retinal tissue
derived from the subject.
In some embodiments of the methods of the invention, the RNAi agent is
administered to a subject such that the RNAi agent is delivered to a specific site within
the subject. The inhibition of expression of TTR may be assessed using measurements
of the level or change in the level of TTR mRNA or TTR protein in a sample derived
from fluid or tissue from the specific site within the subject. In preferred embodiments,
the site is selected from the group consisting of liver, choroid plexus, retina, and
10 as. The site may also be a subsection or subgroup of cells from any one of the
aforementioned sites (e.g., hepatocytes or retinal pigment epithelium). The site may also
include cells that express a particular type of receptor (e.g., hepatocytes that express the
asialogycloprotein receptor).
15 V. Methods for Treating or Preventing a TTR-Associated Disease
The present invention also provides methods for treating or preventing a TTR—
ated disease in a subject. The methods include administering to the t a
therapeutically effective amount or lactically ive amount of an RNAi agent
of the invention.
20 As used herein, a "subject" includes either a human or a non—human animal,
preferably a vertebrate, and more preferably a mammal. A subject may include a
transgenic organism. Most ably, the subject is a human, such as a human suffering
from or predisposed to ping a TTR—associated disease.
In some embodiments, the subject is suffering from a TTR—associated disease. In
25 other embodiments, the subject is a subject at risk for developing a TTR—associated
e, e.g., a subject with a TTR gene mutation that is associated with the development
of a TTR associated disease, a subject with a family history of TTR—associated disease,
or a subject who has signs or symptoms ting the development of TTR
amyloidosis.
30 A ssociated disease,” as used herein, includes any disease caused by or
associated with the formation of amyloid deposits in which the fibril precurosors consist
80
W0 2013,:‘075035 PCT/U82012/065691
of variant or wild—type TTR protein. Mutant and wild—type TTR give rise to various
forms of amyloid deposition (amyloidosis). Amyloidosis involves the formation and
aggregation of misfolded proteins, resulting in extracellular deposits that impair organ
function. Climical syndromes associated with TTR aggregation e, for example,
senile systemic amyloidosis (SSA); systemic familial dosis; familial amyloidotic
polyneuropathy (FAP); familial amyloidotic cardiomyopathy (FAC); and
leptomeningeal amyloidosis, also known as leptomeningeal or meningocerebrovascular
amyloidosis, central nervous system (CNS) dosis, or amyloidosis VII form.
In some embodiments of the methods of the invention, RNAi agents of the
10 invention are stered to subjects suffering from familial amyloidotic
cardiomyopathy (FAC) and senile systemic amyloidosis (SSA). Normal—sequence TTR
causes c amyloidosis in people who are elderly and is termed senile systemic
amyloidosis (SSA) (also called senile cardiac amyloidosis (SCA) or cardiac
amyloidosis). SSA often is accompanied by microscopic deposits in many other .
15 TTR mutations accelerate the process of TTR d formation and are the most
important risk factor for the development of clinically significant TTR amyloidosis (also
called ATTR (amyloidosis—transthyretin type)). More than 85 dogenic TTR
variants are known to cause systemic familial amyloidosis.
In some embodiments of the methods of the invention, RNAi agents of the
20 invention are administered to subjects suffering from transthyretin (TTR)—related
familial amyloidotic polyneuropathy (FAP). Such subjects may suffer from ocular
manifestations, such as vitreous opacity and glaucoma. It is known to one of skill in the
art that amyloidogenic transthyretin (ATTR) synthesized by retinal pigment epithelium
(RPE) plays important roles in the progression of ocular amyloidosis. Previous studies
25 have shown that panretinal laser photocoagulation, which reduced the RPE cells,
prevented the progression of amyloid deposition in the vitreous, indicating that the
effective ssion of ATTR expression in RPE may become a novel y for
ocular amyloidosis (see, e.g., Kawaji, T., et al., Ophthalmology. (2010) 117: 552-555).
The methods of the invention are useful for ent of ocular manifestations of TTR
30 related FAP, e.g., ocular amyloidosis. The RNAi agent can be red in a manner
suitable for targeting a ular , such as the eye. Modes of ocular delivery
81
W0 2013,:‘075035 PCT/U82012/065691
e retrobulbar, subcutaneous eyelid, subconjunctival, subtenon, anterior r or
intravitreous ion (or internal injection or infusion). Specific formulations for
ocular delivery include eye drops or ointments.
Another TTR—associated disease is hyperthyroxinemia, also known as
“dystransthyretinemic hyperthyroxinemia” or “dysprealbuminemic hyroxinemia”.
This type of hyperthyroxinemia may be secondary to an increased association of
thyroxine with TTR due to a mutant TTR le with increased affinity for thyroxine.
See, e.g., Moses et al. (1982) J. Clin. Invest, 86, 033.
The RNAi agents of the invention may be administered to a subject using any
10 mode of administration known in the art, ing, but not limited to subcutaneous,
intravenous, intramuscular, intraocular, intrabronchial, intrapleural, intraperitoneal,
intraarterial, lymphatic, cerebrospinal, and any ations thereof. In preferred
embodiments, the agents are administered subcutaneously.
In some embodiments, the administration is Via a depot injection. A depot
15 injection may release the RNAi agent in a consistent way over a prolonged time period.
Thus, a depot injection may reduce the frequency of dosing needed to obtain a desired
effect, e. g., a desired inhibition of TTR, or a therapeutic or prophylactic effect. A depot
injection may also provide more consistent serum concentrations. Depot injections may
include aneous ions or intramuscular injections. In preferred embodiments,
20 the depot injection is a subcutaneous injection.
In some embodiments, the administration is via a pump. The pump may be an
external pump or a surgically implanted pump. In certain embodiments, the pump is a
subcutaneously implanted osmotic pump. In other embodiments, the pump is an
infusion pump. An infusion pump may be used for intravenous, aneous, arterial,
25 or epidural infusions. In preferred embodiments, the infusion pump is a aneous
infusion pump. In other embodiments, the pump is a surgically implanted pump that
delivers the RNAi agent to the liver.
Other modes of administration include epidural, intracerebral,
intracerebroventricular, nasal administration, rterial, intracardiac, intraosseous
30 infusion, intrathecal, and intravitreal, and pulmonary. The mode of administration may
be chosen based upon whether local or systemic treatment is desired and based upon the
82
W0 2013,:‘075035 PCT/U82012/065691
area to be treated. The route and site of administration may be chosen to enhance
targeting.
In some embodiments, the RNAi agent is administered to a subject in an amount
effective to inhibit TTR expression in a cell within the t. The amount effective to
inhibit TTR expression in a cell within a subject may be assessed using methods
discussed above, ing methods that involve assessment of the inhibition of TTR
mRNA, TTR protein, or related variables, such as d deposits.
In some embodiments, the RNAi agent is administered to a subject in a
therapeutically or prophylactically effective amount.
10 "Therapeutically effective amount," as used herein, is intended to include the
amount of an RNAi agent that, when administered to a patient for treating a TTR
associated disease, is sufficient to effect ent of the disease (e.g., by diminishing,
ameliorating or maintaining the existing disease or one or more symptoms of disease).
The peutically effective amount" may vary depending on the RNAi agent, how the
15 agent is administered, the disease and its ty and the history, age, weight, family
history, genetic makeup, stage of pathological processes mediated by TTR sion,
the types of preceding or concomitant treatments, if any, and other individual
teristics of the patient to be treated.
“Prophylactically effective amount,” as used herein, is intended to e the
20 amount of an RNAi agent that, when administered to a subject who does not yet
experience or y symptoms of a TTR—associated disease, but who may be
posed to the disease, is sufficient to prevent or ameliorate the disease or one or
more symptoms of the disease. ms that may be ameliorated e sensory
neuropathy (e.g., paresthesia, hypesthesia in distal limbs), autonomic neuropathy (e.g.,
25 gastrointestinal dysfunction, such as gastric ulcer, or orthostatic nsion), motor
neuropathy, seizures, dementia, myelopathy, polyneuropathy, carpal tunnel syndrome,
autonomic insufficiency, cardiomyopathy, vitreous opacities, renal insufficiency,
pathy, substantially reduced mBMI (modified Body Mass Index), cranial nerve
dysfunction, and corneal lattice dystrophy. Ameliorating the disease includes slowing
30 the course of the disease or reducing the severity of later—developing disease. The
"prophylactically effective amount" may vary depending on the RNAi agent, how the
83
W0 2013,:‘075035 PCT/U82012/065691
agent is administered, the degree of risk of disease, and the history, age, weight, family
history, genetic makeup, the types of preceding or concomitant treatments, if any, and
other individual characteristics of the t to be treated.
A "therapeutically—effective amount" or “prophylacticaly effective amount” also
includes an amount of an RNAi agent that es some desired local or systemic
effect at a able benefit/risk ratio applicable to any treatment. RNAi agents
ed in the methods of the present invention may be administered in a ient
amount to produce a reasonable benefit/risk ratio applicable to such treatment.
As used herein, the phrases peutically effective amount” and
10 “prophylactically effective amount” also include an amount that provides a benefit in the
treatment, prevention, or management of ogical processes or symptom(s) of
pathological processes mediated by TTR expression. ms of TTR amyloidosis
include sensory neuropathy (e.g. paresthesia, hypesthesia in distal limbs), autonomic
neuropathy (e.g., gastrointestinal dysfunction, such as gastric ulcer, or orthostatic
15 hypotension), motor neuropathy, seizures, dementia, athy, polyneuropathy,
carpal tunnel syndrome, autonomic iciency, cardiomyopathy, vitreous opacities,
renal insufficiency, nephropathy, substantially reduced mBMI ied Body Mass
Index), cranial nerve dysfunction, and corneal lattice dystrophy.
The dose of an RNAi agent that is administered to a subject may be tailored to
20 balance the risks and benefits of a particular dose, for example, to achieve a desired level
of TTR gene suppression (as assessed, 6.57., based on TTR mRNA suppression, TTR
protein expression, or a ion in an amyloid deposit, as defined above) or a desired
therapeutic or prophylactic effect, while at the same time avoiding undesirable side
effects.
25 In one embodiment, the RNAi agent is administered at a dose of between about
0.25 mg/kg to about 50 mg/kg, e.g., between about 0.25 mg/kg to about 0.5 mg/kg,
between about 0.25 mg/kg to about 1 mg/kg, between about 0.25 mg/kg to about 5
mg/kg, n about 0.25 mg/kg to about 10 mg/kg, between about 1 mg/kg to about
10 mg/kg, between about 5 mg/kg to about 15 mg/kg, between about 10 mg/kg to about
30 20 mg/kg, between about 15 mg/kg to about 25 mg/kg, between about 20 mg/kg to about
84
W0 2013,:‘075035 PCT/US2012/065691
30 mg/kg, n about 25 mg/kg to about 35 mg/kg, or between about 40 mg/kg to
about 50 mg/kg.
In some embodiments, the RNAi agent is administered at a dose of about 0.25
mg/kg, about 0.5 mg/kg, about 1 mg/kg, about 2 mg/kg, about 3 mg/kg, about 4 mg/kg,
about 5 mg/kg, about 6 mg/kg, about 7 mg/kg, about 8 mg/kg, about 9 mg/kg, about 10
mg/kg, about 11 mg/kg, about 12 mg/kg, about 13 mg/kg, about 14 mg/kg, about 15
mg/kg, about 16 mg/kg, about 17 mg/kg, about 18 mg/kg, about 19 mg/kg, about 20
mg/kg, about 21 mg/kg, about 22 mg/kg, about 23 mg/kg, about 24 mg/kg, about 25
mg/kg, about 26 mg/kg, about 27 mg/kg, about 28 mg/kg, about 29 mg/kg, 30 mg/kg,
10 about 31 mg/kg, about 32 mg/kg, about 33 mg/kg, about 34 mg/kg, about 35 mg/kg,
about 36 mg/kg, about 37 mg/kg, about 38 mg/kg, about 39 mg/kg, about 40 mg/kg,
about 41 mg/kg, about 42 mg/kg, about 43 mg/kg, about 44 mg/kg, about 45 mg/kg,
about 46 mg/kg, about 47 mg/kg, about 48 mg/kg, about 49 mg/kg or about 50 mg/kg.
In some ments, the RNAi agent is stered in two or more doses. If
15 desired to facilitate repeated or nt infusions, implantation of a delivery device,
e.g., a pump, semi—permanent stent (e.g., intravenous, intraperitoneal, intracistemal or
intracapsular), or reservoir may be advisable. In some embodiments, the number or
amount of subsequent doses is dependent on the achievement of a desired , 6.57.,
the suppression of a TTR gene, or the achievement of a therapeutic or prophylactic
2O effect, e. g., reducing an amyloid deposit or reducing a symptom of a TTR—associated
disease. In some embodiments, the RNAi agent is administered according to a schedule.
For example, the RNAi agent may be administered twice per week, three times per
week, four times per week, or five times per week. In some embodiments, the schedule
involves regularly spaced strations, e.g., hourly, every four hours, every six
25 hours, every eight hours, every twelve hours, daily, every 2 days, every 3 days, every 4
days, every 5 days, weekly, biweekly, or monthly. In other embodiments, the schedule
involves closely spaced administrations followed by a longer period of time during
which the agent is not administered. For example, the schedule may involve an initial
set of doses that are administered in a relatively short period of time (e.g., about every 6
30 hours, about every 12 hours, about every 24 hours, about every 48 hours, or about every
85
W0 2013,:‘075035 2012/065691
72 hours) followed by a longer time period (e.g., about 1 week, about 2 weeks, about 3
weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, or about 8 weeks)
during which the RNAi agent is not administered. In one embodiment, the RNAi agent
is initially administered hourly and is later administered at a longer interval (e.g., daily,
, biweekly, or monthly). In another embodiment, the RNAi agent is lly
administered daily and is later administered at a longer interval (e.g., weekly, ly,
or y). In certain embodiments, the longer interval increases over time or is
determined based on the achievement of a desired effect. In a specific embodiment, the
RNAi agent is administered once daily during a first week, followed by weekly dosing
10 starting on the eighth day of administration. In another specific embodiment, the RNAi
agent is administered every other day during a first week ed by weekly dosing
starting on the eighth day of stration.
Any of these schedules may optionally be repeated for one or more iterations.
The number of iterations may depend on the achievement of a desired , e.g., the
15 suppression of a TTR gene, retinol binding protein level, vitamin A level, and/or the
achievement of a therapeutic or prophylactic effect, e.g., reducing an amyloid deposit or
reducing a symptom of a TTR—associated disease.
In some embodiments, the RNAi agent is administered with other therapeutic
agents or other therapeutic regimens. For example, other agents or other therapeutic
20 regimens suitable for treating a TTR—associated disease may include a liver transplant,
which can reduce mutant TTR levels in the body; Tafamidis (Vyndaqel), which
kinetically stabilizes the TTR er preventing tetramer dissociation required for
TTR dogenesis; and diuretics, which may be employed, for example, to reduce
edema in TTR amyloidosis with cardiac involvement.
25 In one embodiment, a subject is administered an initial dose and one or more
maintenance doses of an RNAi agent. The maintenance dose or doses can be the same
or lower than the initial dose, e.g., one—half of the initial dose. A maintenance regimen
can include treating the subject with a dose or doses ranging from 0.01 ug to 15 mg/kg
of body weight per day, e.g., 10 mg/kg, 1 mg/kg, 0.1 mg/kg, 0.01 mg/kg, 0.001 mg/kg,
30 or 0.00001 mg/kg of bodyweight per day. The maintenance doses are, for example,
administered no more than once every 2 days, once every 5 days, once every 7 days,
86
W0 2013,:‘075035 PCT/U82012/065691
once every 10 days, once every 14 days, once every 21 days, or once every 30 days.
Further, the treatment regimen may last for a period of time which will vary depending
upon the nature of the particular e, its severity and the overall condition of the
patient. In certain ments the dosage may be delivered no more than once per
day, e.g., no more than once per 24, 36, 48, or more hours, e.g., no more than once every
5 or 8 days. ing treatment, the patient can be monitored for changes in his/her
condition. The dosage of the RNAi agent may either be increased in the event the
patient does not d significantly to current dosage levels, or the dose may be
decreased if an alleviation of the symptoms of the disease state is observed, if the
10 disease state has been ablated, or if undesired side—effects are ed.
VI. Kits
The present invention also provides kits for performing any of the methods of the
invention. Such kits include one or more RNAi agent(s) and instructions for use, e.g.,
15 instructions for inhibiting expression of a TTR in a cell by contacting the cell with the
RNAi agent(s) in an amount effective to inhibit expression of the TTR. The kits may
optionally further comprise means for contacting the cell with the RNAi agent (e.g. , an
ion device), or means for measuring the inhibition of TTR (e.g., means for
measuring the inhibition of TTR mRNA or TTR protein). Such means for measuring the
20 tion of TTR may comprise a means for obtaining a sample from a subject, such as,
e.g., a plasma sample. The kits of the invention may optionally further comprise means
for administering the RNAi agent(s) to a subject or means for ining the
therapeutically effective or prophylactically effective amount.
25 This invention is further rated by the ing examples which should not
be construed as limiting. The contents of all references and published patents and patent
applications cited throughout the application are hereby incorporated herein by
reference.
30
87
W0 2013,:‘075035 PCT/U82012/065691
EXAMPLES
Example 1: Inhibition of TTR with lNAc conjugates
A single dose of the TTR RNAi agent AD—43527 was administered to mice
subcutaneously and TTR mRNA levels were determined 72 hours post administration.
5 The mouse/rat cross—reactive GalNAc—conjugate, AD—43527, was chosen for in
viva evaluation in WT C57BL/6 mice for silencing of TTR mRNA in liver. The
sequence of each strand of AD—43527 is shown below.
: s: sense; as: antisense
Duflex# Strand Oligo Sequence 5’ to 3’
AD—43527 A— AfaCfaGququfchquchchanaAfL96 (SEQ
89592 ID NO:
A— uUfanaGfaGfcAfaGfaAchchngfusUfsu (SEQ
83989 ID NO:
L96 = GalNAc3; lowercase nts (a,u,g,c)
are 2’—O—methyl nucleotides, Nf (i.e.,
Af) is a 2’—fluoro nucleotide
10 The ligand used was GalNAC3:
15 This GalNAc3 ligand was conjugated to the 3’—end of the sense strand using the linker
and tether as shown below:
88
W0 2013,:‘075035 PCT/U82012/065691
—0\P40 OH
90/6
\n‘“ < S
N
H
N
O
O
The structure of the resulting GalNAc3 conjugated sense strand is shown in the
following schematic:
onal RNAi agents that target TTR and have the following sequences and
modifications were synthesized and assayed.
Mouse/rat cross reactive TTR RNAi agents
Sense strand 5‘-3‘ Antisense strand 5‘-3‘
AD- AfaCfaGququchquchchfanaAfQl 1L96 GfachAfaGfaAchchngfusUfsu
43528 (SEQ ID NO: 10) (SEQ ID NO: 11)
10
Human/cyno cross reactive TTR RNAi agents; parent duplex is AD-18328 [having a
sense strand 5’-3’ sequence of GuAAccAAGAGuAuuccAudeT (SEQ ID NO: 12) and
antisense strand 5’ to 3’ sequence of AUGGAAuACUCUUGGUuACdeT (SEQ ID
15 NO: 13) with the following modifications: alternating 2'F/2'OMe w/2 PS on AS.
Sense strand 5‘-3‘ Antisense strand 5‘-3‘
angGfaAquchchqungquchfustsa
45163 (SEQ ID NO: 14) (SEQ ID NO: 16)
AD- faCfcAfaGfaGququchfanQl 1L96 anngaAquchchqungquchfustsa
45164 (SEQ ID NO: 15) (SEQ ID NO: 17)
L96 2 GalNAC3; lowercase nts (a,u,g,c) are 2’—O—methyl tides, Nf (i.e., Af) is a 2’—
fluoro nucleotide; Q11 is cholesterol; 8 is phosphorothioate.
20
89
W0 2013,:‘075035 PCT/U82012/065691
AD—43527 was administered to female C57BL/6 mice (6-10 weeks, 5 per group)
via subcutaneous injection at a dose volume of 10ul/g at a dose of 30, 15, 7.5, 3.5, 1.75
or 0.5 mg/kg of AD-43527. Control animals received PBS by subcutaneous injection at
the same dose volume.
After approximately seventy two hours, mice were anesthetized with 200 ul of
ketamine, and then exsanguinated by severing the right caudal artery. Liver tissue was
collected, flash—frozen and stored at —80°C until processing.
Efficacy of treatment was evaluated by measurement of TTR mRNA in the liver
at 72 hours post—dose. TTR liver mRNA levels were assayed utilizing the Branched
10 DNA assays— QuantiGene 1.0 (Panomics). Briefly, mouse liver samples were ground
and tissue lysates were prepared. Liver lysis mixture (a mixture of 1 volume of lysis
mixture, 2 volume of nuclease-free water and 10111 of Proteinase-K/ml for a final
concentration of 20mg/ml) was incubated at 65 °C for 35 minutes. 5 ul of liver lysate
and 95 ul of working probe set (TTR probe for gene target and GAPDH for endogenous
15 control) were added into the Capture Plate. Capture Plates were incubated at 53 °C i1
°C (aprx. 16—20hrs). The next day, the Capture Plates were washed 3 times with 1X
Wash Buffer (nuclease—free water, Buffer ent 1 and Wash Buffer Component 2),
then dried by fuging for 1 minute at 240g. 100ul of ier Probe mix per well
was added into the e Plate, which was sealed with aluminum foil and incubated
20 for 1 hour at 46°C i1°C. Following a 1 hour incubation, the wash step was repeated,
then 100p] of Label Probe mix per well was added. Capture plates were ted at 46
°C i1 0C for 1 hour. The plates were then washed with 1X Wash Buffer, dried and
100ul substrate per well was added into the Capture . e Plates were
incubated for 30 minutes at 46°C followed by incubation for 30 s at room
25 ature. Plates were read using the SpectraMax Luminometer following incubation.
bDNA data were analyzed by subtracting the average background from each duplicate
sample, averaging the resultant duplicate GAPDH (control probe) and TTR
(experimental probe) values, and then ing the ratio: (experimental probe—
background)/(control probe—background). The average TTR mRNA level was
30 calculated for each group and normalized to the PBS group average to give relative TTR
mRNA as a % of the PBS control group.
90
W0 2013,:‘075035 PCT/US2012/065691
The results are shown in Figure 1. The GalNAc conjugated RNAi agent
targeting TTR had an ED50 of approximately 5 mg/kg for TTR mRNA knockdown.
These results demonstrate that GalNAc conjugated RNAi agents that target TTR are
effective at inhibiting expression of TTR mRNA.
Example 2: Inhibition of TTR with TTR-GalNAc conjugates is e
Mice were administered a subcutaneous dose (either 7.5 or 30.0 mg/kg) of AD—
43527, a GalNAc conjugated RNAi agent that targets TTR. The TTR mRNA levels in
the liver were evaluated at 1, 3, 5, 7, 10, 13, 15, 19, 26, 33, and 41 days post treatment
10 using the method described in Example 1.
The results are shown in Figure 2. At day 19, administration of 30.0 mg/kg
GalNAc conjugated RNAi agents still showed about 50% silencing. Full recovery of
expression ed at day 41.
These results demonstrated that the inhibition ed by GalNAc conjugated
15 siRNA ing TTR is durable, lasting up to 3, 5, 7, 10, 13, 15, 19, 26 or 33 days post
treatment.
Example 3. RNA Synthesis and Duplex Annealing
20 1. Oligonucleotide Synthesis
Oligonucleotides were synthesized on an AKTAoligopilot synthesizer or an ABI
394 synthsizer. Commercially available controlled pore glass solid support (dT-CPG,
500A, Prime Synthesis) and RNA phosphoramidites with standard protecting groups, 5’—
thoxytrityl N6—benzoyl—2 ’ —t—butyldimethylsilyl—adenosine—3 ’ —O—N,N’ -
25 diisopropyl—2—cyanoethylphosphoramidite, 5 ’ ethoxytrityl—N4—acetyl—2’ —t—
butyldimethylsilyl—cytidine—3 ’ —0—N,N’ —diisopropyl—2—cyanoethylphosphoramidite, 5 ’ —0—
oxytrityl—N2——isobutryl—2’ —t—butyldimethylsilyl—guanosine—3 ’—0—N,N ’ —diisopropyl—
2—cyanoethy1phosphoramidite, and 5 ’ —0—dimethoxytrityl—2’ —t—butyldimethylsilyl—uridine—
3’—O—N,N’—diisopropyl—2—cyanoethylphosphoramidite (Pierce Nucleic Acids
30 Technologies) were used for the ucleotide synthesis unless otherwise specified.
The 2’—F phosphoramidites, 5 ’ — 0—dimethoxytrityl—N4—acetyl-2’ -fluro—cytidine—3 ’ — 0—
91
W0 2013.:‘075035 PCT/U82012/065691
N,N’—diisopropyl—2—cyanoethyl—phosphoramidite and 5’ dimethoxytrityl—2’—fluro—
uridine-3’-O-N,N’-diisopropylcyanoethyl-phosphoramidite were purchased from
(Promega). All phosphoramidites were used at a concentration of 0.2M in acetonitrile
) except for guanosine which was used at 0.2M concentration in 10% THF/ANC
(v/v). Coupling/recycling time of 16 minutes was used. The activator was 5—ethyl
thiotetrazole (0.75M, American International Chemicals), for the PO—oxidation
Iodine/Water/Pyridine was used and the PS—oxidation PADS (2 %) in 2,6—lutidine/ACN
(1:1 v/v) was used.
Ligand conjugated s were synthesized using a solid support containing the
10 corresponding ligand. For example, the introduction of a carbohydrate moiety/ligand
(for e. g., GalNAc) at the 3’—end of a sequence was achieved by starting the synthesis
with the corresponding carbohydrate solid support. Similarly a cholesterol moiety at the
3’—end was introduced by ng the synthesis on the cholesterol support. In general,
the ligand moiety was tethered to trans—4—hydroxyprolinol via a tether of choice as
15 described in the previous examples to obtain a hydroxyprolinol—ligand moiety. The
hydroxyprolinol—ligand moiety was then coupled to a solid t via a succinate linker
or was converted to phosphoramidite via rd phosphitylation ions to obtain
the desired carbohydrate conjugate building blocks. Fluorophore labeled siRNAs were
synthesized from the ponding oramidite or solid support, purchased from
20 Biosearch Technologies. The oleyl lithocholic (GalNAc)3 polymer support made in
house at a loading of 38.6 ram. The e (Man)3 polymer support was also
made in house at a loading of 42.0 umol/gram.
Conjugation of the ligand of choice at the desired position, for example at the 5’—
end of the sequence, was achieved by coupling of the corresponding phosphoramidite to
25 the growing chain under standard phosphoramidite coupling conditions unless otherwise
specified. An extended 15 minute coupling of 0.1M solution of phosphoramidite in
anhydrous CH3CN in the presence of 5—(ethylthio)—1H—tetrazole activator to a solid
bound oligonucleotide. ion of the internucleotide phosphite to the phosphate was
d out using standard —water as reported in Beaucage, S.L. (2008) Solid—
30 phase synthesis of siRNA oligonucleotides. Curr. Opin. Drug Discov. Devel., 11, 203—
216; Mueller, 8., Wolf, J. and Ivanov, SA. (2004) Current Strategies for the Synthesis
92
W0 2013,:‘075035 PCT/U82012/065691
of RNA. Curr. Org. Synth, 1, 293—307; Xia, J ., Noronha, A., Toudjarska, 1., Li, R,
Akinc, A., Braich, R., Kamenetsky, M., Rajeev, K.G., Egli, M. and Manoharan,
M. (2006) Gene Silencing Activity of siRNAs with a Ribo—difluorotoluyl Nucleotide.
ACS Chem. Biol., 1, 176—183 or by treatment with tert—butyl
hydroperoxide/acetonitrile/water (10: 87: 3) with a 10 minute oxidation wait time
ated oligonucleotide. Phosphorothioate was introduced by the oxidation of
phosphite to phosphorothioate by using a sulfur transfer reagent such as DDTT
(purchased from AM Chemicals), PADS and or ge t The cholesterol
phosphoramidite was sized in house, and used at a concentration of 0.1 M in
10 dichloromethane. Coupling time for the cholesterol phosphoramidite was 16 minutes.
2. ection- I (Nucleobase Deprotection)
After completion of synthesis, the support was transferred to a 100 ml glass bottle
(VWR). The ucleotide was cleaved from the support with simultaneous
15 deprotection of base and phosphate groups with 80 mL of a mixture of ethanolic
ammonia [ammoniaz ethanol (3:1)] for 6.5h at 55°C. The bottle was cooled briefly on ice
and then the ethanolic ammonia mixture was filtered into a new 250 m1 bottle. The CPG
was washed with 2 x 40 mL portions of ethanol/water (1:1 v/v). The volume of the
mixture was then reduced to ~ 30 ml by roto—vap. The mixture was then frozen on dry
20 ice and dried under vacuum on a speed vac.
3. Deprotection-II (Removal of 2’ TBDMS group)
The dried residue was resuspended in 26 ml of triethylamine, triethylamine
rofluoride (TEA.3HF) or pyridine—HF and DMSO (3:426) and heated at 60°C for
25 90 minutes to remove the tert—butyldimethylsilyl (TBDMS) groups at the 2’ position.
The reaction was then quenched with 50 ml of 20mM sodium acetate and pH adjusted to
6.5, and stored in freezer until purification.
93
W0 2013,:‘075035 PCT/U82012/065691
4. Analysis
The oligonucleotides were analyzed by high-performance liquid chromatography
(HPLC) prior to purification and selection of buffer and column depends on nature of
the sequence and or conjugated ligand.
5. HPLC Purification
The ligand conjugated oligonucleotides were purified by reverse phase preparative
HPLC. The unconjugated oligonucleotides were purified by anion—exchange HPLC on a
TSK gel column packed in house. The buffers were 20 mM sodium phosphate (pH 8.5)
10 in 10% CH3CN (buffer A) and 20 mM sodium phosphate (pH 8.5) in 10% CH3CN, 1M
NaBr (buffer B). ons containing full—length oligonucleotides were pooled,
desalted, and lyophilized. Approximately 0.15 OD of desalted ucleotidess were
diluted in water to 150 pl and then pipetted in special Vials for CGE and LC/MS
analysis. Compounds were finally ed by LC—ESMS and CGE.
15
6. RNAi Agent preparation
For the ation of an RNAi agent, equimolar amounts of sense and antisense strand
were heated in 1XPBS at 95°C for 5 minutes and slowly cooled to room temperature.
The integrity of the duplex was confirmed by HPLC analysis. Table 1 below reflects the
20 RNAi agents which target human or rodent TTR mRNA.
94
W0 2013f075035 PCT/U82012/065691
000.0 0000.0 M6000 mnood mood mm00.0 mm00.0 mm00.0 030.0 3030.0 3030.0 330.0 0330.0 330.0 m30.0 m30.0 m30.0 mmfiod 030.0 030.0 mmfiod
Scarce/021500.; 00.0 _>_: 50.0 wmd mm.0 mm.0 $0.0 mm.0 om.0 mod mm.0 .vm.0 90.0 mmd Hmd 000.0 #50 30.0 5.0 50.0
0025000 0.0 _>_: 0.0 00.0 03.0 N30 m3.0 33.0 03.0 .30 33.0 .30 .30 03.0 m3.0 3.0 030 0.3.0 03.0 20.0 .30 N0 03.0
.008 3.00 00.0 00.0 00.0 00.0 00.0 00.0 00.0 00.0 00.0 00.0 00.0 00.0 00.0 00.0 00.0
0030020000500000 0205060850202000052 00500202050000850302250050 0000002020500608502022505m 00500202005000080002022.0005m 08038050003003000<<003< 0050020200500.608502022505m 005002020205085020205050 005002020005085020205050 005002020505050502020505m 0050000802020030053000300 0050500052020030053005300 0000.5820.32008502020505m 00500600032020:000055505300 000000800:0:00.000505022000505m 3000320255000:85020230050 $0003202300635008250200005% 3000520205000:850202000030 00508000002020:000002005200 02050000850202000050 0232900850202000050 0050020203000:85023002500500
G00 0_ ”OZ Ea «000 0000 0000 0000 0000 0000 0000 0000 0000 0000 «N00 0000 I0000
92 00002 00000< 00002 00002 00002 00002 00000< 00000< 00002 m0000< 00002 00000< 00002 EEEaEaEa
mfisoobm
900.: 50000050230
5
no
0200033
can 0000020000000 0000005022000022000023002 3000000203.605220000230002 500000:02200522000023002 500000:02200522000023002 00080330038900.0030 500.00:020.60522000023002 500.605020.605228223002 0522000223002 =0800<00<0000000000000000m 200220002050520005025505 2002050205052835000505 5000005023006228223050 20020000005052.0005020505 0.088%0.0000008008000000m 5030053332,023020602 052320028020002 58000530030000035000.0005: 200238225052000.50.30055 5000005022000020300020002 50000050220000228023002 3000000203.600022000023032
000830 80 0_ HOZ 00 00 00 00 NN 00 «0 00 00 R 00 00 00 00 0». 00I00
22% 90 EEaa00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 MEMaHaHE
"H
2an 0.6.000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000
95
WO 2013075035 PCT/U82012/065691
90.0 H300 mofiod wofiod 00.8.0 whaod wfiod wfiod wfiod nmfiod mfiod HN0.0 NHN0.0 oHNod NNN0.0 .vaod mmNod mmNod mN0.0 mN0.0 NmN0.0 mmNod NNOd ENQO wNod 0m0.0 .quod
«0.0 «0.0 mod mud N50 No.0 No.0 mud nmd Nw.0 omd mud No.0 mud mm.0 om.0 050 no.0 mod de mmd mw.0
«N0 BNO 3.0 mN.0 wad 2.0 mad $0 R0 8.0 3.0 #0 0N0 000 3.0 3.0 Sud mm.0 .390 mad BNO BNO 3.0 0m.0 mN.0 mad
:0 000 80 000 «00 30 H0 :0 m00 80 000 N00 3.0 m0.0 00.0
ways3023320:equge/EQDN 3.88080323002823800380: 30032023005:ESUZSZEGEDN 853003032020:525300520: 353002032020:303200520: 3535502020:330200520: Esmmbubszgm:3030290530: $00380%:SEBSEBSEEWoEE <0mofl0<00§00009000000050<<0800<0 8536832220:3095360530: $53202:3063992020225552 3532023506:85023225053 85365320205895550530: £99&0:seguesgfiagofl:m 855020022200NUNSEoWSEUJ UWSEUUEZNEWS3030300330: 3538802020:530300530: 3530.9000220230$550320: 3532022005:8502322505m 3532023006:8502:2390? 2532022005:8502333005: 350302032220:3033005303 30032023006:8502523005m fiomefizfiafio:85023230053 20$:£02:3900305502§05m 3006:SSUEEEoWSN 853008020205309200530:
EaEaEaEa mm: 93 2: M3: 3: mm: 00: B:
£82 £82 EEEaEaEaEaEaEaEaEaEa $32 $.32 $32 EaEaEaEaE5 382 $82 382
Swabs:NSWNWEEUEZJMSN <0mmm<88m<3003<80333000020 .53883230£2$<5£<20§< 02930262:320605 0302300225052695330605 03023000300526=5020505 03028023005262:020505 $3830:fluoumm<0<08<0<0380<0 023003050303050205093 03023003300526:325505 328:3220252282230=2 53ng3296flozzubgaoaé 025553035320505 550053230£o£<§$<aoa< 30230023005283020505 023005£030325505 2$005283:025505 20003053000283520055 525%322030225£3032 52852/36aofifibmzegé .5232.3230£9$§0£<20§< 002250520033320503 55005330302253<303< 550%3230£0§§0£<20§< 52855:NGGNMEEBEEJWSN 53830023039336£3032 0302300225053030025505
REEEggHagEgg!E aEI !EH
£08 083 $08 088 088 £03 303 303
£08 088 GEEHagHagEggHagHagEggHagHagGEE $08 088 088 HagMagEggHagHag 308 $08 $08
96
WO 2013075035 PCT/US2012/065691
omod nmod mnmod 0<0.0 Nvod 30.0 55.0 95.0 0m0.0 Hmod mmod wmod omod mm0.0 mm0.0 «00.0 «00.0 000.0 000.0 0h0.0 Nnod «no.0 mnod nmhod Nwod mwod owod
no.0 mud mud owd N50 mud 0.0 mod No.0 wwd 0.0 mud mod NWO mw.0 N50 N50 N00 «0.0 mud «0.0 mwd mud mud
mN.0 mN.0 mud 3V0 NN.0 Hmd m¢.0 0N0 «N0 N¢.0 omd 0N0 50:0 .1010 0N0 Nm.0 «m0 mm.0 nmd mm.0 mwd N<.0 wN.0 mmd 2V0
8.0 00.0 N3 H0 H0 NS 000 30 NS :0 00 H0 NS NS 20 :0 :0 30 30 00.0 3.0 m0.0 3.0 3.0
3505:853<2<m505m 353282220+92282023225552 35380003222053030300330: $03202380003883323008m mflow33230000300502323003m my?e302329030053<a<<8000% my?3202300630050303230022 $53202300630050282000020 $036?00030000<=<800m mmama/:023290320302323905m £03202:800038830323003m $032023005300500282000020 $30830:30838080030200032 §0§§<30052380023230032 mmam3322005200502323005m 3038232000888022300820 m$03202303020200<EE<£00ER. 363202300530050282000020 m$03202300830053530£832.. mmam3523006300502323005m 303282322030203<3<<8000% £9582530558569220052 m$932023000303202323003m 85300803222053030200320: mmu,0030300333303003353803:m $532023006300503330£005m $53£02:39002050302855m
Ea mm: I00HH mm: $8 8:
232 832 EEEaEaEEEaEaEEEaEaEaHEEaHEHEHEEaHEEaEaEEEa Nwofimd‘ $82 ES?
523050220egsfibmzaogz 328332302522822303< 20022602300533320505 525053<smmmmm8£<aoa< 338000852320£83??? 328000852320$532303: 528.8535000aoefiugaosé 32.8000852030335??? 03053308282302 538.5smaommafiueimg 53.0033230820323032 25320$532303: 8260030£00m0<0<08<0<0§0m SQBESEE00<0+0£<5£<303< 33800325320£33283: 2080830802080ER. 20:20£03<5£<303< 33800flufiaoeogsgsmg 2020m0oe<20m+<303< 3380030520303582303: 32.800BEanomzsgsmzz 3320:325030205235? 522005aémaofifigugaosz Emmaflufiaawseug330605 5030053.0393009396933032 S5033330ggefibfiéfi 5285533208228223052
no 0“ E E m E 8 mm mm E 00 a!!
E308 0008 EEEEaEEaEaaaaEaEEaEEE3mnofim $03 $08
M308 $08 0008 808 808 9.08 8.08 3.08 0008 $.08 0008 308 0008 $08 $08 $08 308 0008 0008 $08 0008 808 088 :08 NNOHD $08 $08
97
WO 2013075035 PCT/U82012/065691
mwod mwod mmod mood mood mood moHd oofid moHd 0.3.0 ONHd 002.0 03.0 ONHd NNHd mNHd mNHd omad mmad NSWO 93.0 53.0 53.0 Hmfid Nde Nde wmfid
N50 owd mod 0nd and mwd mwd <50 mmd mud mwd 5.0 mwd mwd n50 mod mwd 0nd mwd nwd mwd mwd N50
.36 mfid 010 de wmd N._V.o Bud .vmd mfid Nfid mfid md 3.0 mg 3.0 3.0 $0 $0 $0 3.0 2.0 3.0 wio wmd
00 3.0 00.0 3.0 00.0 :0 3.0 :0 00 8.0 :0 m0.0 :0 3.0 00 2.0 m0.0 8.0 2.0 3.0 3.0
my,mmefizeamfiesgé3332005m 392523505350535228005m 300320235053:05023230052 $03202300003005350280.00% meom3<£<3006=SUS£<§2000020 m53202300605082322605m m$0320230063030x<sém08320 $03285038035002203230?m m$03202EDEQSUSEEEEB30m £03202:30638502523005m $0320m3506200502523005m Sums$0203.90:Eusuzséaomsm 05063300$230052 30mESEEDmESSUSUZE/Eofl:m 35320205053028$23005m m$03202:505200502523005m mmu,0m9&0?05300505023230?m 0505050823230052 309520230062008223005m §0§§<303030£8£23905m 353202350530082323005m 30032023505338$22505m $6320m3:000300502022603m oszmGzSqué$0992 m$0m320230063038250280.3% ma0m3&0:30063005023230?m 353202300630082333205m
$2 00: hm: 00:
$32 0532 RS? $82 EEEaEaEaEaEaEaEaEaEaEaEaEaEafigEag5figEEEafigEaEa
525053<0G£o£§0£<aoe< 52502220Ewaogfigegz 3.30053<Eo£o£<5£<aoe< 550053<30£0£§0£<302< 32.8003032058308??? 52200:023026£§0£<an< 2<ao£o£§0£<aoa< SE85E<=mmmmm8£<aoa< SE85E<ao£o£§0£<aoa< SE8532030358223032 SE85:m30£0£§0£<553< 5500.5Egonflfifiuzzsflsm 050050255floafibmzaosé 55005Egogafibgaog ”5250.533.5.6floafibmzaosé 52.605smegoafibgagé 338%3052030355??? 3.305322930£<yo£<aoa< 52505eggsomzubgaosm 5285Esaugoafibgaogé 52505323025£<5£<303< 5.9.300:3320aoafiugaozz 0230£03<5£<§02< 58853230Eoefibmzawgz 522005Egogeiugag: 522005gameoflfiuaimg 52805022950£§0£<an<
mm mo. ! 3 00H SH NS mg 00H mg 00H SH 00H 00H 0: H: N: m: 02 m:
0.88 088 Roam 088 aEEaaEaaaaa33aaaaaEHE5%EEfig
$08 088 Rog $08 308 0008 308 $08 $08 £08 £08 0008 $08 0008 0008 0008 $08 808 $08 308 308 0008 308 0008 0008 0020 820
98
WO 2013075035 PCT/U82012/065691
N030 mead mead A030 05nd Hhfid mhfid 0wH.0 Nwfid mwfid mmfid HON.0 HON.0 <0N0 mONd wNNd m0m.0
mwd mod No.0 wwd H00 H H50 wwd 00.0 mwd mwd and N00 nwd mwd N50 .30 mod mad «0.0 mod No.0 mw.0
mwd 9V0 omd 930 mwd mm.0 m¢.0 N._V.0 M30 .30 .30 5‘0 N30 m0 mm.0 mod .30 .vmd H00 omd #50 0.0 No.0
3.0 3.0 3.0 3.0 3.0 3.0 00.0 00.0 3.0 00.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 ‘3
0 3.0 3.0
$6320m53020320302/2245005m mmam3202550038502323005m ma0320232203005092300.5m fi0m32023000.0300502022603m m53202550630082028005m 353202329030082323005m 0230063850232809:m $532:2006300502323205m ma0m32023090200562:$.60”? 3522823566350502028000% $532:3296200502323005m my,om3202350.6053202323005m 3.6$2<a<esm0030050$23005m m53262300530200$23005m $532023005050503330£832 my,03202550535050$23005m 30$0282.,22992205630225552 mmu,0m320220052850223005m mmu,0m320230052005022303:m my,0m3202£220300502323005m $.63823505350502323205m $005202:30538502323090m $532023006303002:$603m m$0320220039200302023005m 350630050232263:m $53262:30638502323005m $53
m023006335022,...505m
33 33 33 33 33 33 33 33 033 33 33 33 33 23 £3 R3 33 33 033 33 33 33 33 23 £3 R3 33
N032 832 2032 A”.032 0032 B32 0032 0032 0332 332 332 332 332 332 0332 332 332 332 0332 332 332 332 332 0332 0332 R32 332
SEES020338323002 5380532303026523032 5.9.300532563328323032 52200:3303033623032 53833229302533032 5220053229302823032 02.80030396969282022 2963025332032 5380552303092523032 5230.502203033823002 303028332032 5500.50230302523032 52.0053325025230:m 55005332502523032 5280502303033823002 52505332502523032 3823
$338333 230302523032 525053220302523032 52505220302823032 538532303033623052 5.9.300532303032522203 5500552303032522022 530033230302523032 52383230302523052 52200502203025223032 52200522363033823052
03 E N3 m3 «3 m3 03 33 03 03 03 33 N3 m3 33 #3 03 53 03 03 03 33 N3 m3 .3 03 03
N030 833 «03¢. 830 0030 B30 0030 0030 033 330 330 330 330 330 033 330 330 033 033 330 N33 «.33 333 033 033 R30 033
0030 830 2030 830 0030 B30 0030 0030 0330 330 330 330 330 330 0330 330 330 330 0330 330 330 330 330 0330 0330 R30 0330
99
WO 2013075035 PCTmS2012/065691
mod HQH nwd mo: wad Hmd Hmd wmd mod mwd mwd mod mod owd mwd mod wwd .36 «ad no.0 wmd mud mwd
and «0.0 No wmd mwd mmd wmd .36 mod mud de .36 and #50 .36 de mod wmd No.0 mud mmd mmd m.o No.0
2.0 :0 :0 :0 2.0 0:0 :.0 0:0 0:0 :0 :0 :0 :0 0:0 :.0 20 :0 :.0 :0 :0 :0 2.0 :0 :0 :0 :0
$632023506:SUSUZJZNWWSm my,0032023505320502323005m £03202:30555303232305m $5320$505300502323003m m0003202300630030222960:m $53m022:06300562223005m $532:2:0630:20223005m :33032052223005m $53202:30628502028005m 2m”,om020230902005020230?m 3506220502023005m $532:3:05220502023005m $53202:00533582323005m $53202:500200502023005m mmu,om”,020220050505020230?m $.53m0235055”,00502023005m $5320m2:055”,00502023005m my,0m22622.030200502223005m 202£005300502023205m £0382£220300502023005m mm,00320230530303232253:m m$03202+05053850232309:m $63mas05903850232303:m $00520m300630§02223030m maom320230630050222399:m 850305323205£03036is8: 85058322205309200530:
0m: 02: 2: 2: 2: 3: 2: 2: 2: 2: 2: 00: 3: mm: 3: 20: mm: 00: B: mm: 3: 00: 3: N0: m0: $0: 2:
0::2 02:2 2:2 ::2 2:2 2m:2 2:2 3:2 3:2 2:2 2:2 02:2 2:2 2:2 2:2 3:2 2:2 2:2 3:2 2:2 2:2 00:2 3:2 3:2 3:2 20:2 00:2
”5250053230:032523002 52505323202523032 0532303025229632 55005323030325£25622 50280332305825323092 52200532003032523052 52200532003025325532 SE850222025223032 32.5050296Ewe/25223002 SE8502203032523002 53.5052232025323052 SE852232025325502 52.00502003025223032 550053236flog/$823002 539605angmzubgaosm SE853230£0m§0323202 SE85a230£0m§0£<55=2 SE8522363025320002 528502203032523032 SE8502230328323052 5250:32303225223032 5.9.300532303032082363? 5880532303032533032 53003023053258235:m 52805323030325223002 30308005320505 030230022505manna/25505
D: 2: 0: 0: E N: mm: 2: mm: 0: B: mm: 0: 00: :0: N0: 3: 3: mo: 00: no: 00: 00: 0: E N: m:
0:: 0:: 8:0 mm:m 2:: 2:: 0:: 0:: 5:: 2:0 0:: 0:: 2:0 2:0 2:0 3:: 2:0 2:0 5:: 2:0 0:: 0:: 3:0 3:0 3:: «:3 0::
0:8 02:0 8:0 N28 00:0 20:0 2:0 00:0 3:0 2:0 0:8 8:0 3:0 2:0 2:0 3:0 2:0 2:0 2:0 2:0 2:0 8:0 3:0 mm:0 3:0 2:8 3:0
100
WO 2013075035 2012/065691
mWo mWo HWO mWo on NOH H NQO HQO H HQO mWo on mQH on ONO HWO on HWO mfio wfio «W0
on <90 mWo mWo N50 wWo mWO mWo mWo 500 Do mWo oWo mWo on HWO mWo on #90 add on moH wfio mfio
Nfio Hfio mflo mWo wflo NNO Nflo on mflo mflo Hflo mflo wQO nQo mflo No nQo No #50 mio nflo NWO 00 mfio
853580323sz om+3mm+u£UE<£<m5
$me 30m:
3033 3033
PG: 363 35380832223:39:63:96: 85£088:«28332366:Eu: 853563223:53:63:36: 85395532339389536335: mgamefizeafloSSySU$29695m 232902858?Emmusm mgamefiuassgssuog$29695m my,mme§<33m655§8<3Emmusm mmam326235»?BSUZJENGMSm mmu,ome§<=5$oes§5y§Emmusm mmam332:5»?DUSUZJENGMSm $5musuéuéesmuéesuusyasEmmusm mmu,omE<§F<esfloaaysa<=Emmusm 9.5mSEUEJSMGEDUSUZEEMMSm $5mafiuéesmmeDUSUEJEEGMSm 2522332350823396?m 52553028502:363% mmam32823530:SUSU”,<2<N%Sm 35393023sz385023230?m maem3523539505023226»:m maem3E?339033333<3<£om5m 3932025530EBSUEJZNMMBm maoaszuzeaflo385023230»:m mamm332enroEDUWDyF/«suégflsm mamm9&5eafloasysfiagomusm
wan man owNH HwNH NwNH mwNH «wNH mwNH omNH nmmH
omHHm< anHm< EEEEEEEEEEonHm< moHHm< ONHHm< HhHHm< NNHHm< thHm< «NHHm< thHm< oNHHm< NNHHm< mNHHm< thHm< EEE
2§<£§<£29330332909: 2&2382353396353253: 2&2382253:333<mu6m3 333302230335332365 2&2382253:53352355 2&2853295835329095 5m~b£33<§o£om§o£3532 SmEBSUPDUP/EofiomUP/E£3532 53505a<56mmmu€yo£<53< SEEDSUPEoeoNGU£3532 5:805agofiéegobeimg 550055236Mme/$693353: 5585geommflgbgfiosz 55855236mafifibgegm 55855236mafifibgsmsz 526853<3o£o£<5£<303m SmmbgazaoflopauouomZEosz <29<Gm§o£<3oa< 528055230await$3632 528653236£o£<5£<=m2< Sage:3<30£o£<5£<3m£ Sago:Egoaoafiogegz “—DmmeuwDPZEUmemuEuummam: 58585Egofioefibmmewg $3385322030336aims: 33852<Eo£o£<yo§3o=m u—Dmm+UUWDjw<3me+Ommuumm3m3
m m
«2 m: o: EH m: E 8H m: an m: 3: an an R: mm: an 8H 2: NE m: z: 34 8H 3H m3 m3 com
32m Ram a3EEEEEEEEaaEE3EEEEEaEEaa
omHHQ anHo meHo mmHHQ ooHHQ HoHHD NoHHD mmHHD QmHHD moHHD moHHD hmHHD meHo moHHo OhHHQ HhHHQ NNHHQ mmHHQ meHQ mmHHQ omHHQ NNHHQ wNHHQ thHD owHHD HwHHD NwHHD
101
WO 2013075035 PCTmS2012/065691
N50 <50 mWO N04 mWO w50 mWO NQO n50 mQO mQO mQO N50 00.0 R0 $0 00.0 2.0 3.0 w; $0 E
woé N90 mWO wQO m50 00.0 NWO N90 50 H50 NWO mQO N90 #50 H50 20.0
2.0 20.0 2.0 N0 $50 3.0 m0 2.0 2.0 3.0 2N0 2.0 2.0 2.0 2.0 00.0 2.0 $0 2.0 EEEaEEa3EaEa
mmu,0m352anaeaasfiefimflsm 353282300530050233000m ma0m320235303005023303:m ma0m02023000030053<3<£o$0m m$03202=50655£0£<2<m030m m53202550630050202300:m ma0m3&0:303030053<E<£oflsm ma0m9&0:303030053<E<£oflsm $02080£0:00028502023005m 8532020506220502020005m 85320232900503023250:m mmu,om9&0:05050505020205?m $5mass:£2.96EBSUZEEQWSm 8532020505050582020005m 9&0?EDEoSSUSUUFEEEom:m mm,om36205050505020205?m 3532020505050502520005m 3.63202:5082205022250:m mmu,0m35230052005022/23005m 3.62202:508300562023000m mm,em320235053005023303:m ma032023005338303380:; ma0m02022000.0350533222003m m$03202300605303<3<<0083% magma/2802300605020002023830,... m$03202300605050223000005m $5mesa:229005050332505m
EEaaEEEEEaaEaaaEEEEEE
52280533203002802363: 32300533500303? 3008:32303033502363 5030053403me0800msmsm 50380503300060006032.5202 502805022005038023033 <EOEOE<UUE<EOE< :mmuusstMmMmmuummJMJm E<EOEOE<UUE<EOE< 5008903E<PGNME<UUE<EOE< 52300532300508502303? 30000330303025502303? 5009003E<EOEOE<UU£<EOE< 50096905E<=m£0£<£u£<s+ofi< 5029605E<Pémm£<£0£<303< 3.8053230 5228053030050205023033 502805E<sm£o£<£ufl<s+ofi< 3005053330
300205023900 52300530209602096023032 5030053<30£o£<80003m30 503005E<30£0£<£u£<303< Smfiufiukuififio£00280
050205023900 023032 5003053<30£0£<£0£<303< 5030050320960305023033 5030053<EOEOE<UUE<EOE< 339605003003???
8N Ea mom 00m mom wow 8N mom 00m 02 22 2m 2m 02 2m 02 2m 02 2N 02 2N 02 02 mam RN
E aEEaaEaaaaaaEaaEaafigfigaaEE3
meHQ #wHHQ meHQ emaao thHD wwHHD meHD omHHD HmHHD NmHHD mmHHD «mafia mmHHo omafio hmfifio meHQ mmafio 00NHQ HONHQ NONHQ MONHQ VONHQ mONHQ oONHD NONHD wONHD mONHD
102
WO 2013075035 012/065691
.vmd N50 :6 Hod nwd no.0 “OH moé «wd moé wwd Nwd H wwd nwd de wnmd wad Hmfié BOA HA #50 mod No.0
m.o mmd <50 mmd H50 no.0 nwd mud Nwd and mod wwd de and mKd and Nmmd DVOH mood m.o .wmd Hod de mod
Ed Ed HNd de 3d wad dmd Rd mNd 3d Rd mNd Hmd NNd Hmd de mmd «mad Ed Hmwd :d 2d NNd Rd «md
my,mm352edfioedsdafigguo$5m my,em352EDmGEDUSUEEEUsowsm uumédsduzgfiofldm mm63202EdmdoedgduziiuoneER maom3202edmdoedxduzagomusm mm525:2JSMEEBSUEEEU982:m $329235”?SSSEEomSm mama/:2339oEDUSUEJENGWSm $5352:erJEUSEQ/EWGSm 35323632336m323095m Emma/:23EoBEDUSUUF/E/Eofl:m Smarts:EoEEDUSUUF/E/Eofl:m mmdmafizsegdadadm323095m Ema/EOE:3.295058%Eofldm 8%3623oumgagddgéflofldm £3252522oedbauéagéflosm £325:goumskuaduuma/Eofl:m £952632353236525NEGWSN mm”,mmESE=53o2§§<2<£o§m mm”,omESE=53o3§§<2<£o§m mm,em352EDEwSSUSUEEEoWSm maex2523smdoédeduzgaowdz =5mme85023230332 medm3§<33$odeduzafimfidz Emma:533369332533£3032 Emma:533369359633£3032 Emma:533369362de£3532
deH 33 22 mm E3 mNmH £2 R2 £2 $2 dmmfi £2 Nmmfi $2 «m2 $2 32 R2 wmmfi $2 33 32 Sm $3 32 £2 $2
322 :32 222 232 322 SQ? 222 :22 232 232 832 :32 NNNHQ 332 «~32 $32 £32 RS? £32 232 9.32 3.22 SS2 $32 $.22 $.22 $.22
SE85Esoaoafibmzaogé SE853<ao£oe§d£<em3< 536053230memagma 5383.0:03<30£o£§d£<aoa< aggedzgdmé 53d8332<aoflogubmzaosé SE85figmammsmzaosé SE85E<=mmmmm8£<3oa< 52855seaomfl<UF<U2<UF<=fl2< SE85Endangmzagé SE85gammmmmsmzagé SE85gammmmmsmzagé ”59.9605E<=mamm8£<aoa< 55855fidmfiomzuxfi/Eosm SE85E<=mamm8£<aoa< Swab=3<=M<m£<§<§o=m smammsmzagé 32835szmmmbumfidmsm SE85egogafibgaog SE85egogafibgaog 525053<30£o£<5£<3o3< 3385Egoaoafigfiguzm 3.5053230£o£<§u£<aoa< 3583E<ao£o£§d£<awa< 325:5NSMEMEEUUENSWSN 325:5EDMEMEEUUUFEDWSN SE85Egoeogxdmzaog
mm am dmN Ea mmN dmN mmN dmm RN wmm mmm 8N SN SN 3N 3N mg 3N SN E 3N 8N E NmN mmN «mN
088 3% 2N8 mHNHm ENS 3N3 3N3 ENS 2N8 2N8 dNNHm HNNS NNNS mNNHm «NS mNNHm dNNHm 8N8 Mama mNNHm 038 ENS. NmNHm mmmfim dmmfim mmNHm dmNHm
038 320 ~88 mama 3N8 23d ENS 5N8 2N8 ENS 830 HNNS NNNS mNNS «NS mNNS mafia 8N8 Mama ENS 098 ENS ~98 mmNS «28 mmNS dmNE
103
WO 2013075035 PCT/US2012/065691
Duood mood mood wood wood wood wood wood wood wood wood wood wood wood wood wood
and wwd mwd woo who dwd nwd hmo mmo Duo mmo mwo mmo wio o._u.o o._u.o .36 mm.o 010 N10 nmd
Hod no.0 wmo mod who mmo .36 who nmo oHo End End NHo mad Duo Sud NHo mad :6 mad mad mad
$0 3.0 N0 £0 $0 000 2.0 2.0 NN.0 8.0 2.0 8.0 8.0 00.0 00.0 8.0 00.0 m0.0
$09,233:3205303025£0552 $0330303205303025020552 ma0§§<§m§3§0£§208020 ma03202350530053?2000020 ma03202300630300?2000020 mm5320205303850282000030 230§o§£0£<2<<825% 35m3200300638500282000020 mm,mm9&0:groggfisiuo25% mm,om0202350635058502000020 mm53202eswogesuzafi08320 0m53505020206£§o<um<0=<008 mSuZUZanfimflomS£95 0m53505020230£85963m5: 3.52;005020230£35253m5: 88000<u<<o<<uo<o<0<3 0m53505020230asuaamsm5: 3.52;00500<£<mm£§o£o£0£95 35mg00500<£<£o£§ommm5~55 353505020205$053030~55 50535050202303550095m5: 3m5350582028336£03:m5: 35mg00320230£36263:m3: 3m535553§<mm£§o£030m5: 3mus358302023£35830m3: 3m53505020230£052.63:m5: Fukuoou<u<<o<<uo<o<3<33
EafigEaEaEaEaEaEaEag5EafigfigEaEaEagaEa@Eg5EafigEaEaEaEa mnmfi momfim<
388:5QWEWZSUZNSWQ 385309020280230032 503005Egoaoafiugawsz 5220053<30£o£§0£<302< 530033<ao£o£§0£<awa< 522005Egoeoeiugagé 2<ao£o£§0£<aoa< SE85E<ao£o£§0£<aoa< SE85E<ao£o£§0£<aoa< SE85E<20m5£§0£<303< SE85E<ao£o£§0£<aoa< 02020808203005000283< 30505220530059630ng 23525050005059630ng 8505059630ng 88<<=<88038308<U 22532050030059630ng mmfiseaxaaoeabus9630ng mmfiseauSgoeaaa9630ng as:«505055505science/0 23532050538536300me 06sagaéozmgmz 285300863003suaozbmz 285£003063205302085 2E:£20505200520308? 2E:$8852359630ng Htkt<<3<susuwssusswsw<u
am 9% RN Ea mmm 03 SN N3 mom SN mom mom 8~ mom mom 08 EN N8 mm 08 RN 08 RN 08 0% a
aa3 EaaEaaaaaaaa3EaEaa3EEEamoNHm
830 0020 $20 0E8 £20 $30 $30 330 330 0:8 830 0030 0:8 0030 $30 $30 $20 $30 $30 330 820 $20 038 0020 830 $30 moNHD
104
WO 2013075035 PCT/US2012/065691
000.0 000.0 000.0 0000.0 000.0 000.0 000.0 000.0 000.0 mood 0.8.0 0.8.0 0.8.0 0.8.0 0.8.0 0.8.0 0H0.0 HH0.0 HH0.0 HH0.0 30.0 30.0 30.0 Nfiod NHOd
0m.0 wio Hmd w<.0 mmd 00.0 Hmd 5V0 0m.0 mwd mwd 2V0 mm.0 m<.0 wwd 0<.0 5V0 010
mad mad mad 3H0 3.0 3.0 mad NH.0 Sud mad mad 3.0 000 3.0 3.0 2.0 :0 8.0 000 :0 to
CS
8.0 3.0 8.0 8.0 8.0 8.0 8.0 8.0
a0.535050202050200050525a 30.535050282000205£005053 35032050202060206060:05: 30535020202000020020302038 3050300502020002526£005: <<o<<uo<o<=<3 35055050202060205000505: 30.53505082060200250050.5: 8808<U<<0<<Uo<0<=<3 S0.5350508205$5505050.5: 30.535050202000055£0250.5: 8808<u<<0<<00<0<=<3 30.535050202000055£005253 30.5fifiSUEUZEoEEo000.50.5: 058§<00£<UG0.60.50.5: 88085<<o<<00<0<=<3 a:35050202000020530050.5.5 a0.53508202000020505050.5.5 350300502020502000000050.5: 02020000239300505: 3050320502023002303005053 3533050202300205300505: 3503003202000020003003233 303300502020000200000000505: 30535050202000020000000050.5: 353503020230080030050.5: 3.5330502023002000000050.5.5
32 0an 084 Eu 08H 080 000a 0.2
$32 0032 0022 8S2 0032 0022 08H? :22 figfigEaEaEaEafigEaEaEa@Efig@Eg5EaEEfigEaEa
0500523520300.60: 2005050505320530303002 200525050530053630802 020208082030033032802 28505086320520303002 88038305<U 2005320506300530303000 200505086350539203002 030<<=<880383030<U 20050505000350539203002 200508085320530300.60: 88<<=<880383030<U 2003050505320530300.60: 2005055520350530:00.60: 20050500803205303000002 88<<=<880383030<U 80505050003505303000002 $05£3505350530303002 200505055350530300.60: 200505085350530303002 200505050535053030802 2.9.05£83538530303022 28:£0050630303039<Ue< 285030300385203000002 2005050500350520300.60: 2003008800550530300.60: 0E:05050.63505303000022
N00 00m «00 000 000 80 000 000 000 00 000 000 000 000 000 80 000 000 000 80 000 000 000 000 80 000
308 0030 0020 8S0 0030 0020 083 :20 aaEaaEaaaaaaEaaEEaaE
308 0008 0008 808 0008 0008 088 :08 ~88 088 088 088 088 808 088 088 0008 008 0008 0008 0008 0008 0008 0008 0008 0008 0008
105
WO 2013075035 PCT/U82012/065691
mfioo mfioo mfiod .300 .300 330.0 ofioo mfioo wfioo 0N0.o HN0.0 HNoo NN0.0 mmoo m<0.0
Nmo Sud mmo 3V0 n._V.0 woo 0m.0 0m.0 0m.0 m._u.0 mio Hmo nwo owo .30 «mo wwo wmo mmo wwo «no .30 mmo mm.0 mmo
.30 End 0H0 wad wfio Hmo mad nH.o 0H0 NHo nH.o Swo <N.o nN.o omo NNo mmo mHo mHo Swo 0m.0 mad wmo 0H0 mad 3.0 3.0
no.0 no.0 no.0 NH.0 woo no.0 noo mHo woo mHo no.0 no.0 0.00 .30 no.0 no.0 no.0 no.0
3953555830230 3953555830230 3m+3m3+3muFDu+<£<£0 :fl:35m5£<£<£0£<u 3
m5
”Sm”,3305m958<£<mm£<£0£095m5: 3m5353929230NEUGEOEDm5: 3535m59m8<£0£35£0me£95 35mgamazon—4.30335£933 3&3359398280335£9.35 3m53+ouéu5um£<m534.803095 M5umu2£0£<£6£0£335 33353202923093953095 3m5mgomuFDuZoZmqu85303335 39539595082808.4553095 39533958302me853095 353395962933093863095 J33+DM+D£<£$<G93863095 3+3M+<o+<£<£mv 353533029230 3.53
$.35
30
mtu< 35028530£38030me 3m53593029230£406.30me 3m53593840330£<£OEOED 333559584023034963095
m5 :33593840230mzuuFOEOEDUEUS m3 m5 m5 m5 m5 m5 m5 m3 m5 m3 m5
3 3 3£533838<u<umm<3ummou<€mtflu 3 3 3 3 3 3 3 3 33m._._u._._um:0_o<vum<_uo_ummuuwnmm<ntumtus fl<u+0m+0<uo<n3nn £<u+0m+o<u3<n3nn fi<£0<nm<n3<n3nn Eo<um<uo<uonu 3&53+DM+<U+<£<£0£<UEU<Uw<U:Squu Ututu E<£0<um<u3<u3tu 3 3 3 3 3
aaaEEEEaaEEaaaaEEaaaaaEEEEE
235330580320530303093 235330503505303025 N35 Z35 “E35 u<33838033£3 235
303230
m: 338380338:30553034. 305803303303930mucq Ewan—Dmsuwofiwswouwo39353093 usunUUUMJFU0U33wrongs—Eva Emflofiougfio359530055893 w<mm3m5u5uu635uu5Egaoflomg 9595963585EQJMEUFE w<mm3m5u5£05u5u530303092 EwfloflofioumiofioEgaoflomg 33533958655853353092 Emma—3338580395953033532 33958635330303093 mm<_u._._umzu_utuum._.n._.nu:._.uwUsmfiuogm mm<Us<UDUUoUEOED£D:mEQmumucq UDUUoUEonEDU+Dsmfiwmumucq UDUUoUEOED£D:mEQmumucq mm<Us<UDUUDUEonEDU+Dsmfiwmumucq mm<Us<UJUUDUE0nEDU+Dsma+<mum+< m: am<Us<UDUUoUEOED£D$30834. “—4.3533058033033030£022 2w£3£3£3£033£320308093 Emflofiofiouwoiofio30303093 w<mm3m5u5u+033u530303093 £38396EDuSEQEOmum?
mom 0?. Sm NH». 3». Sm 2m E Em mam 2». 0%. mm N». mmm «mm mmm omm Rm mm». am 8». mmm wmm mmm
aaaaaEEaaaaaaEaaaEaaaaEEE5EEE
HmNHQ NmNHQ maNHQ QmNHQ mmNHD omNHD nmNHD woman woman oomfio Homao Nomao momao «Oman momfio oomfio nomHQ womao momHQ onHQ HHmHQ NHmHQ mamao VHMHD mamao oHMHD nHMHD
106
WO 5035 PCTmS2012/065691
Hod mmd Hod wmd .vwd Nwd mud owd 05.0 mmd and and mod mmd mud «m6 nmd .wmd mmd nmd mod mwd mud
de 0H6 0H6 Sud 9nd omd mNd wad HNd Hmd mad mad nmd .36 Duo mNd wad wmd omd mad 0N6 0H6 mad NNd mmd nmd omd
3.0 00.0 00.0 3.0 8.0 00.0 00.0 8.0 3.0 8.0 00.0 8.0 8.0 00.0 8.0 3.0 3.0 00.0 00.0 8.0 00.0 00.0 :0 3.0 00.0
a050305020020502050505~50 333505020230020003005~53 33350502023002053005£00 3050300502020502050003£0: 30503000000<£<£9$§o£005£0: a:0300502023002080525£0: 353303020230$55300505: 3533030202300205300505: 0053505020205£35050:05: 0053505020225$35050505: 35330502023002050505250 0053508202050205050505: 00535050202050205050523 005030050282060205050505: 35330502020000205052505: 0m53505082050205050505: 005030058202050205050505: a:35050202052205£00505: a0535050200050205050505: a0535050202050205050525a 3050305020200003053005~53 3050300500§<00£§o£00505: 30502005020200002060623£0: 3033005020020602060605£0: 35330502023022060.60.5£0: 305032030200300205300505: 3053503020230085050505:
EaEaEaEaEaEaEaEafigEafigfigEaEaEaEaEaEaEaEaEaEaEaEaEaEaEa
2005050506350500303022 05053005303000002 2005300505300530302002 200500205530033030502 0306:8520303002 23508552005203050: 0505200530300822 2005£00505200530300822 2003250505300530303002 2E:050505050:30300802 222.£0050505053030082”,< 2E:£00505050530303002 +<$<S£00505300530303002 235050505300500300802 235m8505050530300833 Ema:050505300539203002 2005050505300530000802 2E:05050508530300802 200505050505055530£002 0505350520303002 2005050500300530303022 2005300505320530303002 20050850630033020502 20050303063005003000002 2E:£0050608520300822 2E:£0050520055530893 2005300505550:30300.60:
000 80 Ea 000 0.00 :0 90 000 30 £0 000 80 000 $0 000 $0 000 000 3.0 000 000 8.0 EE 000 000 ~00
Ea EEEEEEaaaaaaaEEaaaa EEEaE
088 220 0008 308 0008 0008 0020 0008 0008 808 0008 0008 0008 2.20 0020 0020 «008 0008 0008 808 0020 0008 0008 308 #08 $08 308
107
WO 2013075035 PCTmS2012/065691
mn.0 mwd wmd wwd de wmd dwd mod de mod and Hmd and H00 nw.0 Nm.0 .30 mod no.0 mod mm.0 mm.0 .vmd mwd mmd wmd
.vm.0 N30 mwd HN.0 mmd mad Hmd mN.0 mad 0N0 mm.0 mad M30 nH.0 Sud wmd 3.0 0N0 mmd mad 8.0 mad wmd mad wad
mad 3.0 :0 w0.0 Hmd w0.0 wad .290 n0.0 0.00 0H0 NN.0 0.00 .390 nod 0H0 0N.0 w0.0 no.0 mN.0 n0.0
3953+3M3£<£<£9<w<£0£095 395mgamazon—$30$405303: 3$3m35m5£<om£0£<£0£025 395$:395520330$963095 3m5m3+3m3§fi¥<30£<£0£0m5 3m5m3+DM+Dum£<£OUF<UF<UUFO£095 3m5359384035E<£OUF<UGED 3m535930383303.4863095 5m5m3+3msfi<fi<m+o93863095 3m5m3+3mu5u+<um£9<¥<£o£095 3953”,33202330m+<£0£0mu5 3m+3m3+3mu5£<£<m+0mm£o£9.35 395m5u5m5£<£<£0£<umm+0m5 3953+3M+38<£$<G£<£0flog 3m5m35m95£<£<£03.353033 m5£<bw<£0£<£030m: 3&339593840330£<umflg<u5 3&33593840330fl<umflg<5
m5 3m+3m35m95£<om£0£<£0£0m5+$3 3m5m3+3m5£<£<£0$305303: 3&33533929230mzumfloflafia 353+DM+D£<£<£9$<£O£095
m3 m5 m3 m5 m5 m5 m5 m5 m5 m5 m5 m5 m5 m3 m5 m5 m3 m5 m5
3 3 .5m5353392330$135303:£33 3mSmEDGSuZuEEOmmutu£095£33 353+333023803.3653095£33 +Dm5m3uFDmuFD£<uuF<flo$863033£33 +3m+3m35m5£<£<£0mw<um£0m3£33 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
aaEEEEEaaEaaEaaEEaaEaEEEEEE
“—53:£3058033U+D3v63+9<¥0£< 2mm:«5058035055530£034. 335 “Em—£3
«58380350550630£0£4. 2853:0580350330302692 2853&38035822030£095 Emma:3383895595353m£0£< 3353383803595$302593 EmNSEDuuSuuG:353965963093 3933EDU3963595u5u635£0£< “—4.3533959655953035893 23953395863533965963093 “335mUSUUFDumPSuuSuSuGPG30m; 33959595803959530396935 33383963389553963093 5959535303093 335958380395u5u5963m£0£< “33539580559535303093 235338209635953530963 2509505353 “2&3: 3&3:
meUVDumEDuS £90580:
3&5
3539.630 353530 303530
m2 m2 a? mmm3m3u3um33u33M3m8mm 333338205358330309634. 385338280330335303093. 285203580235$308093 m2 33598296359535353093 33598296359535303093
mom gm mom 8». $m mom mom Em Em NR mm Em mum Em Rm mum Em 0% Hmm Nmm mmm «mm mmm omm Sm mmm mmm
Ea5aEEaaaEaaaaEEaaaEaEEEEEE
mwmao o¢mHQ anHQ wvmao mfimao OmMHD HmMHD NmMHD mmmao Qmmfio mmmao ommao nmmao wmmfio mmmfio oomfio Homfio Nomao momao womao momHQ oomao nomao womao woman OnMHD HnMHD
108
WO 2013075035 PCTmS2012/065691
omo mwo «0.0 «0.0 no.0 mn.o wmo mwo «mo mn.o on.o No.0 ono Hwo mmo nm.0 004 wmo mn.o mn.0 mwo
mHo Hmo HNo 0<.0 oio nH.o 0m.o «No Swo <m.0 wad wmo 0H0 0N.o omo mad Swo mHo nN.o omo nH.o mad woo wad nN.o Hmo «mo
.30 mod mad mHo woo wad woo no.0 .30 mod Swo no.0 woo mNo woo woo woo woo wad no.0 no.0 0N0 0N.o mHo
3
3m5m3+3M+28<£<£0£<£0flog 339292253.353033 35355583023033530me 938<£<£9$<um£0m3 3m5m3Emu—Dozozflozzumflwm5 3m5m3+3m5£<£<w$03.3%”,me 3m5flaomguzuzgw938.0363 3m53533830230mucqumflwflo 3m535950293363380mmflo 5m5m3+3m58<£<m+0m+<u+0m+0m3 3m5SEEP—0284.30m+<um30m5 3m5m3+3m5£<£<m$om+<u+wmmflo 3m3mbo3OU3oUmUUm£0mw<£0m+o<U 3m53555929280£<um£0m5 353+3M+D£<£<£0w<w<£0£0m3 mu,Dm3+35+DU+<Uw<£9<UF<uuFOUF<¥D
my,
m5
3&33593850330$3803me 3&3353202093303.353me 3m+3m3u5+0+3uw<£<flo92803095 uFDmufiuzuzflwmzfio£935 3m5m+3+3msn¢<£<£0939630m5 3333393842.430£3535me ”5m5m3UFDM+D£<£<£OE<UUFOEOE:
m3 m5 m3 m5 3&33593840330£<£Omm£2<u5 3m3m._._u._._u0U3oumuvmflom+<u+0m+o<u3.3953 m3 m5 m5 m3 m5 m5 m5 m3 m5 m5 m3 m3 D<P53 m5 3m53533925230335mmflo£33 m5 m3 m3 3&3m35va<£<£0£0£<£o<UOU<FEUm5 9&5
3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
E5E5E5E5E5E5E5E3E5E5E5£5figgagaE5E5E3figEa£5figEaEafigEafig
23525058035953+03mflu£< 2&3: 2.9.3333058033053m3$0mu£< 28583898033053535£u£< 23533828033535353093 3333283533535359693 3&3: 3&3: 2&3: 3&3:
350335359693 EDUUSUUGEDUUS3M3+o£u£< 335333553333+03+0£0£< 33523959635953535963 95959635953+o3m£u£< 239595955535953m3096m? 23532058033u+33+03+0£0£< 396358335353093 £3959635953535893 mm<_u3m3u3u+035u33M3m8mm :38:9595553595353m£u£< EmEDSDUBUGEDE3+03+0£0£< 2&3:m3uu5uu635uu53+03+0£0£< 2&3:EDUEUGEDUS3535303 mmmHUmHUuHUuOU3HUU33M3Mmumm 23533828035u53+03+0mom+< 2.9.33320580353:3m3u6mu6m+< Ewan—2300580338335303092 £0u3£035£335353093 +<mw<w3mw3uu5303u5uu§EOEOmUfiE 0333333852383353%me 2339538033U¥D3M3+Omu£<
0% Eafig mom «mm mam gm 3m mam mam fig mg mg m8 83» mg o: H: N: m: o:
a aEEa3aaaaaaaEaaaaaaEEaE3EE
NanQ manQ wnmfio manQ onmao nnmao wnMHD mnmao owmfio meHD Nwmao mwmao woman mwmfio owmfio nwmfio wwmfio mwmao ommHQ HmmHQ NmmHQ mamao Qmmao mmmao woman nmmaD woman
109
WO 2013075035 2012/065691
N2 w; m3 8.0 Rd ONO “NO mWO mWO wWO wfio mQO «OH mQO mWO mWO ONO ONO
EaEaEa :3 m3 moo 50 $6 3.0 HWO mWO mfiO wNO mfiO mWO nfiO ONO ONO
wdo m; NflO NflO mWO NNO mflO ~50 mNO OWO HHO ONO nQO wQO wQO
aEmflu%:8<83nmou<u<80u<8u£u<33 3mSSSMEe/‘egwmzu028223m5: 353550295393582825m5: 33$35m=§<§$oEgomwfism3: 35mfiamzozeoggxguow£333 333886238333S: 3m3m33o8<u<mo<<uo<om3<33 3mSmJSMEEUBEoNZUUon963333 3mamasmzumu<<Mm<OMmo<sm33 3$333320szEEBEQEEEB smsmbbm:u<um<0mm00mm<3m33 3aDSSMF/‘yzaofiéefiué823333 a:mu,22o96:59&62992325m5: 3msflfiuon528E<uou<u88u<um<3ufig 3m5SSMSUEUZNG$559695£95 3535338625$359695£95 352;aflsfiuzflogumfiofi:£95 3m3a2292839225226”,939$3255 3m+DmJ+DM+DUw<Uw<mw0mw<u+0m+0m3 38396
mewD a9595a$20§<2m£<bm£9<3~55 §§<£o$553095m5: ombmeamrfiwewmmmwoEuzbgawom 88mgDmEEomemmGEu80330m 30$382865sz NEH/Emmmmsgsaoméu oysmgeogmzmmeu565M696: Esaéfloflomzmmaugunman”?
<32.mhuuzuoussuknsmsogugu +<mm5mhuuu<83033u536383638 3253.40.33.00358:303<£um+< $25mauSumSSuesasmO/Emm $<m<uhum50fiv<cu52335EOE<mU£< SE:
usumssu: +<m<uhu<nkufi<3635u5 UF<m<vHu<anuE<u+o3535 mm<3m53um33us
$32335
Dwam<umm <mm3m3u3u03833m:08m< 323353303235353,0333%? mmm5£3u5u+0353530303633 mmm3<3usuMJDOJJODMmO<m 363336 mm 363336
m+< m+< mmucqsm3+usum53u35m=m¥<umm msuusum._.usu3_.nm:m<uumm 3383803535553636m? 33383555333536363638 mmmsmsusum::u::m:m8mm 38233835358330363638 833285632329539;: +33:£3058035053639<U£< ©9580Samsmzubwaufinfis3636 om$3803905335358335363,0 845383330EEBDUUEOEDUE 34539839030396536363533 mmHDEUUEUUSUUSEU o3EH8525MB”2883858:36
E3E5E5E5E5E5 mg «S m9 mg EV mg mg 03 HQ N? m? «Q m? 03
aE55E533EEEEEE
mmmao OOfiHQ HOVHQ NOVHQ MOVHD QOVHD mOdaD OOVHD Rowan wowfio mO¢HD OH¢HD HH¢HQ NH¢HQ mawfio <H¢HQ mfififio mafiao mafiao wfifiao mfififio ONVHQ HNfiHQ NNVHD mmdao QNVHD mmdfio
110
WO 2013075035 PCTmS2012/065691
3622335sem§§u§o$§3a 3mame§§o£om§§u33,553 mewa505665950 $330EomZmGBabuSmmmUeB “33533098852995528 me<mmu,<m6£om50§uEoMSSEUU m33559958053936355a mawmewmzflosbsyswo8955: $59659392836ng385m 932896ng385m £95965qu330555538 $99395quafloat:883% $6mEmeuEyo$355595?a wsufiubguy/E:38590: mafimfi96£85WWNUJSUUJEUSU $396Eufloaammmbassaoysu mmEmMSUUFEUEoWSS585E038 mgmgefiteommx:208E038 85308239550528 $625£85308355:3550 $5820835353385553053 ma:8253933338533896: 383805908:853055532 3flufiueamfiog3883098stm 8286359553853956523 8289536355SUSMUBUUJEU 33oNEEDBPGUUFPGUUSyou
022$3%mwoeézbysubaua: o323w38823032<U§5535 096$is333625389505 omdongUU303202596235 omdomzmwoauzmfiao£83535 oodomZEoSUyPEQSB£85536 oSZEomEmSU9665958385 2329a£39553995598385 oSbEomzmmsoagéuéao£855 oSb£93263§<§63o£855 $259230mmmUPDUUUP/‘UGMSMZUUEU o$82M.022$:UUUP<GWSH<5=U magmbflomfiuéEUUEWEJGEUUS 022mb9.962%Pououéfloaombys omdofiéuzmmgflagumayor/Eu 02559266muémusuobmuémusmzub ©25ngmmmZfloSUUZmEEomU o2633625?£588353oEu omdomfifloumfio339353095? magma£06290flsosubflomsmué 833%szgoflsaaeuuzmag 03233306gowfifiosbyamuéaa 035.2090mm£<m§$<m32u£om5 $35EomfiogouzflwzzwBUamps wmdoszflomNHuFQEEGEUUZMG wmdoszfiowozmb£99<£oa§<m5 modemsgongozfioagflsxum5
mfifi Add wvv omw Hmfi Nmfi mmfi «mfi mmfi omfi nmfi wmfi mmfi How Now mew mew E—
0N<HQ NNVHQ wmdao mNVHQ OMVHD HMVHD NMVHD MMVHD emwfio mmwao om¢ao hmfiao wm¢ao mmfifio o¢¢fio Hfififio Nwdfio mwfiao <<<HQ mwfiao o¢¢HQ medao wvfiao mfifiao omdfio Hmdfio defio
111
WO 2013075035 PCTmS2012/065691
mmofismageas285805you 0835ng3833030553580 3835ng3839388250 ezobsmUSUUUS£86: 35EoEBSUUJMUSES£86: 3$935353:?5532593m Ewazussbaamascot3862% $95gaspswouauoaafiuyo32m $63535596353:859;: $285eueafluayoasobusgm 330853302:gm EUSUFBUPGUBBUSmbuobafizm 3582:58:29am 85352330968JESUSPage: 35389530583383£96: 3538960558auguszgmsm 333628550:55333? abausmuoeoubg860523”,er 36353055:myoysmmaoefi 363623505matessamsmbm 883595285853<mmm5mbm éafiogufiefiuea£26302: omsmmbeueuifiuga£<mm3§<s 358552:m§§<£<65yams: 396395385883:2»:yams: magmaoyoefiugmzegafizssm magmacubefiu:$398232
$3
$32
0263:£990gouvavévégmusuuogm my/«$025330382 o$3939om2m§<6m2£w2§< 032909:mmmwomwobzflogmvseu o3<m6m§$om6£9FUUF<MBNUF<WEUU oSSEomG:aflomufiéuofloméflwau 935EoEoSEHogufioflogmfisb oSSEEom:EoMFoUF<UFox<Mo£<E3 345329965Eomfiéuéfiflogfl: @3535manna/$99390965g 025:5£965E<m§§<mb£ofl<£o gzmmmusEEEofiouzmfig 859533963:egoafiofiflog 0229535afloafiofimzmbflomz 0329522305afioamzmbflomé 025.535:wwoflafioflofiouzmfi 035flos$:”,3*<$omu,3u,<¥omu,oEouzmfi 028355:gm+o$oSUF<m+om+<mbflo 03636555NGWGSZWEWEWUNG 02533.5:32<m+o55£om5£ox< 035$:«855323965£05382 0323533:gamwowgogmfigmb 03230338:33399032332? @32ng833326633£0336 03233332635aséuémusgflwg 036.235:manaagéfloszflog oSUNZEQEESEDEGMGJZWEWE
th Nn¢ mnq «Aw mhw ohw 55¢ whw mhw oww wa Nww mww www mww oww nww mmw mmw Hmfi qu mow IE IE
mmfiao #mdfio mmdao omfiao hmfifio wmdfio mmdfio omdfio Howao Nowao mafiao emfifio mafiao oofifio hofifio wo¢fio medfio Ohfiao Hhfiao Nhfiao mn¢fio wndfio mnfiao ohfiao hhdfio whdfio mhdfio
112
WO 2013075035 PCT/U82012/065691
85
8583
3885 39389683 mmUmuU 8585 Stamps
.8
8080: 853038083 FEED:
m m3
~23 mm
3285053330:
230 252: $235mCEDEGmJEUEUm:
m5
30m 8588053008:m£<m58m530m 34089533032823396: 3888342005mmfloszuminmfis 858530983293338353095: 3.585388323339633695: 8063:6968:£<mm3<£<55muésu§u 39038 8530653???969555935: 853580323<mamUGmUSJMMSEUJ muuF<3u5u6u63u5u5u mo+<35mmsu5u5u E<£<mu5mum53965363an 3885:2933:moflsfiomsfiufium uNEDMGUSUSUSUEJ 8835£<£02<um35mu633593: fiSmUm32095853:m umbmé<£<m5£ug263333095m 8532963.48.4::mGEDUSUEPEm +<£03<£<s:mGEDusuZJEN fifiefifibe:smflaegabgmzm §<§<m5mb£3mm55833343 $2353<£<=5mmEDUSUV<3<£0M m$<m36320233333330m2<mu6m EDEoMJEUEUUESNEWS: 9:490: mflwm3<£<333633£D£<td<£033m
23
832
NUJSSZWGWSEoMG 55eueaazwowsemym omdfibmzsmzfiaaaawmfiszyo ©3208532033553£039sz 8538233:NUSUSE/EomSmG 3423822533NUSSJEWGMSNG omdoefiugséagous95mamas: 3535822962595asfioflosé $32»?ng95952895335$: $225990?NSMSEU95329095 8596938£3223535336 85963596£322559596MB 035358023295£35335 om::mZmEZUuEmSES533335 0229696managioafisssm5 omgefiafifib925535535m5 025fistmmmUafi<5m5535:2 025asfisozauasssms595:2 0253230mmmvayéséeéfifisas 025323930£<5”,<v,<2o3<y535 ©3835«SWNEEUUZNEWS9635 035:5eaozmzmbbzaamus9695 omduezeémao£<UU£<963<95 8:853320aofifiobgaoafis 032535NJM+<MUF<UF<UFUUUP<EDMD£U o32532$39<3<+<Ua<m5m5flu mod:
£095
3
m
30
m”,
03:80
9330
E<
08 8m mom 8m mom 8m Sm mom mom 03 Sm NS m3 Sm m3. 0?. Em mg mm omm NNm mNm «S
EE EaEaaaaaEEEEaaaaaE EEE
owfiao deao Nwdao mwfiao fiwdfio mwdfio owdfio hwdao wwwao mwwao Omfifio Hmfiao Nmfiao mmfifio «mfifio mmfifio omdfio mafiao wmfiao mafiao OOmHQ HOmHQ NOmHQ momao QOmHD woman woman
113
WO 2013075035 PCTmS2012/065691
$0,930,523.43?:USEJNNGWSm $53833.53:BEUNSZEHEEN $23083333353:$33,: 32823590388232263:«Em 3e<§<35m53gauze/«ampsgm SUE:3593:8353£<§oa<£<m Samesemumssbafls£<mm2<£<m eBSUNEEEED923% 823599538$296?NEE/é masmguémussbsbm:muémuéuszmzmzs magmawflosbeug£<mu6=m£<£<= EsmfloeBSyégEomsuéfiuépsm EsmfloefisugEoflsmmgflsm 396mm”,336595mayosuézuamuaaom swamps5:695afloafimfiaaom mammaSuSgefimmS£22339? mammasusgefimw:gamflsmz: $53696£3£<mm9,<mv,<+<v,<ao£:3 $5265&3£<mm2<£<mmeom53 =9535£<E<£om= 3585£<3<£om3
£<£§E5$<35= «Rwy/«93%;: 3826m5£39:E<£<SGNSEB 3835336230:m£<£<smm338 85823233:mmmzaaozg95m 338232333mmmzmusmfisaum 36:5muéfloefimgaoufis955: 36:5£<m63<mm£<ao§95°53
omd: mod: mod:
£08352 0353.480 035346555£39$9<£u£<m95m5 03533800: PS 345353289582039338233 :5 $353535 @3255 335 easy—<35 3423033 omd<£3£<z omd<fi<sbm3 omd<£<38<5 wmdumzfldcau @3220
3055 ED
3 3 £<m
3
3 a: 3: 3
30 3<UUED
333$ 8&5 34535323695 muuG :35 :5 :5 33 so;
E
9&2qu 03 3<39$0£<£U 323625 £2.0sz 338655 £965 33963: 223005 332505 333555 3555
9330 9602 93qu 9396
m? 9692 E<u5u6m+0m+<u+u m+0m+<u+u EDEUSMEME
:5
E< 33m; 9&3qu 96 m5 m2 m2 m+Uu+< wad/x353955296ED+<+DH<H<£UU+< mUuSSEEOEOmEuU om4*Um*Ds*D*D*Dm*UU*D+D+<:+Om*Om*<u+U EEU 345923555338655m+DmuF<muF<m+U 3<30mu6m+< omi<30£3fi¢333Eufi¢33<30£0£< $39293 o33£583352333825fififlzfl< JEEOEG 323030 035345533333520063333m: wodOEd‘EDUEED33320539533m: omgwumw<mw<sumeJWDWDWDmWUu+D:*<:*O 30 m5 omd<£0£<§¢3£<£3fid3E<£UEDED
mNm omm Rm 03 Hmm Nmm mmm «mm mmm omm Rm wmm mmm 0% Sm Sm 2% 3% as. 2}. Sm 9% 03
aaE aEEEaHaaEaaEEaaaEE EE
woman womHQ momao OHmHQ HHmHD NHmHD mamfio QHmHD mHmHo meHo hHmHo meHo mHmHo ONmHQ HNmHQ NNmHQ mmmfio wmmao mNmHQ onHQ NNmHQ wNmHQ mNmHQ ommao HmmHD NmmHD mmmHD
114
WO 5035 PCTmS2012/065691
82323meMENEDWESSJUWSU fi<§<£om5£<m£53,;3838 $5£sz33%NEEDSSUGEUN SSEEEEEE$533:865m 32353:£<£<9332959585 $33me£<£<§H<=583820 £<£<smm5EPGBEUNUN 8:3963<£<£<3m£3Enumsombm $995£<£<m5m§5PGUGSUZUEN $995£<£<m5m§5Pawns/62m mméma<£<£<3o§asyéusbmbgm mméma<£<£<ao$3358963% magmagismzssaumusbéyémzm masmngmusmz:EUWSUSENEN =$<m£<£<3om5ssxosuoébmzmzm =$<m£<£<3om5=8558£<£<m 52::UmSUEUZmZfio: mmzmflfiSmEe:BWSUZU$296: SEBWJU£U+<+<£<m5m 32m£<2o~5enumeufiuggflsm 32mg33<3338m§§<§<963% $235335Eumazuzmmaozom $235£338585&2??me $235m5engosaugmmwswom SSE/35.538BENZEGJEWEW $253:eumsumggmmaogm 35:535558939355963?
EaEaEaEEE£32 figfigEaEaEaEaEaEHEEEEfigfigEa
omdwmtmzmmeugSS3538532 oflaeomzzzsb£29535£8532 OSSWZQGNEfi<55§3<yoa§ 8:DmZeoEEBRSS3335635 $36308?£383,323,:£85 035:6£89<£<28<59535£85 wmdamsmzummzfl962:5353&5 omdamSmEbEmu,<mu,28<35953<yo $35Ewaosmzflfisuops95358 @2536393059258m595958 wagesmusmsué£2523595:2 o3:esmuéozxo£2523595:2 025=5soJMEUWEEEUNSJSED 025:52955powgéuasuofisasas om5EsaamsflfioZZmSUEE:35 026:5£205505223323535 smeofiouézgsbfisas 02295322036£u§<£<96m535 028.53533m+3$<§o£<£§<33 028.5322333955£38235 33022<U$<£<5£3 03525555sogofiumuzmvaeue: ©3555:35920206595qu $355555EDMSGUFEBEEEE $353823EDEPSGNUWEEEU 03638265anagsuépoggfiu 032955895aaoszuquZfi:
Nmm mmm «mm mmm E Sm mmm mmm 08 35 Sm mom «om mom mom pom mom mom 03 Em NB mm Em mum E Km mum
aaEammmfim EEEaEEEEaaEEaaaaaEEEEE
«$8 088 ommfio News wmmS mmmHD OQmHD HQmHD Ndmao m¢mao wfimao mwmao mwmao hwmfio Mama 9E8 038 33o NBS mmma «$8 $30 0.38 330 wmmS 320 830
115
WO 5035 PCTmS2012/065691
3635235582223253 $235963820£23055ngm $235325920$233329:m $52:Daoeuenvwmmzwago£032: 85355533323339632: 3m5SUMSUZUZN$622023:95m EDSUMSUZUZN$52039:m5m 3585533223330253235 Ensuésbmbmzm35323235 56m»,320223203255£35m 3623233532? 35365£<£<mfi696523223 852532223323&on mmSSEUENEEo$329,225may? maame<e<£<£o332$:$592: 38mg£<£<m5mmm53$2§om5m 35mg223333022:853% Um¥<§<£<£o3wmmm5322632320 fi<§<£<£o£ommm5$383235 magmgflfiSfio33232653333 353223330«ms/2353533 226G2Sommmmsmmamm662 £26m 2
2 053230303233:533233 3232333030:$252552: 323293326:82053832: 33353034333msflumu3<u5¥<£<mu5u 8235369333NUMEJSZNSU
EE #3 33 33 33 R3 $3 $3 83 3.3 I:ummmoH $3 E 33 0mg 33
$32 $32 332 332 R32 332 $32 832 $32 $32 $32 .332 332 ommfim< $32
02295526353555355323: 035338853220305ng 0353055205SSSGEuNUMENE 032320585335333322032 34232958852223339258/2 033338832055520:5ng 3::33382828355558m: 086855EDWSWEUG 3532:2655£955EDWSWEUG 333395828285953258 35$: 3::
«526382853596355 3:36:23Gusyouabasasflsg 3:85E<SZ§U§<UEDEDWSWE 969993533325 02232525558223333535 3:255:EESUUNUJSJSWS 3::«58052322296£35333: 353220955£825,553:qu 35325553355602053535 3:53:«Some/3265553535 3:33:£280323265336333: G
2
S:3:uMm
526
U
2
3sou:
3 2583:32263823335 032353:353252335835 wad/233332552253355535 $353330:35953596368333 35$:3922532259638205
Em 03 Imwm 2mm mmm omm am wmm am 0% 3mm Nam mam 2% 3m 3m Rm mmm 8m E 38 E moo E m8
aa EEEaaaaaaE33m 33m R3m fi3m 33m 83m $3m N33. mm3m 238 33m owmfim $3m
$39 $39 vomao momfio ommao hmmao wmmHD mmmfio Ohmfio Human Nnmfio mhmfio «hmfio 33o 33o R3o 33o $39 83o $30 S30 $30 £30 $30 owmao $30
116
WO 2013075035 PCTmS2012/065691
mm+<mm5muéflwa<smonSEUmZEU: SZmMSEoeoszs85$:89353 25833523805: mmfiomgowzmsg$233233? meaéo3.032333:5229033 masmmuéfloszfifimfl:9629623 gammy/E:33.3%EEEESUSEUN 5,9933:EDNUMSEUUPEBSEUN Maggie/‘59EUNESUEBZW mawmmfiegzgm:59389583 $39:musgmuésmgpsbus530m m$<mmu5
m5
abuzz 3532328083
mu+<
£33
36
flow mufl<3§5+3u+<mu63 Emmaéefifiaa893532396: $535fiumEeEmmSUSSU96950 $535$525252:830950 a$33358:£%§U35§<m550 auémefiofissommeueoumflofifi mmSmmUmEEEEBSSEGWSUUW gefifigaaJUNWWSUUW azsagambmza382553853 3:35m5eugasauzmmsbxu: mmbmmZefiZeB:53905538 amazefizfisgaufiomabmusu 85353339:823928596: 85:5flue/Eb:8230:8596: 33329338583033669523
mama $3 8: 8: 8: 82 8: 8: 8: B: M62 m2 E:
mmmam< $32 832 8&2 $32 $32 332 $32 822 322 $22 HEHEEEEEEE 232 332
0323.435?m5u+0+2<3+<u5£u£u 053855233555 OSZNGNSSEEUQD£35282 032303220323803£33282 game/$2:JMSNSUBEEEBE wmdwngSSmSEDUEJEEESUU oSSWZEom:29325695£3036 omdsmzflozus36325895£39636 553mg?353325532335 35:6£<UGUF<=SHE<SU532355 omduy.:mu,<mm£:39323695£396 oSUUSMEEG95329336959596 $22535mmmzsusuéusmusxoa<3< o3369.932933295£35323: 025.595?floNSSEJZEUWSm5 3:302:5sz9555:2595m5 omdofifibsmNEE/555$:£3532 656£33953:£3532 omdumGNUUJE/EGZS35323695 omdumfiNUUSEEGZS3632595 032953535«252335£36 032953306anfiozéaws£85 8:06me80534363:£03296 fioszamzzbm3363395 $32956”SUEE<EH<JSMSm5 3535662529532359:m5 o36.5NUMMEUUSGENG£33632
E Be m8 03 HS NS m8 So 30 08 20 0% no NS me «S £0 0N0 Re mmm cm. E Nmo
mmmfim 353 83m Ema N33 933 3.3m mama mama 33m mama aaaEEEEaa EH2.3m 3on
wwmao $30 830 Ema N38 $30 <38 mama mama 329 Mama mmmao oomao H88 N88 83o «88 88o woman woman womao mooao OHOHQ HHoHD NHoHD 230 330
117
WO 2013075035 PCT/U82012/065691
giggingpagowssmsysu $528£3038$535555: .538$638336: 3$823855mmmSUUGSUSUSm 3282885sbmfiaxumsuusysm m8mmZ:Uazuzmmzuyésuosoaoa mauguéeueagmmsoao89696: 82:53:sbflomabflausgmusa £5335EUEomfiomSuaSmSa §<§ue§<flo=§o29569635m $226eBEMGBUB9683695m $58+3eueomussmusuusuésfls3&3 $585eufiéwssmsggms3&3 swamaagmfiaoumau965535m53 38352352836363mg:m5: 3.525£93§85£9§53295: 35mzbfiofiseuwsxaaams
3295: am5329628583636559595: 35325385:03036:$595: figmeomusubmSu8593523535m 35253883885MBsmesaam ogig€855.35ng3:963 omzmméeueoeu8303:93:30: 39335385ng325595»? mammmSeumSuSSmS9&335$:m 5333955536;: mammaueosbsbsmqrs95335;:
5gy5§<m5m5303< omimzmzummzubioNEE/$53: omd<m2m2§om25§oNEMZESMS 038.2030SfioauUSmEmGe:aw omdueoegfiuwo86593968336 omd<£<m2m863<§u963323: omd§<fl<§§ofl<§o35323: 632.3%mMEUHE/‘UUSH/Eofl: 8353936mu,um¥ou,<u,u£:fl<mu,om5 was£<UUF<M§<UU6§<UUEo93m: 8::$5.3Efiéxouéuayoaoyam: 0amaoagofimbxsméflo 85329025muémuouéuémuousgflo ©2295
£5mmEmZUEM/Euaomz 032$:£<§<m+<m+<§om+§u96m2 om¢<£<2<896m§<bm5muo§m+< omd<£<2<2696m§<uom5muo§m2 omd<£<m5mmx<mv,<u,ou,<uu,omu,<uu,u=+o o332$2$§<w<§<5fl<596 ofltfigéEEPEGNUWGNUUS OSUNZNZSZNU32303030385 ©2292ng£§<§<H<UGH<UU 25£§<§<$§ofl§u 035Eu£<$EEUEUFEEUWGNU 033m8£<§<a<m§$o£96968 oflsefizmme:£53335? 3453522295$823325?
mmo qmo mmo 0mm mmo mmo :6 as £5 as :5 £5 0mm So Nmo $0 «we mmo omm Bo mmo mmo
aaaE EE EEE a gE aaEaaEEEaE
mfioao cacao NHOHQ wfioao mHoHD ONoHD HNoHD NNoHD mmoao «Noam mNmHo onHo thHo wNoHQ mNoHQ omOHQ HMOHQ NMOHQ mmoao wmoao mmoao omoao nmoao wmoao mmofio Odofio HQoHD
118
WO 2013075035 PCTmS2012/065691
maaabmusesgm:EESSSWSNEW mxamUUMSUSUSm:323::$593M 3836:Engaaozfiom 3885530303 UmbmmuSuSuSmS: fiammszzesesm:
Enigmefiam umuOmEDUSUSmS:$53295£35m $535M:
Ewan Emacsbeoeamszs29533095 :$9596:Eoflfi $580,353???EDMSEEWENUN WmSBSUSWSEEsasmSmmmeUm 3&353635953963225525 3838369533:JEoE<NWMF<U+<U 85853332353smusmzuéuémbmb: 8585333235:aflsmzmmmbgs 3839695anessmaamuégfifis3 383533395smegommxfiss $393853? UmSmmusengSm:£38535: 363595:539.EomZUZySEB 3635£33530:253385350 533235333:2330263338 magma/EDEDWS$303833? 35353:awefimwfisga386m 3535a:Eo3<mmm2£<§35ubm 32mgDEDWSNZMMNUNUSSE86: 3:35ezmsmzmmmbmbg285: 323%SUFEUFEPSUUWSW
tmm£<gv,<v,<+uaomu,omu,um+m 038:5 ©9895
£8$<£<3$<Usoeoeumué 3%Efiafifizflfixao 8:853:82£<£2$§<3<H§w @3553:8£<£<§<£$£w5 3:883:25mu,<mu,<§<mb£om5mb 35385smuu,<mu,<u,<u,3mu,<y,<fl<m+< oodosbeasuéfigéus£52332 $35930:apogsééafiueoflo 840,339,895EUNUF<UF<UF<E<§G£0£0 @3636SUEZUZEENS£52m: 995£53323:£52m: 333333835muouauémuéafibflo 0333338535abuauégafibflo 022963638532529395£52 022529285E<UGUF<£<£3£§< om¢<£<m3m8§§<b£<£<E<mb omd<£<3205522<b£3338 omdwgaogmaoxavszyamuafi:m2 omdofi<£o§o5x22§<fl<33m2 om¢w$<£<msm55553%?ng o353330533555ragga: omdufiogmmegubws3329395 omdumfioefifiozoegasEEENENS maggomzmmmsgbba:yoga: oodfiomzzzflsflayo95303$: 038.20g39629285352m:
m3 mom $0 mom 0% Em NR. me E who 0% Re who mum owe mm. «mo mmo owe
E E aa agEEEEEaEEa aEEa
Nwoao m¢oao «wean mvoao ofiofio NQoHD onHD onHD omofio Hmoao Nmmao mmmao «moan mmofio omofio Amman meHQ mmoao OOOHQ HOOHQ NOOHQ mooao vooao mooao woman woman woman
119
WO 2013075035 PCTmS2012/065691
$0535353252355:869% 3m52:5338.430momUEDSUuuGEOm 3535MB32583338532 353532322085328%ng 35363230320853589532 55E:£32883329969632 5525£92682:E8332 35325962335565532 3532535283552532 2532328535y655£<£<m 25323288:gasosmgfiam 32355265JBUHEEEEQ 323536295:38252230: $392552:38535223222 322632635385352335m Mammy/$55358$:m222fio32m $6222653583332£32m $25963552222229:2m $6285355222223:yam $23283355m:922253232 a
2
b
2 5
5
b
5 5
U
2mmmmzsosm.wm
2
2 265
2 2
E G $8283538532232?£230: 82853559:?EEGSZNGMSM 328953553323230:mmeSm SUSS3553mm2233223032 $635386322233$9632
2: om: 2m: N22 g $2 a: mm: 2: 32 mm: som:m~mm:mmmm: ImMJOOMH 82 82 82 82 82
$22 onofim< :22 N22 222 $22 $22 222 222 $22 222 $22 822 $22 $22 $22 322 222
2252928532°22 0359280?NEEEOSUUEDmquucq o35929662323:onBU95£22 245.5.5232$036385=22 6633996283=22 2::382022325533595mt 2::3325632EEEDWSUU95NU 2::35.5832225552:=2 §<UMB22535385=2 25:5EBnaugzzgflsxuas 25:535620592229:@3835 2:553:89696235636385 2:353296mbmuéufiéflosuésbxs 2459095:82552335935 2::NU£295020552293935 0253295:seugfifigfloaosb 5522855325355 25:53:ESEUGMEEMSWS 23:5«USS352669335? 2:85:28snaggflogflog 25
5o: 032
b
255 S
5s: S938::
626 :62
E G
2 2
EMmmz 2ummm
G 3 2208:5253:33620532325 25385:BSEQPGNUWBEEQ 253855205355689325 $3592535295522222 245925555222325922
$0 g $0 EE N8 mg mag So man con 22 N2 m2 «on m2 OE mom lmom a2 EEEE
32m ongm 22m N38 22m Ea a aa gmm2m «m2m 22m 22m $2m 22m mm2m 82m 82m 32m 22m 32m 22m
$29 onwao :20 N20 22o dhmao mhmao ohmao human whoao mhmao owmao Hmmao NwOHQ mw2o $2o 22o 22o $29 22o $20 829 320 32o $20 320 220
120
WO 2013075035 PCTmS2012/065691
EsmesubmsmzmEwessomSmZm omSSSUUEDmZNEugmmmusmvém fiamgbeeegfimfl:afigoaogm zmsmgueoegfimfisgmmeomzm 3fl385$3mw<£<mm3<£905m¥<fl<3 3m389%sz£<mm3<£om§<£<= absuégeggm:gmfiéoefiss 56§o3o£<£<m=gflosmgflss UmbmmusméflgoaQEMSEZNZJSW Umbmmusmzmzfié:Eoflsmmgasm 35memu,<£<mu.:mmmu,o=u,o+<u,<mu,396m Emmawmzfiaflsmmmuéaommasaom Maggi/EuE<mmmu5m+<+<+<95m2m wasmm¥<£<£oa<mmm5m+<mmagma EoEEESflammeogESEwart =m§£<£<m5£<mm36£<§963$ m$<m£<£oE<m*wm:m+<mv,<+3¥3mu,<m+ua mafia?£o£<£om§<£<=393% $2535£<3o=m£<£2203§3m 32223223033$:smefiSm $28532«593%£<32$<mba<m $2me3<£um5mm£<33mmmb32m 32$:
$£339$§3gm 82$:gmfioeommflagmmx:8% SESZMGWSWZN$3326E<£<m mawmzzfloflfizm$59€82<£<m magma/‘muéemumzm:aomébusgmzm
3.2
322
om405300mv0u:JW<U*D+D+D:+0mw0m*Om*< 035303000532055530 0353592835 035
35830535 083533053530 wz3*0wqc0UwD:+<¢0+D3033+0m*0M+0 omgw<mwzsw5umo;0:+3;<;0:+33+3u;<u*0 omd<m5=5w0+<£0 om.=0
$455 $353093: $353535 omd<m5 0353,43:
so 3 035303.455
m”Gun,3“.FD“.F<U“.F3 om4+0mw<=*3+3+0m¥0u*3*3*<u+33*D:+0m+0 om4w5u*<m+333u+<u*0+3+3m+03*33*3u+< om4*Du*<m*3+303u+<u*0*3*3m*0:+33*3u+< 3+0 3+0 E02235 0353035002me
£055 80“.
55 3+0vF<uF0u5 35+0+<u+0 su£<355+0 $359325
£09633 35938693 35938093 :5 :5
£030 EE<+03535£<£0 30 3“.395
£0 233530 305532233530 om4%ws*DU+<m33+Du+<+0+0:*3m*03*33+3 wnu*<+<+33+Du*<+0+03*3m*03+33*3 om40<m053+0mm:*33+0+<+0u+33*<u+33+3 om405mwwswbumm*33+D+0+<u*0:*3m+03*3 :5 m”F035 Hm”603.3035an om4+330<m*50500mw<3$5w5$0m+0u$33$<u+3 05mw0::u$<mw5w5w3u$<u*0s*3m*0 om4033*:mwowawauw<mw5+swsu+<UW0:03m+0 wmngswzsw<MJ:w0m*<*D*D:¥0m+0u*Ds+< 0353:3265augususaufiuysg 35838035
0N5 HNN NNN me «Nu me emu 5N5 wNw me Omw Hmw wa mmw wmn mmn emu hmn wmw amp 0.:
cacao nmoao waoao mmoao OONHD HONHD NONHD monao VONHD monao woman woman wonao mONHQ OHNHQ Hanan NHNHQ MHNHQ wfimao mHmHQ OHNHQ NHNHQ wHNHQ mHhHD ONNHD HNNHD NNNHD
121
WO 2013075035 PCTmS2012/065691
meammuamfiemvgm:Eo£<8m+<£<m 3m+<mm+0m95m$<£<s3m$<£82<m+<fl<m §<§em5m2£<ssmzmbsmmzmzm mmzfiogogezsm£§2$<£<£<s $339633:3343523%;: mawmmusngeoymmbzfifiégmusa mmuémmszgsSmN962%$295a mammewgfloemummys93229395: mwémsuéfifisaomfi:£293953 masmmémzeamzsafifisafisasm $5mmuzgesmuésszmzm$535m 3532952.035:muémuéuéuaasszm 3532333535:£<£<§53<~ mafiagagflusmmu,<mu,<+<u,:=u,3mu,<m esfl<£u=mmuamuamgusmzm $235awe/USmmmvamvéuéssuaflom SEEDEofiESmma<£<33<£om mmzmafizgefi$23355£<m5m SESSMENUEE2:35a329% $536£§3£<mEESSZNEWGN <053<m§<333$5me figmmzmbszmzmfi:32$<m6m2m 3eammzmbszefimgg:23%;} £<£<m333226393? sawmflfisgflfime:aimmuémzs mafimbzzgefisEsgfifigfism “9,5903%?ngEQUEWWWZNSN
mm: «mmfi mm: am: 5:
222 ¢N5Hm< mg? $22 R52 EEEaEaEaEaEafigEEEEfigEEfigfig
025:53525332253502535 omdDEDED:mm538$<3330m505 035=535523:522355505 0323535:303202333356 333535555328;52:025 wod<m5=5 @3333stst 0323.435:
3: 3 omd<fl<=555
333220 3339,96 ED ED omdme<m95u5u53u5
9&3: 9&3:
PEUGSEU
36 EU
$0 96 UzmSEDu: 305593953593 wan—33455:JEDE<+OUFDEUE<EDEU $333396 wan—33.4365:35352535839535 mod:3233395333525P5939535 omdUP—Dmgcqm:EDEDSEHDEUmEED 35359225DEEDSZHEUNEED 8595:2235EDSSNEJSUZNS 026953222353955963323: mmm533553<m553< 3553:223335553295:me $25885:2235553596382 om:3285523329535£03502 @3555;£<£235333<m55 035.5555EEDSSJSPEMBEU 8335583<£<§53535£w95 55323/55535959635 0353:5895£35353:32$: 03333389635£25333???
2: E a: 3: E 0E :K mi 9R own Hm“ mm“ mmn $5 mmn om“ B“ ME mm“ 9: mmK E“ m3 9K R:
mNDm #NDHm £5 £5 35 EEEEEEEEEEEEEaaEaEaEEEEE
mafia wmnfio mmho 0E0 Rho thHD mNhHD OmnHD HMNHD NMNHD mmnao «mnao mmnao omhfio REG meo mmDo oES HES NEE mES SEQ mES 2R8 5R8 MES 950
122
WO 2013075035 PCTmS2012/065691
33.235 3
35332 own—333234334333 33233232 3323323235 332332353233.on 3335 3 3
33285 85 3323 332332 3323.33, 332333, 3 35
35 3353
3 3 3.335
32 332332 3323335 332335 33353335 323.3535 33233532
32 35332323235 32 332323235 323235 3S
35 323235 3535 35 3323,3235 3S 35
3Z3 3232323 3S 35 35 323533 323535 323535 32353233 323632 353323535323 3323535323 3323303235
3 3 3 3 323
3
3
3 3S 3 35 323233
m 3
3 3 3 3 3
3 33236333323233
323855 32366235 3 mwOm$0w<+<E<muG 3 3233336 323335 323332 323332 3: 3233633 33 3
32353332 323633 36336
35 3U
35 33E 36
3S 3U 336336
3 3363225 3 33335238 323 3 323 3
3 3228 323633323233 32362535 32 32323332 3555 3323633
3E 3S 3632,3335 336335035 3U 33336 3336
3:3 323 323 323 33333336 32323 32323 3363 3363 352232353 332353 33635 33635 32336 36333235 33235623633 336335 3S 3S 35
m 3 3 3 328235323 3336323 323 323 3363 353 3 3 3 3 3 3 3
om4w333<3wbuuu$b33<+<+<3+3333333m3w om4+333<333$030033sy<$<3<3333333+3m+0 035:5me38533223333353: ngEDEQDU£UEE<EEDEDEDE< 34593345:uUuSBEmEEDEDED wm4+3mwzsw<waDUWUUWDWD+<m+<3+D3*D:*D wm4*03*03w3m33+UUWUWDWDm*<m*DJ*DJ*D om4+u:*0333w<+3JWUUWU+D+Dm3<m333333+3 om4¥uU*Dm*D:mJWDUWU+03333<m+<3+DJ+D om4+Uu~Dm*D+D+<:+Du*U*U*D3+<m+<3+33*: $358030:
3 3436803055
E: E:
3363636 3363636
:35 :35
"3339533 "3339533 omeDU¥UU*Dm:3+<3+D*U*UU*D3+<m+<3+3 %Uu*D+O*D3+<3+3+U+Uu*333<m3<3+3 ©2:SU£E%ED£QDU£UED£<£D fiotzoaD£3t¢u£u€3£<£3 omAwostU+UUJM+D3+<*D*DU*UU+D33<m3< om4+0333quwU+DM+D3+<+D+DU*UU*D33<m+< omAwUU%D:wUuu:+03+D+<+D3+Uu*0333m*< om4+ouw3:waUVU:*0:+D+<+D3+0030333m+< om4$<9303$DUUU$Dm33333<3330+Uu+33+< om4+<oyu:wau$UUWDm$3$3w<smau$0u*33+< $UowDJUUwUJ$0$Dw3m$D:*Uu*UJFD omA$<meowaDw0u$usww+333mWDJWUu*U:*D mafia—£405::uUfiEQDPEEDuUuS om4+<m¥<u*uw3w3u*0u+3+o+33+<3+DU*UU+D omgw<mw<mw0uJJWUUWU+D+OJ*Dm33330u+u
won 333 OR 3.33 3R mR 35 Rn ME 3R own an an $3 in mmn own an 3.33 83 NE 3.3 33
aaE EEEEEEEEEEHEEEE aE aEE
ommao Hmnao Nmnao mmnao fimhfio mmhfio omhfio hthD wmhao mmhao OwNHo Hanan Nohao mohfio «ohfio woman ochfio momao woman momao ONNHQ HNNHQ NNNHQ mnnao QNNHD mhhfio ohhfio
123
WO 2013075035 PCTmS2012/065691
mm+<mm6m2m5£<uaway/EMS=5: “5&5e<3<mbm§os<§oa5353 mawmm6£<e<5mmm63&3:95: §<mmm2£o§a33:3: $9ng£32355»:9595: my,em£<3<£u£omm£§o§59595: mam323283039330:39595: $235£§<flomm£om5u§59595: $235£§<flom§om5§9595: $232yo309%@022953538 823253030$395:3538 magazuzwomfimmfls95559596: $5mm+<£<$o$<mmmu533=39596: =m+<mm+u£wwo~u.<mmes95559583 flogmmas3539523 uégfiwmses35559696: mm+<§<m53<£o¥
353539696: mmbmeomafifios353555285: mmUEomeZmG:3233533523: fifimeEmeSg:SJSSUEUJSN é<§wfl<£om53353:8963? mm+emm5£<3o33:SSJSUSUSJEM fiefioefioeasJEDEBBSJZM meommEEoisSs335383530: 335:3558:5393 mawmmémaeaeaz3595633393: mawmmzmuéeaeas328333293:
om5+<m%<mwuvuw53w0u+0+5+03+5m*5:+uU+u 03%qu £< omdo 3.76 omdw 035
3.4 wad/BE mode £0 egg—<30 mad: 098 mod/~05 @3230
£< @3295 30 E<
~28 0323.433qu wmd<£<£<8£538803035£530 omi<£<£<w<5u5 wmd<£<£<m om._u_<mu,<£<m omd<fl<$<m 333.4 ~22? £0 £<m$<m 30 £3
m+<m m+<m m £<m
mob £<w$<u+u wmgw<mw<mw<mmmWUUWDWD+Uu+UJ+OJ+5n+5 gi<£<£$<§£0£255803035£5 m m m £<+<+< m omd<mw<3<+<+< m 352303022 m £<9<t3< mm 035323930 omd<wb£<mm 3225
35889535 35805535 $396+ 9396+ m? m2 m? m2 mucq m+< mch m2 m? a? m? m3 mm; 02m; ED ED
396630 95559595 95568595 £965 £965
5588595 5588595
$542.4 m???
39696 39696 935535968595 935535968595 m+<uF<uGu5 m+<uF<uGu5 a??? 9&2? 9322 a??? 93:; F322
m? FE m2 m?
3< 3+< :5 3532803959685 39696 39696 m+<+<+<u+uP5uUuu5 $005 9605 €un 9296
£085
P586 39596 m5 8085
PO 39335 39335 E< E< 3035 3035 30 30 3686 3605 39596 3596 36 36 928635 928635
mmn 03 an 08 8m Now mow 8w mom mom Sm wow mom 0% Sm Nam mam Sm mg Sm Em 0%
EEa EaEEEEaEEaEaEEEaaE g
Amman wnnao annao Ownao Hwhfio Nwhfio mwhfio Qwhfio mwhao wwhao hwnao wwnao mmhao omhfio Hanan thfio mmhfio wmmao mmmHQ ommao mmNHQ wanao monao OOwHD Howfio NowHD mowHD
124
WO 2013075035 PCTmS2012/065691
$330633353333363695959695: $335333ng3336363330333 mm3mm53535353358353me:5: mm3mm§3333333358333333: aflommS3535353363335353:m mflomm33+335333:695mmEDEDm mflmeD3533350353355P533m mflmeD3535:539533m3+333m MW9.5395353536333963953:93m mflDmED9533:639596::3393m 3953535359593339555:393m 3953535359533395::3393m 395353336363396959559393: :muFDmEDEDP—UEUJJ 39535359595:mW+DEP539395m 395mg:359583:mMQFDEDJm9395m 3953536:635mm3535339330: 395mg:96:63:mMEDEDmmm3EO: 39535959533? 36363:
£035:
3 3963963330333:
9635339393: 3535839533m3353339595: 35363635303333333330353 3536363530:3333333033: 35858333933::3m3353333u 3585833393::33m3m3m535u m5mu5: 33335595
96: 9393:?”536: 9333:mm3£29535u53
$2
3:2
023 o33330533333333 @9333 0339396“. mod: wad: 3453333833 3.7533 @3535 @3535 mad: @3535 @3335
3383 93 £33365 @3335 @36me @23me
m6: 93m P533m 3333 35 3533 man—695:5 0238335 95 woe—093mb wmd<m3m3u
m
3 3 3 0333303:
m
m :3 340: $33633 933395 033363355 023833555 3 3 355 m: omem3£U3S m
mm33333 m m 3 m
$0 333353 339353 85 96 363335 363335 93 93 :3 333336 33 33 3: 33 :5
9633 $033 3035 3035 93+ 93+ £365 9365 9336 3333 P533
93 93 93 93 93 93 93 93 03m3 03m3 96 96 93965396 365396 :3 933305 933395 333396 96
93 93 93 93 93 93 93 93 93 93 93u+3u33mu3mu3 33mu3mu3
939393 93 96 96 96 3396 mmd<£093mu9539533336 :3 9395
93 93 93 93 93 93 93 93 93 93mu3mu3 93mu3mu3 96 96 93m3m3 939393 3396
9695 9685 9396 9396 £6
96 96 93 93 93 93 93 93 93 9393 9393 93 93 93 93 95 95 9333 omd<mw<£<§<95JSUF<UF<£<US£<M< 3396
mg mmm «mm mmm Rm mg mNm 0mm Hmw wa mmw «mm mmw omw Rm wmm mmm 0% 2% 9% gm mg 9% 5% Mam
agaE gaEEEEEEEaEEaEa aEEgga
wowao mowHQ oOwHQ nowao wowfio mowfio OHwHD HHwHD NHwHD mawao «Hwfio meHo meHo hHmHQ wHwHQ meHQ ONwHQ HNwHQ NNwHQ mmwao #NWHQ meHQ omwao thHD wNwHD meHD omeD
125
WO 2013075035 PCTmS2012/065691
3535335:53m£<§5m35y53 35353o35352330553033m 3835@6353:mm£<3o§3u35m 8532MB353%EamSSSUSJEM 8532333534;3:is852% 353535eagmmzossufioaa96: ne/5963589596: 3:395353%???2995:2is 3gmisSsszmsmS35%3&5a $53595£<£<=m9529559695: $635Eageémassuos$595: $535gazes»:285529538 $535ENENSMJEBS$9533 3535
£<£<2o§539353538 35353???383%?538 353233333:853<§3355= 35mi<£<m5m5385333355: §DE<£<2033823$955385: aSE<£<Eo=S§S963385: a$<§<m5msssu329955535m §<m£<£3333833&5353% 3232393538:EosaSbuSszm 355:Eogaagnefi 223533385:$332522?” 3235333853333583533 £23535535mg:aubusagom 8:352:53:NMEDEUUJE<EFom
$2
5:2
@225£35333,3”,2<£<£ue,<mué omdzgmzmszaaas£<£§3£< 035«Zyéfifizgaaa~23??? QSUEEommmUmSSSEggs: 333220228£2953293832 mmmzagsus3593355 93:65 waggafigggssEnigma 02253336mu,<m¥uu,<u,:=u,33u,<m¥<mu,u 032355www<£<§<=533£<£< o$<£§2<UF<MF<£823535gm: 025928:Ewafisopsasgg madmfizguégo£2895353$: mu,<mu,<u,<u,§<3535£< omdomZmEUSmuamuauauéegsasg mad/$59382<NUGUF<UF<NUNS95:2 $2233353239393969535:2 om¢<£w9<m§5£§<§x<3333 84255355£§<§e<3535 mad:«Emawagessémvambmuse: 035«REE/«2303225£96333: $353230?£§2$<9<£§<33 0353<£o§<£§2$<$<£§<35 @3835£<mm£<£uu52£o£83: 938:5
£<SS9593932: £39m£<p§§££m£<§£a wagging/«£58:9359,52 3:85efifiomuégbs£32930:
mg 0% «mm mmm omm Rm wmw mmw 8m 2% New mow Sm mom mom Sm mom mom 03 mum Em mum
aa gEaaaEaaEEEEaaaaE EaE
Hmwao waHQ mmwao Qmwao mmwfio wmwfio hmwfio wmeD mmwao o¢wfio Hewao Nwwao mwwao ¢¢mfio mfiwfio ofiwfio wwwfio wwwao mwwao omwao Hmwfio waHQ mmwao fimwao mmeD wmwfio hmeD
126
WO 2013075035 PCTmS2012/065691
35$:335:2?35382223? “$333505zigzag:NEE/é 36353035393385523038 353553530338532638 $333533:3883:2235: um+3mzuFDu333333353539396: 3953963953033385333595953 395306333033:uuBP3mMm5u5: 39585 353333
3039333835 395805333333895mu3MmEUED: 39635963538:E<m+0+<u5u533u 39635£09538::u3flwm3533u EDuU:
3 um+3m3+<m535ubss
935330
35
3 939355333an mu3mu3JUJSEUm 553535355:253993332: 3535:5285:gagging? 355:525555332 swampsesutesmmmZeugsuomSm 35mg3385E<mmm5§55£<3<m U£D=W<mmm505=§<3<m $535°83:«$332203:96m $335535gmmsbsaafiayam 353805323090533523235 3536053230EUSEBNEEUFE 358635$<9<BJSEU+<S£0960 3536EDEEEEEDEUS£0960 368533338:358593528
$2 $2 03H :2 N5 figEaEaEaEaEaEaEaEaEE $2 $2 3E
Mama? 3&2 8&2 8&2 mama/3 $32 $32 «$53
©9253:mmwofls/‘Uefiomzmb 03238352230eésuagogmb 036.285:263/3223??ng o30.28552aofifisfiSSEER 53£<HoUF<UF<NUJUF<mG£< bssmu,<mu,ou,<u,<mu,ua<£omu,< @3253?:EEPGUFEEDyam: 3353295323052335yam: 342332895£<§6£<£ua<£o omgmzmfiéoss£<§6£<mba<£o omdofigomfis932593355m2 853302595322559395m2 QSSMEEEN532$<Mofi<£ua< om:agesozsbaagéflo£532 02:35flammflBSSEEoMEES 02233330NSUSSEEomZmZUS omdsfisgmmgegazgrog/Fa 025«532253655Egg/Fa omdoEEGNEomSUS3233393 OSUEEGEENG£995image/3 ©3595«SWQZWESUED985$ ©3595£3§<£§<§u953&5“: omdosbeém£52303323%? 8553236£<£E<SUS3&3wa $36985msnguéuéeuasmzmfi 5»?£59,363:NEWS $36995:36$§£5£353<96
Em Rm E 2m a Nmm mmm «mm ma omw am wmw mmw 0% 8w Nam mmm «mm mmm mam am gfi mam 8m mom
mmmfim mmmfim 038 :58 #53 gEEEaaaaaEEaaEaa EHggg
Mama $80 880 $80 News mowao dmwao mowHD woman woman wmwao mmwao onwao thfio NR8 mafia «$8 mafia 0&8 Rwa MEWS $89 owwS Swan NwwS mwwS «$8
127
WO 2013075035 PCTmS2012/065691
3835:2338:28233560 85353<3<3§3303:2596me 05353&253533$35M 353230.285:82330255: 853230338:snow<3<mmuu6uu63 3:3255353539626533 32332535:UEDNBSUUWSU 3$35£853833339855: 5Enumafifiuxosbs §<§<eu§=b§flombuobmSuS3 mmémmzeuesaugflogsmusuus3 363505352?mmzuuobuéauysm 36350533?mmzuuoumauasm $553253:mumbubfiusysaou $353553:$553538 9.333=58<E<WSUUGSUasmbm $335232<2<m§§o8959% 3835eoflseomUyOWSED336m 38353082685338202% 8.5SSUEEEESG282%me 853592329505Eu39%;: 352633«558385565£8 3msmzbezemumgufiag@638 guana5328338 3.3823<3<5Um5353528 atmysmuégaum§32996955: 55E:sogaumaus283:5:
HNON
:22
0263985230932595053296 omdumeSSeamzzuzmvzaueamz om¢§om555fingzzmzauesg 0323090:82302230385=2 o3220993832362230£33=2 omdogmfimasNEPENEMEEUJS 353999359,293935535 ommaua<§o$309505 84236655auassuégaomsus mad/EBgummy,8525593530 $22.5«SEEM,BEESMENZWEEU oflbefiéummfi395235£3095 oEUmuzmuébuémuéauuégo£9695 aoSMoMSUSNEH/Fag omdogfiésuw0929533939393 gmmaoflgsuoazaogfio o3633302053956E<ao£<£o 0259502mmaufloGSUS£35m: 02528225NUWGGSUS955m: 022:thmmwfivévévéeusuaeég omd<eum§$<$§$2o5:23am: 03538503036693595m: 85383523056638595m? omdomzeumugmzbfimfiaugao wmdomzeuGUNEMUEUEMGEUEEG wad/EmEoumgeggmuémsg:m5 magma£29,BEEoEUWGWSUSm5
mom moo. mom 03 So NE mg So ma go Do mam 2m 0% mm mg mmm «No. ma omm Rm mNm mmm
a a a aaaaaEaaEEaaaaaEaEEE
mwwao owwao nwwao wwwao mwwfio omwfio Hmwfio waHD mmwao dmwfio woman woman woman wmmfio mmwfio oomfio Homfio Nomao momao womao mOmHQ oomao nomao womao momfio OHmHD HHmHD
128
WO 2013075035 012/065691
Umuamafizubemva:SWUQFPEJUUSU 823235805sueambmm3850 figmewmbeumsg38625596: 35358538:305355: 333958205:$835633? 33353865:$633858? 8536538533320655: 806355985336958965: $28068osbesmfiéaubusU595m $28655333338852:m ,85acummBUUSUJUE/‘m m58063323360335853$ 0885guesmuommauxsbusa:gm U585euasmbmmauysuaS96m 08mm”,BS236may,u=u,uu,3u,u=u,<mu,o= Umomflauseméo35968335: 8538333053850565NEWS: 3626EDWUWEBUSUSSNEWS: $535Eoeomsseuaéazwoa:3 we:3520533855:amass: 3fiSSMUmZEUU8505259535m 3mbméambmzsngaea$3332 3535303888533063:32m 853530385853239532m iambmzeueagxaNGUGBEDNEN sasmmucgsbeouausflowing/é 3585£88.58Emfiuésszmzm
omdoewmzamb3395539832 853%25830£<§§om¥oeu3< 09%sz95022633333 o3&2902550226530M583 8:030£0?JUMUUF<UF<MUF<UGWBEU 035.5£9Q<EUMUUF<EH<UGMwas oSEE/$2»?BEUENENagy: fl<§oEBEUENE59%: wasflogmmmuésuouébpémuayémué 8::3o393653996£33596 oatszgmauéEDUGUENGEUMG egosuamuEGEmGEQUEUENGEUMG 3:85 035:5
m5mmflofl<58m8m+<m+<aw 8:85£935EomZSUMUfl/EEG omd<9963<mmmuamuééSsoxEoNU o3&59,3623%”,9<5y6£<£oNU amaoflwué/Eumuomu,<fl< 02252230mv,om§6u,<aumuo£<mu,< oats/tbsmmvamvavéoysxofiao omd<£§82<9<fl<§o95050296 095338:goggsomzsbmbg 03533065£o£9$om23umb£< 8::3<£<83<9$9<m69552< 0353%?qu2&2623933592 805NUGUF<BNG$<EUWU £2605egséfiogaumb 938:532mSuoa<§<fl<flom52o
03 mmo mmm omm “mm wmm mmm So Sm 2% mg Sm ma 03 mmm «mm mmm omm
a E EaEEa aEE a EE a EEEE
NHmHQ mamao «Hmfio mHmHQ ofimfio hHmHD meHD mHmHD ONmHo HNmHD NNmHD mNmHo «Noam mNmHQ ommfio Amman wNmHQ mNmHQ ommHQ Hmmao Nmmfio mmmao Qmmao mmmao ommfio hmmfio wmmHD
129
WO 2013075035 PCTmS2012/065691
3636ensueuae/Eog333$ mfimmzauezezgflomSSSmZeom Mmbmmzeueaeausaomngzaom 8535555:mwoeaafifias umwOmmM—DquEUEU: auomysuusuSflom: EQUSUSNGMSE sesggm:
meOED
3
mmucqmtws mafigusseoxommwa95223032 3:$3335mmmfiflsm masmfisbsbgmwe:afifififiafi $586stating:E<mmfloa<m EDEEGWSNEU 3680,3330»:asmzmmflsflfi gnomeugefiég33<NUF<UGUGE<£UN Umbmgbeuefiés33<£<mma<mu6m £<p§65£§<m “$335235?Egaomsfifizm =5363§o233mgwéuszmbaom 3836:2395:mmzwosmmbaom 89535£0333:mmaomvésfiuamuém 3535£3335mmm+om5mmu+<m+<m esE<m§oes<baoa<u 3532m5333<m~303<8£o£<u fiamewgszefimfla£<§<m2mbm Deacomsssfifimw:£<U§<£um 33<£<mm3<£8<6£55: 339953<£<mm3<muomm£<y6= £52628is $995eagfiom:£833,093:
028:532225es§<w<flomu55 038053:£332<u6£o£omuF<eu 8:85352250526£3335 03253::E§u§<3§§om5 m325322<£<u§2<$<$<m5m5 035.285ssmémbuousmuéfiofiog 3:353:55FENUUQDEGEGNGQ 3E<£<UUE<H<H<MG 84536555E<£<§ua<fl<fl<m5 85358395NEEUUSNGNGNG 8535999595NEEUUSNGNGNG 3835E<UF<UF<UUE<H<M< 02595359635E<UF<UF<UUE<H<M< 02696958y532<2§y§3o£o 0363529360535223859696 0259533=88322<£<53<M< 02595335253293935335 025520:fioyésusgmbxsao 02553055£§295£<5§£o omdosssamgefibss3293532 03838555356553233632 03833383333653229605 0389:5563:563322595 032303839:3<§5353<£<5 0325:5553:agobssszfifib 0325938202239595935 33592969695282:959396
Rm 39. Nam mom mom $5 mom 03 Em N3 m3 Em mg Rm Rm m8 0% £6 mmm
E a EE E Ea EEEEEaaa EE EE
mmmao owmfio HQmHQ Nvmao MVQHD edmfio mQQHD onHD hemao wemao memao ommfio Hmmao Nmmfio mmmfio wmmfio mmmfio ommao Amman wmmao mmmfio Oomfio Homao Nomao momfio emmfio woman
130
WO 2013075035 PCTmS2012/065691
3%:ngmfiugofifioeau $635323,430:msusomsuaeau $535£3mem§<m§<bm55m $535«2.209:mm£§<mum32um 3memP—d‘mH—d‘mu—OP—d‘muEOE/$963396: 3m532336328£33355: 3532969:ESNMEEUBS96is 3m5mmzflomSfifimmEEum:96is game/$53<mbmm£§9§5y6953 3230,3558awe/Em:8595: $23595362$96395893350 32mEmmsmuagmfiufls83:38 maimfiegogm8539963596m 82mg3<muo£om§oasumas96m 36%,:£§<fl<8m53905955: $995£§<MEGWSEUWJ $555935»:
95053 £363,392:593m mm,mma<£o£o£<ume§o=saumusm $29,523.48?593555960 maammzuzmzmbm:59538528 32283355:BEEEEUMSWUM 32383355:853583399 $282M:Sums8333280382: me<§<m25m58m533382: $00396£53895EUUGSMGNSm mwomewfl<£o350m23sonata”? asyéaouzszm
025366305955253532m: o35«2055533329353532m: omfimzmbm:auaoSSmbysesg 859458055305338335? omd<£o£<um2§96323633:: o356338339653259532 smusEUUSEJSNUUSED @225»??me5353538335 omgfifiomSBJSUUFDHDE/EUED om¢<£<y,ou,<u,<uu,oasbusmusafiosus $369290?muomSSUaosS£85 omdwgegouémbmuésb3535£85 o28m?£<um£§o§5§m53&5 REHEEUEmuzxoSusxsmSgyo amigomzsmz999596363:yo maggoessomz396559635yo 8830525”EUGEBSWSa: 026533355£853,359:=2 om$633303:963535 o2586522£33303:59695 omdsmbmbmm«205220535053: oa:353802336225950333 oSZEouzum£56283:9696 032300256£<8UFQF<£M5596 o3:”EMUSMZE<653<595§ 935£398<UMUF<NUF<§0£5595:: %maomu,<u,<+umu,<£umu,396
«mm ma £3. R3 96 3m Nam mam mam 3m mam 83 83 83 83 88 88 88 88 moofi
E5EE E EEE a Ea EaEaaaaEE
oomao nomao woman momao Ohmfio Human thfio manD enmfio mhmao ohmao human whmao mhmfio owmfio meHQ Nwmfio mwmao wwmao mwmao owmfio nwmao wwmao mwmao ommfio Hmmfio NmmHD
131
WO 2013075035 PCTmS2012/065691
fiammzmthEum:saxogmuzgm 358295385:38322033933 86325386:36333322: $23533gums:85305232is m$<m£um530m533803003295: $285355358333935£95: $2853863589363£95: $06megownssomaoa<SUP<£335m Stags203338368?$535M 853553:=8»%Ue2<2333<= :sewage:$3532: $52;ng3509633232259595a $535333353§<E<§9595m sasmxoeaeumsmua:93553235 smsmeweseomusmuys£33233 36%,:385200323235£396: 39$:355200323:ngNU: 693mm?£<222<3<Usm fiémaagbmsmbm:geasmefism magmaaxoaoe<gm£3EDESNUJEW 592:Engamsgszm saamgbgmbeammga3<§§3£om 303:$33238330m 3385392323325263235 338539232935$383333 geomflsmbfiagg323265£05m EQMSMUNSNEJ=2<E<u=£o£um
mm:
282
0353239856NZZUWZNUWSPG ©3235~53SUE/«220535635 032:5£356352206339635 032$: ©2595 8:85
ozéfiumzaums @322:33Eogxozzflugflufi3 omd<£<35mambmbuéuéefiaflfia o3<£<32<5mbyQEEfiGefiG 0353,33:36a<UUFomu,<mbmu,<£u 8::£<£3ué<aox<§ogmbmzmb $323293?gawgbflgfiog 83323355NSMQ<UMUF<NUF<05£< 025m59&3a<ao§§o£<mbfl< £5353<399§o£<8m+< 0253292395NUFEPGNUGMENEUG 02632322295musuébmbggyé 0223333amassu,<+3u,ouu,<uu,omu,<mu,u omngmSZZNSE<§ox§ofi<mb 025.52%E<=§<u5mbmbfl<£< 025£o£<§<£<32<5mbMUM/Ea 026335S£<m5§<96£§o£< 038323325£<£22<2o£§o£< 0359530:m3<£<55m5mbeumz £o§<3<£<35£3965? 036.5:sz£3£<UF<SE<963<UG 3553265NSNUF<UF<SE<E§<UG 35985mma<a<§<aspsmbfiu 359852632322235Esmbmb
HHOH NHOH mHoH «HOH mHoH oHoH “HOH wHoH mHoH ONOH HNOH NNOH mNoH «NOH mNoH oNoH KNOH wNoH mNoH omoH Hmofi Nmofi mmofi dmOH mmoH
mmmHQ #mmfio mamao ommao hmmfio woman woman OOOND HOOND NOOND mooNo «OONQ mooNo oOONQ NOONQ wooNo mOONQ OHONQ HHONQ NHONQ MHONQ «HONQ mHONQ QHOND NHOND wHoND mHoND
132
WO 2013075035 012/065691
EmmEouzefisg$585255: 853592333333333563 «2:5:9205263950 MmsmmbmsgaasmefiSmmmUmSu 358232.233:mamUJZGUF<yFoJUFUW 35823233359 3235:2265 3285
massmsuéaum “8:5£3532:SSNBEUWEUEM M835£3532:SSNBSWSUEW 823295353:82%2555303 323233359582<M<Umaumu6= mmsmyaesszafis9639650532 3532353235:fiombmfiomsm 32E:358:5:mMEUGSUHoEE 5335359530:fiéaoafloafi mumbflagoflsmz: $23532255mmgmusummszs $535m5£3<$y628969€p§3 «Unzmmyéeumma/E:a a$332355«5898555£95: inmatefis£08385?£35: 3535NUEEEWEUWGSEED353 efifimgumwosma:95: 323205smegmsgofiazzgs:3: 323205Eoeuméomw:$9595: mm5mmbgmzeoawo33,353523 $5$9533568303339538 £538”?£55955:
©2255:mysfiaggegofi 032055523:easaysszeoya 035.338:3333233595? 8:089:55aoe<§<£§5£3mb omdumzu‘oaedmsuPsS93953236 03595656323253NENSEEG 03558”anNBSEEEEED 355396393£99€3<£<35m3 33533303253gains: oQEUWEEEUJEGS«US$953: oflsgeosmsuuésé3232933: 8::gunfisomusxafio32:23:: was33535995295959395 3:33.59955552MBegg: REEDNUUEUWSED96:23:? 022:5NUUGEUMSUQD£03232? 022$:23033558ng95m: 022$:E<me+<y§903<fla£393 02233.5GaoagoSUSfloE/E< omd<£<32<bso996505£03232 ©3233:smubw<§o53<m5ms 259486363E:m3 032.2%?saugoZUMSUSmGE $223332:auxgbflsesgg 036.23%3256255:295 omdo£<£$<532562055323: gigging:8655932330
mmofi mmofi owofi HQOH Ndofi mdofi «wofi mfiofi ofiofi “fiofi wfiofi mfiofi omoH Hmofi Nmofi mmofi «mofi mmoH omofi nmofi mmofi mmofi ooofi Hoofi NooH
ONONQ HNONQ NNONQ MNONQ VNOND mNoND oNoND NNOND wNoNo mNoNo OmoNo HmoNo NmoNo mmoNQ «MONO mmoNQ omoNo AMONG wmoNQ mmoNQ O¢ONQ HQONQ NQONQ MVOND QQOND mQOND oQOND
133
WO 2013075035 PCTmS2012/065691
3235ewflumSUmmS£33536: 88m3<E§wsbmm3<£223335m Sb§<$§oeumm3<m53SEBSM Eameoeumsoam:$335555: 033339320?$333520: 333553099WNSEPSSUSMSW 33355590:EDEDJBSWSW SGQUMSUGWS32323563530: 35:63:59:2359583630: ???EDJSUSMSWSN mgsfisbfioefigs953953:m atmmsuuémsng353955963: mmbmmSuGuszssagagmaoszm 8535963233:sesssasmsmzm 3233:DEBSMJWSNEM $58595£35:EUEoSGJEEom mwsauémSfiéSgsubsosme/Eom ambmmuéefiSsSg853295£95 efisea38533?
NEH/U 86$:£3535:UEoEoSZNGNUN 85mg:gesaaaego:Eombm $53233=5enusmSmSzzmzuzs $9323:35358333:$352: $5323535533032265333 was$235355smzoafimflue:a 32E:35385943383633235: 32E:finenesmsfis£<m§<353
omd<m3< @330 330 0330 330 mad: wad: mad:
30 035 30 30 09:0
30 om3<3<3<3 003033 33033 @2533 ©3533 33030 33403030“. om3<3<303
3<3<3<3D 30 30
3<m om3<3<m3<m 30 30 303: 30 0253333 0323030
m om3<3<3<m 3<3<u 3<u 3 3
m a??? mm3<3<mw<w<w< 3032 02 30330 30330 mo 3330 m m m mm mo 3 33 omd<33m5§ 3340339305 30
33 33 3< 3< 3< 3< 3< FE 3< 3< mm; 3<3<+0+<M+< 30 30 30 30 30 30 33
3330 3<3030m3<30 330309330 0 333030 395330933030 3339330933030 3335 3335 33$: 33$: 3<+<+<33 3<+<+<33 3<UF<+< 3<UF<+< 3<+< 3<+0+<3<m+<+<+< 30+<+< 30+<+< m3<3<30+< o35933352023302 30330 30330 30330
309333 3030 3030 3<30m3<30 3<30m3<30 33 33 3< 3< 3< 3< 3< 3< mucq 3< 3<3<UF0UF<MUF< 33330293 30
33 33 33 33 3< 3< 3< 3< 3< 3< 3<
30 30 3030 3030 33 33 33 33 3<
30 3< 3< 30mv533 303333 309.5 309.5 30 30 F< 333093 3030 3030 3<30 3<30 30 30 3< 3< 34:33 3<3D wm43<m3<3303u333m303<30m30m3<m+<m33 33
moofi moofi noofi moofi moofi onoH HNOH Nnofi mnofi «nofi mnofi onofi nnofi wnofi mnofi owofi Hwofi Nmofi mmofi «mofi mmofi omofi hmofi mmofi mwofi
mwoNQ wfioNQ mQONQ OmONQ HmOND NmoND mmoND QmOND mmoNo omoNo hmoNo wmoNo mmoNo ooONQ HooNQ NOONQ mooNQ wooNo mooNQ OOONQ NOONQ wooNQ mOONQ ONOND HNOND NNOND mnoND
134
W 2013:0;75035 PCT/U82012/065691
Momwxs:
wagoflfioammoam
a
E
m
m
$23535:830&3<£9&U§=5: $235essbeosmszeosg353 figmgagaezmsm:£<m2§<33333 $5353853:?$333333: 333mg:3w03w03w03mmw0mew<wDED3+3: 3535363636:269632395: 353595333:2332553535: 533932332:3535: 3m526easeszmmfluesuss9595: 3mSmJUEwanfimyom5:3595: am585333:«$8295559595: aSsSmusmS£38235:39595: 383535329683332959595: anomamawefiésmus3539595: 33293595559535: fiammSmngzume:9539595: Emmamafiogg3532959595: $953258?353539595: 25020::
825nm
w
2
Q<
swrov
wZ
$038203:
omd<fi< 0323,43 0323.4 $323.4 omd<£< $323.4 mad/«3.4 omd<fl< one—<93 omd<£< man—<92 omd<£<
EamsuS 2 mzsm omd<3<£<55 Eda wmd<£<£<§¢Dflsfistd<£<£<fl<fl< omd<£<mw<m 845 omd<E<E<m 8.4m omd<£<fl<m £<m um
m £4.23 m 9&2; m 34.22 £<+$< m fl<¥<¥< m m £<w<+<
0505
303230 303230 333$ 303955 303955 95%”, 33m”, m? m+< m+< m+< m+< m+< 8w
E<+U+<u+<®+< 3<U+<u+<va< E m2”, 0
DUSUF<£<UUF<M+< 295 295 £29595 .w
30 EU EU EU 93305535 @5535 £29595 .5 2%:
£0 80 EU EU EU 9393553635 3.3359583 mw<+<u5mu5u5 .8
EU 203635
m+< m+< 30 E<u+<u+<®+< m+< £<£< 30 E<u+<u+<®+< EU EU EU EU
m+< m+< m+< m+< m+< m+< 30 30 3+<£<£< 3+<£<£< EU EU 3+<u+< 3+<u+< 8,25
a
Nmofi mmofi «mofi mmofi omofi nmofi wmofi mmofi OOHH HOHH NOHH mOHH «OHH mOHH ooHH NOHH 82820::
838304 3:865
03
wmomo mmomo onomo NNONQ whomo mnowo owomo HwOND Nwomo mwomo «womo mwomo mwomo hwomo wwomo mwONQ omomo Hmomo
135
W0 2013.:‘075035 PCT/U82012/065691
Example 4: In vitro screening of RNAi Agents
Cell culture and transfections
Human Hep3B cells or rat .E cells (ATCC, Manassas, VA) were grown to
near confluence at 37 °C in an atmosphere of 5% CO2 in RPMI (ATCC) supplemented
with 10% FBS, streptomycin, and glutamine (ATCC) before being released from the
plate by trypsinization. Transfection was carried out by adding 14.8 ul of Opti—MEM
plus 0.2 ul of Lipofectamine RNAiMax per well (Invitrogen, Carlsbad CA. cat # 13778—
150) to 5 pl of siRNA duplexes per well into a 96—well plate and incubated at room
temperature for 15 minutes. 80 ul of complete growth media t antibiotic
10 containing ~2 x104 Hep3B cells were then added to the siRNA mixture. Cells were
incubated for either 24 or 120 hours prior to RNA purification. Single dose experiments
were performed at 10nM and 0.1nM final duplex concentration and dose response
experiments were done using 8, 4 fold serial dilutions with a maximum dose of 10nM
final duplex concentration.
15
Total RNA isolation usin ADS mRNA Isolation Kit Invitro en art #: 610—
£1
Cells were harvested and lysed in 150 pl of Lysis/Binding Buffer then mixed for
5 minutes at 850rpm using an orf mixer (the mixing speed was the same
20 throughout the process). Ten microliters of magnetic beads and 80 pl Lysis/Binding
Buffer e were added to a round bottom plate and mixed for 1 minute. Magnetic
beads were captured using magnetic stand and the supernatant was removed without
disturbing the beads. After removing the supernatant, the lysed cells were added to the
ing beads and mixed for 5 minutes. After removing the supernatant, magnetic
25 beads were washed 2 times with 150 pl Wash Buffer A and mixed for 1 minute. Beads
were capture again and supernatant removed. Beads were then washed with 150 pl
Wash Buffer B, captured and supernatant was removed. Beads were next washed with
150 pl Elution Buffer, captured and supernatant removed. Beads were allowed to dry
for 2 minutes. After drying, 50 ul of Elution Buffer was added and mixed for 5 minutes
30 at 70°C. Beads were captured on magnet for 5 minutes. 40 ul of atant was
d and added to another 96 well plate.
136
W0 ‘075035 PCT/US2012/065691
cDNA sis using ABI High capacity cDNA reverse transcription kit {Applied
Biosystems, Foster City, CA, Cat #4368813 2
A master mix of 1 ul 10X Buffer, 0.4ul 25X dNTPs, 1pl Random primers, 0.5 ul
Reverse Transcriptase, 0.5 ul RNase inhibitor and 1.6ul of H20 per reaction were added
into 5 ul total RNA. cDNA was generated using a d C—1000 or S—1000 thermal
cycler (Hercules, CA) through the following steps: 25 0C 10 min, 37 °C 120 min, 85 0C
5 sec, 4 0C hold.
10 Real time PCR
2p] of cDNA were added to a master mix containing 0.5ul GAPDH TaqMan
Probe (Applied Biosystems Cat 17E (human) Cat # 3 (rodent)), 0.5ul
TTR TaqMan probe (Applied Biosystems cat # HS00174914 _m1 (human) cat #
Rn00562l24_m1 (rat)) and 5ul ycler 480 probe master mix (Roche Cat
15 #04887301001) per well in a 384 well plate (Roche cat # 04887301001). Real time PCR
was done in a Roche LC 480 Real Time PCR machine (Roche). Each duplex was tested
in at least two independent transfections and each transfection was assayed in duplicate,
unless otherwise noted.
To calculate relative fold change, real time data were analyzed using the AACt
20 method and normalized to assays performed with cells transfected with 10nM AD—1955,
or mock transfected cells. IC50s were calculated using a 4 parameter fit model using
XLFit and normalized to cells transfected with AD-1955 (sense sequence:
cuuAchuGAGuAcuchAdedT (SEQ ID NO: 2202); antisense sequence:
UCGAAGuCUcAGCGuAAGdedT (SEQ ID NO: 2203)) or naive cells over the same
25 dose range, or to its own lowest dose. IC50s were calculated for each individual
transfection as well as in combination, where a single IC50 was fit to the data from both
transfections.
The results of gene ing of the exemplary siRNA duplex with various motif
modifications of the invention are shown in Table 1 above.
30
137
W0 2013,:‘075035 PCT/U82012/065691
Example 5: In vitro Silencing Activity of Chemically Modified RNAi Agents that
Target TTR
The following experiments demonstrated the beneficial effects of al
modifications, including the introduction of triplet repeat motifs, together with a
GalNA03 ligand, on the silencing activity of RNAi agents that target TTR. The
sequences of the agents investigated are provided in Table 2 below. The regions of
mentarity to the TTR mRNA are as s: the region of complementarity of
RNAi agents AD-45165, AD-51546 and AD-51547 is
GGATGGGATTTCATGTAACCAAGA (SEQ ID NO: 2204) and the region or
10 metarity of RNAi agents AD—45163, AD—51544, and AD-S 1545 is
TTCATGTAACCAAGAGTATTCCAT (SEQ ID NO: 2205).
Protocol for assessment of ICE in Hep3B cells
The IC50 for each modified siRNA was determined in Hep3B cells (a human
15 hepatoma cell line) by standard reverse transfection using Lipofectamine RNAiMAX.
In brief, reverse transfection was carried out by adding 5 uL of Opti—MEM to 5 uL of
siRNA duplex per well into a 96—well plate along with 10 uL of Opti—MEM plus 0.5 uL
of ctamine x per well (Invitrogen, ad CA. cat # 13778—150) and
incubating at room temperature for 15—20 minutes. Following incubation, 100 uL of
20 complete growth media without antibiotic containing 12,000—15,000 Hep3B cells was
then added to each well. Cells were incubated for 24 hours at 37°C in an atmosphere of
5% C02 prior to lysis and analysis of TTR and GAPDH mRNA by bDNA (Quantigene).
Seven different siRNA concentrations ranging from lOnM to 0.6pM were assessed for
IC50 determination and TTR/GAPDH for siRNA transfected cells was normalized to
25 cells transfected with lOnM Luc siRNA. The s are shown in Table 2.
Protocol for assessment of free—uptake ICE
Free uptake silencing in primary cynomolgus hepatocytes was assessed
following incubation with TTR siRNA for either 4 hours or 24 hours. Silencing was
30 measured at 24 hours from the initial exposure. In brief, 96—well culture plates were
coated with 0. 1% collagen (Sigma 1VL) at room temperature, 24 hours
138
W0 2013,:‘075035 PCT/U82012/065691
prior to the start of the experiment. On the day of assay, siRNAs were diluted in pre—
warmed Plating Media consisting of DMEM supplemented with GIBCO’s nance
Media Kit —Free, Life Technologies CM4000), and added to the collagen—coated
96—well culture plates. Cryopreserved primary cynomolgus hepatocytes were rapidly
thawed in a 37°C water bath, and immediately diluted in Plating Media to a
concentration of 360,000 cells/mL. A volume of cell sion was gently pipetted on
top of the pre—plated siRNAs such that the final cell count was 18,000 well. The
plate was lightly swirled to mix and spread cells evenly across the wells and placed in a
37°C, 5% C02 incubator for 24 hours prior to lysis and analysis of TTR and GAPDH
10 mRNA by bDNA (Quantigene, Affymetrix). In the case of the 4h incubation with
siRNA, the media was decanted after 4 hours of exposure to the cells, and replaced with
fresh Plating Media for the remaining 20 hours of incubation. Downstream analysis for
TTR and GAPDH mRNA was the same as described above. For a typical dose reponse
curve, siRNAs were ed from luM to 0.24nM by 4 fold serial dilution.
15
139
WO 2013075035 PCT/US2012/065691
0mg
i 2 300.0 m 2
998$ _0.0 50.0 So :8: 300.0 81::
638: w
8
888
oxfimbéofi H 0Nw00.0 #3000 0wm000 $85.0 $80.0 vnm000 08838888 2:
8
2
@282 I! 0:800 m0m00 : x
#0
H $80.0 00:00 22808::
:00 0 mood 0 8806:: Eon
«23:8 m 8%.
:33 : 8%:
m:::_::> «£0:E<£<EDHOEDQMDQZEAQEOHD: $00m:0<£<EDW0©::£D£<E<H<0©HDN mm00w3<£<::wuU::£D£<E<fl©wubm 0m::§00:0=:<:<w:::8:30:8585 a::2:08::<:<w=:0::e085:0: U£UE<£<w:&0flBDm©wMD:mU: 08::JN 88::
0%.an :
0:: m< ANMNN AmfiNN AENN EN: 68m ASNN 3808:: 88:38:80
u<ZEUJHHH UOZ UOZ UOZ Uoz Uoz uOZ ©< 2:
A: A: OH :: :: DH 8
OMB OMB 0mg 0:8 0:8 Ommv rwdv
0
Z 0388:
yea—:32 $02828: 8:58:
8.88::
:8
FEE—Ea 001mb:0UomDE<EO£O£<£O£<EGE< 83808:: SERFOJN
$0NN ooflbflvo::w<:0©fl©m<w<£ofl<:w©:w< 001mDEDom3:04:30OEOHAG/wowUmAa/NEOEAQ $0NN 03:32::o:<::w:::oe:a<w8w:: 986::
AhoNN 38: C Eon
HNN 8
53:04 UOZ UOZ UOZ 032:2:<8:<::::E80::33083: 88: Uoz Uoz uOZ am
a: 85w:
A: A: OH :: :: ,8
0:8 001E<3<£Dowflbfla‘fiofibfiaflflwflb DH 92.: 0mg 0mg 0mg 0:8 Ommv 82808:: mold/2:0
:
E A:
”N mg 3:2 $2
Saab 83:0 9%: B: tum
3.0? m-m_< m Hm 8286::
Q< 822 89: Q< 0835304 001— 0:9:
140
W0 2013,:‘075035 PCT/U82012/065691
The results are provided in Table 2 and demonstrate that modified RNAi agents
that target TTR provide enhanced silencing activity.
Results: Improved Activity of Modified RNAi Agents
Parent RNAi agents with alternating chemical modifications and a GalNAc3
ligand ed an IC50 in Hep3B cells of about 0.01 nM. As shown in Figures 4—5 and
in Table 2, agents modified relative to the parent agents, for example, by the addition of
one or more repeating triplets of 2’—fluoro and 2’—O—methyl modifications, showed
unexpectedly enhanced silencing activity, achieving IC50 values in Hep3B cells that
10 were 5—8 fold better than the corresponding parent agent.
Results: Free Uptake IC50s in Hep3B cells
As shown in Table 2 and Figures 6—7, RNAi agents modified relative to the
parent AD—45 163 also showed enhanced free uptake silencing. The modified agents
15 showed more than double the silencing activity of the parent after a 24 hour tion
period and nearly 10 times the silencing activity of the parent after a 4 hour tion
period.
As shown in Table 2 and Figures 8—9, RNAi agents modified relative to the
parent AD—45 165 also showed ed free uptake silencing. The modified agents
20 showed 2—3 times the silencing activity of the parent after a 24 hour incubation period
and 5—8 times the silencing activity of the parent after a 4 hour incubation period.
Taken collectively, these results demonstrate that the modified RNAi agents
ted herein, e.g., AD—51544, AD—51545, AD—51546, and 47, all showed
unexpectedly good inhibition of TTR mRNA in in vitro silencing experiments.
25
141
W0 2013,:‘075035 PCT/U82012/065691
e 6: TTR mRNA silencing and TTR Protein ssion in Transgenic
Mice
To assess the efficacy of the RNAi agents 63, AD—5 1544, AD-51545,
AD45165, AD—51546, and AD—51547, these agents were administered to transgenic
mice that express human transthyretin with the V30M mutation (see Santos, SD.,
Fernaandes, R., and a, MJ. (2010) Neurobiology ofAging, 31, 280—289). The
V30M mutation is known to cause familial amyloid polyneuropathy type I in humans.
See, e.g., Lobato, L. (2003) JNephrol., 16(3):438—42.
10 The RNAi agents (in PBS buffer) or PBS l were administered to mice (2
male and 2 female) of 18—24 months of age in a single subcutaneous dose of 5 mg/kg or
1 mg/kg. After approximately 48 hours, mice were anesthetized with 200 pl of
ketamine, and then exsanguinated by severing the right caudal artery. Whole blood was
isolated and plasma was isolated and stored at —80°C until assaying. Liver tissue was
15 ted, flash—frozen and stored at —80°C until processing.
Efficacy of ent was evaluated by (i) measurement of TTR mRNA in liver
at 48 hours post—dose, and (ii) measurement of TTR protein in plasma at pre—bleed and at
48 hours post—dose. TTR liver mRNA levels were assayed utilizing the Branched DNA
assays— QuantiGene 2.0 (Panomics cat #: ). Briefly, mouse liver samples were
20 ground and tissue lysates were ed. Liver lysis mixture (a mixture of 1 volume of
lysis mixture, 2 volume of nuclease—free water and 10ul of Proteinase—K/ml for a final
concentration of 20mg/ml) was incubated at 65 °C for 35 minutes. 20p] of Working
Probe Set (TTR probe for gene target and GAPDH for endogenous control) and 80ul of
tissue—lysate were then added into the Capture Plate. Capture Plates were incubated at
25 55 °C 11 °C (aprx. 16—20hrs). The next day, the Capture Plates were washed 3 times
with 1X Wash Buffer (nuclease—free water, Buffer Component 1 and Wash Buffer
Component 2), then dried by centrifuging for 1 minute at 240g. 100ul of pre—Amplifier
Working Reagent was added into the Capture Plate, which was sealed with aluminum
foil and incubated for 1 hour at 55°C iloC. Following 1 hour incubation, the wash step
30 was repeated, then 100ul of Amplifier Working Reagent was added. After 1 hour, the
wash and dry steps were ed, and 100ul of Label Probe was added. Capture plates
142
W0 2013,:‘075035 PCT/U82012/065691
were incubated 50 °C i1 °C for 1 hour. The plate was then washed with 1X Wash
Buffer, dried and lOOul ate was added into the Capture Plate. Capture Plates were
read using the SpectraMax Luminometer following a 5 to 15 minute incubation. bDNA
data were analyzed by subtracting the average background from each triplicate ,
ing the resultant triplicate GAPDH (control probe) and TTR (experimental probe)
values, and then computing the ratio: (experimental probe—background)/(control probe—
background).
Plasma TTR levels were assayed utilizing the commercially available kit
“AssayMax Human Prealbumin ELISA Kit” (AssayPro, St. Charles, MO, Catalog #
10 EP3010—1) according to manufacturer’s guidelines. Briefly, mouse plasma was diluted
1:10,000 in 1X mix diluents and added to pre—coated plates along with kit standards, and
incubated for 2 hours at room temperature followed by 5X washes with kit wash buffer.
Fifty microliters of biotinylated umin antibody was added to each well and
incubated for 1 hr at room temperature, ed by 5X washes with wash buffer. Fifty
15 microliters of streptavidin—peroxidase ate was added to each well and plates were
incubated for 30 minutes at room temperature followed by washing as previously
described. The reaction was developed by the on of 50 ul/well of chromogen
substrate and incubation for 10 minutes at room temperature with stopping of reaction
by the addition of 50 ul/well of stop solution. Absorbance at 450 nm was read on a
20 Versamax microplate reader (Molecular Devices, Sunnyvale, CA) and data were
analyzed utilizing the Softmax 4.6 software package ular Devices).
The results are shown in Figures 10-12. Figure 10 shows that the RNAi agents
modified relative to the parent agents AD—45 163 and AD—45 165 showed RNA silencing
activity that was similar or more potent compared with that of the parent . Figure
25 11 shows that the agents 44 and AD—51545 showed dose dependent silencing
activity and that the silencing activity of these agents at a dose of 5mg/kg was similar to
that of the corresponding parent 63. Figure 12 shows that the agents AD—51546
and AD—51547 also showed ependent silencing activity. Furthermore, the
silencing activity of AD—51546 and AD—51547 at a dose of 5mg/kg was superior to that
30 of the corresponding parent AD—45165.
143
W0 2013,:‘075035 PCT/U82012/065691
Example 7: Serum and Liver Pharmacokinetic Profiles of RNAi Agents that
Target TTR in Mice
To assess the pharmacokinetic profiles of the RNAi agents AD—45163, AD—
51544, AD—51545, AD—51546, and AD—51547, these agents, in PBS , were
administered to C57BL/6 mice using a single IV bolus or subcutaneous (SC)
administration. The plasma trations and liver concentrations of the agents were
assessed at various timepoints after the administration.
10 The plasma pharmacokinetic parameters are presented in Tables 3 and 4 below.
The mean resident time (MRT) in plasma was about 0.2 hours after IV dosing and about
1 hour after SC dosing. At a dose of 25 mg/kg, the agents AD-51544, AD-51545, AD-
51546, and AD—51547 showed similar plasma pharmacokinetic properties. Each of
these agents had more than 75% bioavailability from the subcutaneous space. Their
15 bioavailability was superior to that of the parent agent AD—45 163 that was administered
at a higher dose of 30 mg/kg. The subcutaneous ilability of AD—51544 and AD—
51547 was about 100%, whereas that of 45 was 90% and that of and AD—51546
was 76%.
144
WO 2013/075035 PCT/U82012/065691
Table 3: Summary of Plasma PK ter Estimates After SC Administration of
TTR-GalNAc siRNAs in Mice
Parameter
Plasma
AUC
(Mug/mm
145
WO 2013/075035 PCT/US2012/065691
08
mm
mfimoc Mm
>~ MARE
.5 US$083- Saw mm
2.15 mofiogm 3: E
08 @506
>H EEEE EEEEEEEE EEEEEEEE :8 v £38 >H
SW Ewe 2m a USN
5w mm
(Baa Um
ma AQZV .83on Eda
8:2 a mfimow BEEEEU :2»
E E: >H Hon E.OUD<
whoaofifiwm 3 Eda defame we 3 $3
32m Ana: Ho: QUE
go:
03500 $5on 895
2 093:8qu
.mvmm was
v5 Q5 Amm> mm
473% MEEEE USN
€$Ed< owning cauéogbqooqoo AU
E 603328
9:me 05
E 05
“5:338qu we .8.OUD<
mo nougubzo “m8
“v 35a
ommnm
«Bah €8me< ZNOE
Um
0m a u. REES Susana; no
146
W0 20132'075035 PCT/U82012/065691
The results also indicated that the RNAi agents AD-45163, AD-51544, AD-
51545, AD—51546, and AD—51547 achieved similar or higher trations in the liver
when stered subcutaneously than when administered by IV bolus. The liver
pharmacokinetic parameters are presented in Tables 5 and 6 below. The peak
concentration (Cmax) and area under the curve (AUC0_1ast) in the liver were two to three
times higher after aneous administration as compared with IV administration of
the same agent at the same dose. Liver exposures were highest for AD—51547 and
lowest for AD—51545. The mean resident time (MRT) and elimination half—life were
10 longer for AD—51546 and AD—51547 compared with AD—51544 and AD—51545.
Following subcutaneous administration, the approximate MRTs were 40 hours for AD—
51546 and 25 hours for AD-51547, whereas the MRTs for AD-51544 and AD-51545
were lower (about 6-9 hours). The elimination half life of AD-51546 and 47
was also higher (41—53 hours) than was the elimination half life of AD—5 1544 and AD—
15 51545 (6—10 hours).
147
WO 2013/075035 PCT/U82012/065691
8:2
5
@4736
ibb
ac
:235EEEc4 is mm A2 Sm: 85 -m: 37:8 mm?
Um
no£< is 32m £5 i: A2230.
8383mm— mm A2 5m
.Suofifiwm is mu AZ 32m 85 -59 A2230
Mm is mm A? 32m .35 39:8 88
33A £5
mo
Enfifism is cm .94 35 £5 -m: 0230 a?
um meH $80 mg
ozmh 33523 53: $34 Awmzv :5 Awaits
148
WO 2013/075035 PCT/U82012/065691
wv—RE
ma
3
bVMHm
.5
cvmfim VM m“.
lnN
*v Nlfi
l0 IHI32 nmvmfim Emma
(\1
{VMHMAJN m-Q< OO
1\
ova U l\
mo
omoQ l0 I”:
(\1
[\OH "iv
Um m-Q< ><r
go00 an—l film
.5
miom mob a 0.2
>H 113 aH%
«5 ll@222 2 fi' 0 l\
Bin m
3:2 v as
E 3222 mN
muowofimumm EE E
Mm
492%
33A
6 g 3&3
Bank Eu
149
W0 2013,:‘075035 2012/065691
Example 8: In vitro Stability of RNAi Agents in Monkey Serum
The serum stability of RNAi agents AD—51544, AD—51545, AD—51546, and AD—
51547 was also ed in monkeys. The results demonstrated that the nse and
sense s of AD—51544, AD—51545, and AD—51547 showed serum stability over a
period of about 24 hours (data not shown).
Example 9: RNAi Agents Produce Lasting Suppression of TTR n in Non-
Human Primates
10 The RNA silencing activity of RNAi agents AD—45163, AD—51544, AD—51545,
AD—51546, and AD—51547 was assessed by measuring suppression of TTR protein in
serum of cynomologous monkeys following subcutaneous administration of five 5
mg/kg doses (one dose each day for 5 days) or a single 25mg/kg dose. Pre—dose TTR
protein levels in serum were assessed by averaging the levels at 11 days prior to the first
15 dose, 7 days prior to the first dose, and 1 day prior to the first dose. Post—dose serum
levels of TTR protein were assessed by determining the level in serum ing at 1
day after the final dose (i.e., study day 5 in the 5x5 mg/kg group and study day 1 in the
1x25 mg/kg group) until 49 days after the last dose (i. 6., study day 53 in the 5x5 mg/kg
group and study day 49 in the 1x25 mg/kg group). See Figure 13.
20 TTR protein levels were assessed as described in Example 6. The results are
shown in Figure 14 and in Tables 7 and 8.
A maximal suppression of TTR protein of up to about 50% was achieved in the
groups that ed 25 mg/kg of 63, AD—51544, AD—51546, and AD—51547
(see Table 8). A greater maximal suppression of TTR protein of about 70% was
25 achieved in the groups that received 5x5 mg/kg of AD—45163, AD—5l544, AD—5l546,
and AD—51547 (see Table 7). The agent AD—51545 produced a lesser degree of
suppression in both administration protocols. Significant suppression of about 20% or
more persisted for up to 49 days after the last dose of AD—51546 and AD-51547 in both
the 1x25 mg/kg and 5x5 mg/kg protocols. Generally, better suppression was achieved
30 in the 5x5 mg/kg ol than in the 1x25 mg/kg protocol.
150
W0 2013f075035 PCT/U82012/065691
336
m
.5.“
Emma.
wv—RE
m
V
mag—.52
mayofiosho
E
086-95
8 fifiafififififiafi
9523—
mzfih
850m
scream
b
2an HHHEEI EEEEEEEEEEEEEEEE EEEEEEEEEEEEEEEQ EEEEEEEEEEEEEEEE EEEEEEEEEEEEEEEE EEEEEEEEEEEEEEEQ EEEEEEEEEEEEEEEIA..EMNVm“av—:02mi.Logo:0a:owOU-OhmOw“Swim—OHM:59—Saws—NEHSic—om:O—wuflhrflwo—a—NHL EEEEEEEEEEEEEEEE EEEEEEEEEEEEEEEQ EEEEEEEEEEEEEEEE EEEEEEEEEEEEEEEE EEEEEEEEEEEEEEEE
151
W0 2013,:‘075035 PCT/U82012/065691
Example 10: Tolerability of RNAi Agents that Target TTR
In ne Evaluation in Whole Blood Assay
To assess the tolerability of RNAi agents that target TTR (including AD-45163,
AD—51544, AD-51545, 46, and AD—51547), each agent was tested in a whole
blood assay using blood from three human donors. The agents were either 300 nM
DOTAP transfected or 1 uM without transfection t (free siRNA). There was less
than a two fold change for the following cytokines/chemokines: G—CSF, IFN—y, IL—10,
IL—12 (p70), ILlB, IL—lra, IL—6, IL—8, lP—lO, MCP—l, MIP—la, MIP—lB, TNFOL. (Results
not shown).
10
In Vivo Evaluation
To assess in vivo tolerability, RNAi agents were injected subcutaneously in CD1
mice at a dose of 125 mg/kg. No cytokine induction was observed at 2, 4, 6, 24, or 48
hours after subcutaneous injection of AD—45163. No significant cytokine induction was
15 ed at 6 or 24 hours after subcucutaneous injection of AD—51544, AD—51545, AD—
51546, or AD—51547.
To further assess in viva tolerability, multiple RNAi agents (including AD—
45163, AD-51544, AD—51545, AD—51546, and AD—51547) were tested by subcutaneous
injection of 5 and 25 mg in non—human es (cynomologous monkeys) with dose
20 volumes n 1—2 ml per site. No erythema or edema was observed at injection sites.
Single SC Dose Rat Tolerability Study
To assess toxicity, rats were injected with a single subcutaneous dose of 100,
250, 500, or 750 mg/kg of AD—45163 (see Table 9). The following assessments were
25 made: clinical signs of toxicity, body , hematology, clinical chemistry and
coagulation, organ weights (liver & spleen); gross and microscopic evaluation (kidney,
liver, lung, lymph node, spleen, testes, , aorta, heart, intestine (small and large).
152
W0 20132'075035 PCT/U82012/065691
Table 9: Single SC Dose Rat Tolerability Study: 100, 250, 500 & 750 mg/kg of AD-
45163 in Sprague Dawley Rats
-II
SC Injection 7/group
1 0 Day 1 (5 Tox
ggégtssss sssss
-
amma S1)
750
The s showed no test article—related clinical signs of toxicity, effects on
5 body weight, organ weights, or clinical chemistry. No histopathology was observed in
heart, kidneys, testes, spleen, liver, and thymus. There was a non—adverse, slight test
article—related increase in WBC (T68%, primarily attributed to se in NEUT and
MONO) at 750 mg/kg. These results indicate that a single—dose of up to 750 mg/kg is
well tolerated in rats.
10
Tolerability of Repeated Subcutaneous Administrations in Rats
To assess the tolerability of repeated subcutaneous strations of AD—45163,
daily subcutaneous ions of 300 mg/kg were given for 5 days, and a necropsy was
performed on day 6. The study design is shown in Table 10.
15
153
W0 2013,:‘075035 PCT/U82012/065691
Table 10: Five Day Repeat Dose Tolerability Study in Rat
The following e variables were assessed: clinical signs, body weights,
hematology, clinical chemistry and coagulation, organ weights, gross and microscopic
evaluation (liver, spleen, kidney, heart, GI tract and first and last ion site). The
results showed no test article-related clinical signs, body weight or organ weight effects,
and also no test article-related findings in clinical hematology or chemistry. There was a
possible slight prolongation of activated partial thromboplastin time (APTT) on day 6
10 (20.4 vs. 17.4 sec). Histopathology revealed no test article—related findings in the liver,
spleen, heart, and GI tract. In the , minimal to slight hypertrophy of the r
epithelium (not adverse) was observed. At the last injection site, there was minimal
multifocal mononuclear infiltration, not adverse. These results indicate that five daily
300 mg/kg doses of the parent RNAi agent AD—45 163 are well tolerated in rats.
15
e 11: RNAi Agents Produce Lasting Suppression of TTR Protein in Non-
Human Primates
The RNA silencing activity of RNAi agent AD-51547 was assessed by
measuring suppression of TTR protein in the serum of cynomologous monkeys
20 ing subcutaneous administration of a “loading phase” of the RNAi agent: five
daily doses of either 2.5 mg/kg, 5 mg/kg or 10 mg/kg (one dose each day for 5 days)
followed by a “maintenance phase” of the RNAi agent: weekly dosing of either 2.5
mg/kg, 5 mg/kg or 10 mg/kg for 4 weeks. Pre—dose TTR n levels in serum were
assessed by averaging the levels at 11 days prior to the first dose, 7 days prior to the first
25 dose, and 1 day prior to the first dose. Post—dose serum levels of TTR protein were
assessed by determining the level in serum ve to pre—dose beginning at 1 day after
154
W0 2013,:‘075035 PCT/U82012/065691
the loading phase was completed until 40 days after the last dose of the maintenance
phase (i.e., study day 70).
TTR protein levels were assessed as described in Example 6. The results are
shown in Figure 15.
A maximal suppression of TTR protein of up to about 80% was ed in all of
the groups that received either 2.5 mg/kg, 5 mg/kg or 10 mg/kg of AD—51547. Nadir
knockdown was achieved in all of the groups by about day 14, the suppression sustained
at nadir knockdown levels with a weekly nance dose of either 2.5 mg/kg, 5 mg/kg
or 10 mg/kg of AD—51547. The levels of TTR had not returned to baseline more than 40
10 days after the day of administration of the last maintenance dose for the 5 and 2.5 mg/kg
dose levels.
155
W0 2013I075035 PCT/U82012/065691
lents:
Those skilled in the art will recognize, or be able to ascertain using no more than
routine experimentation, many equivalents to the specific embodiments and methods
described herein. Such equivalents are intended to be encompassed by the scope of the
5 following claims.
Claims (2)
- We claim: 1. A double stranded RNAi agent comprising a sense strand complementary to an antisense strand, wherein said antisense strand ses a sequence that is complementary to nucleotides 504 to 526 of the transthyretin (TTR) gene (SEQ ID 5 NO:1), wherein the sense strand is 21 tides in length and the antisense strand is 23 tides in length, n said double stranded RNAi agent is represented by formula (III): sense: 5' np -Na -(X X X)i-Nb -Y Y Y -Nb -(Z Z Z)j -Na - nq 3' antisense: 3' npV'6aV'$<V<V<V%k-NbV'=V=V=V'6bV'$>V>V>V%l-NaV'"KqV"-#" 10 (III) wherein: j = 1; and i, k, and l are 0; p’ is 2; p, q, and q’ are 0; each Na and NaV"GKBCMCKBCKQIU"OCMOCPCKQP"?K"LIGELKRAICLQGBC"PCNRCKAC" 15 sing 2-10 nucleotides which are modified nucleotides; each Nb and NbV"GKBCMCKBCKQIU"OCMOCPCKQP"?K"LIGELKRAICLQGBC"PCNRCKAC" comprising 0-7 nucleotides which are modified nucleotides; npV"OCMOCPCKQP"?K"LSCOF?KE"KRAICLQGBC0" " ===&">>>&"?KB"=V=V=V&"C?AF"GKBCMCKBCKQIU"OCMOCPCKQ"LKC"JLQGD"LD"QFOCC" 20 identical modifications on three consecutive nucleotides, wherein the Y nucleotides contain a 2’-fluoro modification, the Y’ nucleotides contain a 2’-O-methyl modification, and the Z nucleotides contain a 2’-O-methyl modification; and wherein the sense strand is ated to at least one ligand, wherein the ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched 25 linker.
- 2. The RNAi agent of claim 1, wherein the YYY motif occurs at or near the AIC?S?EC"PGQC"LD"QFC"PCKPC"PQO?KB0"LO"TFCOCGK"QFC"=V=V=V"JLQGD"LAAROP"?Q"QFC"))&")*"?KB" 13 ons of the antisense strand from the 5'-end. 30 3. The RNAi agent of claim 1 or claim 2, n the modifications on the Na, Na’, Nb, and Nb’ nucleotides are each independently selected from the group consisting of LNA, HNA, CeNA, 2"-methoxyethyl, 2"-O-alkyl, 2"-O-allyl, 2"-C- allyl, 2"-fluoro, 2"- deoxy, 2’-hydroxyl, and combinations thereof. 35 157 4. The RNAi agent of claim 3, wherein the modifications on the Na, Na’, Nb, and Nb’ nucleotides are 2"-O-methyl, 2"-fluoro or both. 5. The RNAi agent of claim 1, wherein the ligand is HO OH O H H HO O N N O AcHN O HO OH O O H H HO O N N O AcHN O O O HO OH O HO O N N O AcHN H H 5 O . 6. The RNAi agent of claim of any one of claims 1 to 5, wherein the ligand is attached to the 3’ end of the sense strand. 10 7. The RNAi agent of claim 6, wherein the RNAi agent is conjugated to the ligand as shown in the following tic , wherein X is O or S. 15 8. The RNAi agent of claim 7, wherein the RNAi agent is conjugated to the ligand as shown in the following schematic 158 9. The RNAi agent of any one of claims 1 to 8 further comprising at least one phosphorothioate or methylphosphonate internucleotide linkage. 5 10. The RNAi agent of claim 9, wherein the orothioate or methylphosphonate internucleotide linkage is at the 3’-terminal of one strand. 11. The RNAi agent of claim 10, wherein said strand is the antisense strand or the 10 sense strand. 12. The RNAi agent of any one of claims 1 to 11, wherein the base pair at the 1 on of the 5’-end of the antisense strand of the duplex is an AU base pair. 15 13. The RNAi agent of any one of claims 1 to 11, wherein the p’ overhang nucleotides are mentary to the target mRNA or wherein the p’ overhang nucleotides are non-complementary to the target mRNA. ),(" 9FC"861G"?ECKQ"LD"?KU"LKC"LD"AI?GJP")"QL"))&"TFCOCGK"?Q"IC?PQ"LKC"KMV"GP"IGKHCB" 20 to a neighboring nucleotide via a phosphorothioate linkage. )-(" 9FC"861G"?ECKQ"LD"AI?GJ"),&"TFCOCGK"?II"KMV"?OC"IGKHCB"QL"KCGEF@LOGKE" tides via phosphorothioate linkages. 25 16. An isolated cell containing an RNAi agent of any one of claims 1-15. 17. A pharmaceutical composition comprising an RNAi agent of any one of claims 1-15. 159 18. The pharmaceutical composition of claim 17, wherein the RNAi agent is administered in an unbuffered solution. 19. The pharmaceutical composition of claim 18, wherein said unbuffered solution is 5 saline or water. 20. The pharmaceutical composition of claim 17, wherein said RNAi agent is administered with a buffer solution. 10 21. The pharmaceutical composition of claim 20, wherein said buffer solution comprises acetate, citrate, prolamine, carbonate, phosphate or any combination thereof. 22. The ceutical composition of claim 21, n said buffer on is phosphate ed saline (PBS). 15 23. A method of inhibiting expression of a transthyretin (TTR) in an isolated cell comprising contacting said isolated cell with an RNAi agent of any one of claims 1-15 in an amount effective to inhibit expression of said TTR in said isolated cell, thereby inhibiting expression of said transthyretin (TTR) in said isolated cell. 20 24. Use of an RNAi agent of any one of claims 1-15, for the cture of a medicament for treating a TTR-associated disease in a subject. 25. A kit for performing the method of claim 23, sing 25 a) said RNAi agent, and b) instructions for use. 26. A kit for the use of claim 24, said kit comprising a) said RNAi agent, and 30 b) instructions for said use. 27. The double stranded RNAi agent of claim 1, wherein the sense strand comprises the nucleotide sequence 5’ – UGGGAUUUCAUGUAACCAAGA – 3’ (SEQ ID NO:2211). 35 160 28. The double stranded RNAi agent of claim 1, wherein the sense strand comprises the nucleotide sequence 5’- UfgGfgAfuUfuCfAfUfgUfaacCfaAfgAfL96-3’ (SEQ ID NO:2) and the antisense strand comprises the nucleotide sequence 5’- uCfuUfgGfUfUfaCfaugAfaAfuCfcCfasUfsc-3’ (SEQ ID NO:3), -" " TFCOCGK"?&"E&"A"?KB"R"?OC"*V'7'JCQFUI"$*V'75C%"1&"3&"2&"?KB";0""1D&"3D&"2D&"?KB" ;D"?OC"*V'DIRLOL"1&"3&"2"?KB";0"P"GP"?"MFLPMFLOLQFGL?QC"IGKH?EC0"?KB"4/."GP"?"3?I61A+" ligand. 29. The use of claim 24, wherein said ment is suitable for administration to a 10 human. 30. The method of claim 24, wherein said subject carries a TTR gene mutation that is associated with the pment of a TTR-associated disease. 15 31. The use of claim 24, wherein said TTR-associated disease is selected from the group consisting of senile ic amyloidosis (SSA), ic familial amyloidosis, familial amyloidotic polyneuropathy (FAP), familial amyloidotic cardiomyopathy (FAC), leptomeningeal/Central Nervous System (CNS) amyloidosis, and hyperthyroxinemia. 20 32. The use of claim 24, wherein said TTR-associated-disease is TTR-associated amyloidosis. 33. The use of claim 24, wherein said medicament is le for subcutaneous 25 administration. 34. A double stranded RNAi agent, comprising a sense strand and an antisense strand, wherein the sense strand comprises the nucleotide ce 5’- UfgGfgAfuUfuCfAfUfgUfaacCfaAfgAfL96-3’ (SEQ ID NO:2) and the nse strand 30 comprises the nucleotide sequence 5’-uCfuUfgGfUfUfaCfaugAfaAfuCfcCfasUfsc-3’ (SEQ ID NO:3), " TFCOCGK"?&"E&"A&"?KB"R"?OC"*V'7'JCQFUI"$*V'75C%"1&"3&"2&"?KB";0""1D&"3D&"2D&"?KB" ;D"?OC"*V'DIRLOL"1&"3&"2&"?KB";0"P"GP"?"MFLPMFLOLQFGL?QC"IGKH?EC0"?KB"4/."GP"?"3?I61A+" ligand.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161561710P | 2011-11-18 | 2011-11-18 | |
US61/561,710 | 2011-11-18 | ||
US201261615618P | 2012-03-26 | 2012-03-26 | |
US61/615,618 | 2012-03-26 | ||
US201261680098P | 2012-08-06 | 2012-08-06 | |
US61/680,098 | 2012-08-06 | ||
PCT/US2012/065691 WO2013075035A1 (en) | 2011-11-18 | 2012-11-16 | Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ624336A NZ624336A (en) | 2016-06-24 |
NZ624336B2 true NZ624336B2 (en) | 2016-09-27 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2017225076B2 (en) | Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases | |
CN108064154B (en) | Compositions and methods for inhibiting expression of the HAO1 (glycolate oxidase 1) gene | |
DK2999785T3 (en) | SERPINA1-IRNA COMPOSITIONS AND PROCEDURES FOR USE THEREOF | |
WO2015042564A1 (en) | Methods for treating or preventing transthyretin (ttr) associated diseases | |
JP2015177801A (en) | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES | |
TWI669393B (en) | Compositions and methods for inhibiting expression of the lect2 gene | |
US20230357774A1 (en) | Compositions and methods for the treatment of angiopoietin like 7 (angptl7) related diseases | |
JP2020531450A (en) | Adjustable REVERSIR ™ compound | |
KR20200014320A (en) | Nucleic Acids Inhibit Expression of APCS | |
DK2997614T3 (en) | ELECTROCHEMICAL STORAGE MATERIAL AND ELECTROCHEMICAL STORAGE DEVICE FOR STORAGE OF ELECTRICAL ENERGY, INCLUDING SUCH STOCK MATERIAL | |
KR20220047865A (en) | Nucleic Acids for Inhibiting Expression of C3 in Cells | |
NZ624336B2 (en) | Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases | |
RU2804776C2 (en) | AGENTS FOR RNAi, COMPOSITIONS AND METHODS OF THEIR USE FOR THE TREATMENT OF DISEASES ASSOCIATED WITH TRANSTHYRETIN (TTR) | |
AU2017204161B2 (en) | SiRNA therapy for transthyretin (TTR) related ocular amyloidosis | |
US20230041178A1 (en) | Methods for the treatment of trinucleotide repeat exapnsion disorders associated with ogg1 activity | |
OA16815A (en) | RNAI agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases. | |
NZ714530B2 (en) | SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | |
NZ624471A (en) | Modified rnai agents | |
NZ624471B2 (en) | Modified rnai agents |